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ABSTRACT
POTENTIAL BENEFITS AND WITHDRAWAL EFFECTS OF CRANIAL NERVE
NON-INVASIVE NEUROMODULATION ON FUNCTIONAL MOBILITY FOR
INDIVIDUALS WITH TRAUMATIC BRAIN INJURY
by
Kati P. Liegl

The University of Wisconsin-Milwaukee, 2013
Under the Supervision of Roger O. Smith

Objective: Document and describe benefits and withdrawal effects of the
Cranial Nerve Non-Invasive Neuromodulation (CN-NINM) intervention.
Background: Neuromodulation techniques can be used for the treatment
of many diagnoses and conditions. Many current neuromodulation techniques
have or can have negative consequences such as high cost, risk of surgical
complications or infections, effects not lasting without the drug or stimulation
presence, and need for medical experts’ direct oversight. A new rehabilitation
intervention called CN-NINM may eliminate these negative factors, making it a
promising tool for clinicians and participants. CN-NINM combines targeted
training activities with mild, portable, electrical stimulation of the tongue to
facilitate learning. It was created after repeated clinical observations and
functional improvements were noted in related research. However, a great deal is
not known about the intervention mechanisms. To date, no negative
consequences have been documented.
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Methods: An A-B-A-B-A single case experimental design five week
intensive protocol was implemented with one participant with a TBI. Seven
measures were collected including the Timed Up and Go, Romberg, Sharpened
Romberg, 4 components of the Dynamic Gait Index, 5 components of the
Community Balance & Mobility Scale, Gait Efficacy Scale-modified, Community
Integration Questionnaire, and Participation Objective, Participation Subjective.
Results: While several assessments suggested improved function over
the study period, quantitative measures did not demonstrate statistically
significant improvement across phases of the study. No quantitative decline in
functional gait was evident during withdrawal phases. The participant reported
improvements during intervention weeks, including reduced tone and pain,
increased gait confidence, and increased activity tolerance.
Conclusion: CN-NINM warrants additional research. While this study
demonstrated no statistically significant effects during either intervention or
withdrawal phases, several qualitative observations suggest that the intervention
can potentially provide fast results with little to no risk and comparatively small
cost. Further research should involve multiple individuals with a number of
repeated baseline and outcome measures sufficient to attain pre- and posttreatment stability.
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PART I: THESIS OVERVIEW AND PERSONAL REFLECTIONS

2
Overview of thesis organization
This thesis is comprised of three parts: Part I: Thesis Overview, Part II:
Research Manuscript, and Part III: Appendices. Part I provides an overview of
the thesis, timeline of the study, and lessons learned along the process. Part II
includes the research manuscript. This manuscript contains background,
methods, results, and conclusions sections. The research manuscript was
prepared using guidelines for the Open Journal of Occupational Therapy. Part III
consists of seven appendices related to the manuscript and overall thesis.
Timeline of the Study
The following is a chronological summary of the study. The CN-NINM
intervention was introduced to the primary researcher in September 2011.
Meetings to discuss study options and designs were completed throughout the
summer of 2012. In September 2012, the primary researcher met with the
research team at the Tactile Communication & Neurorehabilitation Laboratory at
the University of Wisconsin Madison to discuss the fit of the proposed study into
the research they had completed and to learn about any areas they were
interested in gaining pilot data. On October 11, 2012, the primary researcher
proposed the thesis to a committee of advisors. The committee members
approved the design and hypotheses. On October 17, 2012, documents were
submitted to the Institutional Review Board (IRB) for a full board review. After
several iterations, IRB granted study approval on December 12 2012. IRB
amendments were submitted in April and September 2013 for edits in study
location and location of data storage.
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Participant recruitment was open and active from December 12, 2012 until
September 2013. During this time, multiple presentations were provided to
targeted groups (Dryhootch, support groups, the VA/VFW, MCW etc…) in an
attempt to recruit participants. Many more emails and phone calls were made
trying to gain access to appropriate potential participants. In May 2012, the first
and only participant to meet eligibility criteria completed all the assessments that
would be completed during the study as exposure to the assessments. The
participant began the full protocol on June 3rd and finished on July 5th. Two
trained raters rated the data in October. The primary researcher received a
College of Health Sciences Research Grant which provided compensation to the
primary rater and compensation of supplies to the primary researcher. Over the
course of the study, the primary researcher also presented the study design,
PoNS™ device, and study results at national, state, and local presentations.
Summary of Changes
The original research protocol changed in three ways during
implementation. First, although four participants were targeted to complete the
study, only one participant was recruited that was eligible for and completed the
study. Second, the participant completed a modified set of measures resulting in
the Timed Up and Go, Romberg, Sharpened Romberg, components of the
Dynamic Gait Index, and components of the Community Balance & Mobility
Scale instead of only completing the Community Balance & Mobility Scale. This
modification was included after the participant experienced lasting pain when
completing the Community Balance & Mobility Scale on the first day, prior to
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beginning the protocol. The participant attributed the pain to the orthopedic
injuries and completing tasks he had previously tried to avoid. A third
modification to the initial proposal was the completion of the entire study at
IndependenceFirst instead of at the University of Wisconsin Milwaukee. Due to
the change in location, the daily assessments were videotaped instead of being
completed by a blinded assessor. A researcher unfamiliar with the study design
later rated the videos with a second rater scoring 40% of the data to evaluate
inter-rater reliability. All other protocols and procedures remained true to the
proposal.
Learning Process
Over the course of the year and a half study, I have learned many things
about research and the research process as well as about myself. These include
a better understanding of the strengths and limitations of single case design
research; the importance and difficulties of each step in the research process
including creating a practical and exhaustive plan, word choice appropriate for
IRB, and strategies for participant recruitment; as well as experience
disseminating results that did not show the expected changes.
Single Case Design Characteristics
Single Case Design (SCD) studies are conceptualized, implemented, and
evaluated very differently than group studies. While planning the study design, it
became evident how important asking the right question and selecting the right
design was. Initially, I often mixed designs, asking a SCD question but trying to
design a group study to answer it. Over the course of several discussions, I
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began to differentiate between group and SCD questions. As an occupational
therapy student, I was very interested in my participants’ experiences and the
changes they noted. I was concerned with the process of the intervention which
is documented throughout SCDs as opposed to a single pre-post assessment
more typical to a group design. Small single case studies are essential to test the
design of valid group studies. The lack of published research on the topic I chose
makes the area a great fit for smaller, more customizable studies in order to
inform a more effective group design and be best able to understand the
interventions.
While initiating the study and throughout the study, I learned the value of
the flexible design and structures of SCDs without losing treatment integrity.
When my participant was unable to complete the study assessment as I had
intended, I was able to modify the study before it began to allow him to
participate. Days when the participant was tired, distracted, or not his typical self,
I was able to discuss what was happening with him and make a note of the
situation to explain the data variability. With group designs, these data points
could be considered outliers and potentially be removed from the data set. In
addition, I was able to record the participant’s responses, reactions, and progress
through the study. Although the dependent variable results did not fully support
my hypotheses, I gained valuable information about the participant’s experience
and how a subsequent study might be better structured. Group designs often
lack this personalized and detailed information.
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The flexibility of the SCD was beneficial for my study, however, I also
realized some of the limitations of SCD studies. The main limitation of all SCD
studies is that although they provide detailed information about one participant’s
experiences, they provide no evidence that the pattern affects anyone else.
Another limitation I experienced was related to the data analysis. With repeated
measures and SCDs, visual analyses are standard. With data that clearly
presents as the same or different across phases, this can be easy, efficient, and
supported by statistical techniques. There are several techniques that are utilized
to evaluate and understand repeated measures data. Examples include using the
last three data points from each phase so there is a greater chance of phase
stability, using two standard deviation band methods, or split middle celeration
lines. My data did not fit well into typical data analysis methods. For example,
one analysis method I completed was percentage of data overlap and I evaluated
the Percentage of Data Exceeding the Median, Percentage of Data Exceeding
the Mean, Non-pairwise Data Overlap, and Percentage Non-overlapping Data.
On several graphs, the percentages seemed to indicate a difference in phases,
however, by visually examining the data, there was no difference in phases.
Other graphs had a 0% difference with several overlap techniques but 100%
difference on one technique. This made it difficult to determine what was
significant and representative of my data.
General Research Practice Guidelines
My thesis has helped me to better understand general research guidelines
in addition to SCDs. I learned the value of well-constructed and very thorough
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plans. I also learned the value of flexibility and being able to adapt under multiple
circumstances. There were several instances that required me to plan future
steps of the study. Each time I was faced with planning out details of the study I
took it more seriously, was better able to understand the importance of the plans,
and learned how to better anticipate what might happen in order to prepare
contingency plans. I learned to appreciate a well-constructed and extensive plan
and be better able at producing it. However, I also learned to adapt and make the
most out of unforeseen situations while preserving as much treatment integrity as
possible. This was necessary when the participant was unable to complete the
intended assessment prior to beginning the study and when the participant was
not able to be assessed one Friday during a withdrawal week, and instead was
assessed before the intervention on the following Monday.
This study involved significant effort to obtain IRB approval and taught me
a great deal about the IRB process. My study required a full board review and
several iterations before being accepted. Through this process I learned about
clear, concise writing, which is a challenge to me that I am slowly becoming more
competent at, safety concerns from a participant and data perspective, and had
the importance of carefully crafted plans re-emphasized.
Recruitment was a long, strenuous process throughout the study. During
this process, I learned to leave my comfort zone, often, to be persistent,
passionate, and memorable so people will remember my name or topic when I
call back, and to network everywhere I go. Recruitment was the most difficult and
frustrating component of my study, but also provided a great deal of learning
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about myself and research. An important lesson I learned was to work with
groups that you have access to before you begin the study.
I have learned and am continuing to learn a great deal about
disseminating my information; many of these lessons overlap with those I learned
in recruitment. I have presented at national, state, and local conferences and
events and continue to be avid about presenting the work that I did. I was also
not accepted to several national conferences which has taught me the
importance of persistence and not letting frustration or rejections stop me from
submitting my work again elsewhere. Over the course of my presentations, I
have become more competent presenting my information logically, verbally
conveying information to people, accepting criticism, and being persistent. I have
learned the benefit of networking and stepping outside my comfort zone.
The last thing I learned was that research does not always go or end the
way you want. Unanticipated results are not a sign of failure and do not
necessarily indicate that the study found nothing of value. Although I was
disappointed that the data looked nothing like I had anticipated, I also was able to
learn a lot about the intervention process, research process, and additional ways
to maintain higher treatment integrity.
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PART II: RESEARCH MANUSCRIPT
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Abstract
Objective: Document and describe benefits, withdrawal effects and
experience with the Cranial Nerve Non-Invasive Neuromodulation (CN-NINM)
intervention.
Background: Neuromodulation techniques can be used for the treatment
of many diagnoses and conditions. Many current neuromodulation techniques
have or can have negative consequences such as high cost, risk of surgical
complications or infections, effects not lasting without the drug or stimulation
presence, and need for medical experts’ direct oversight. A new rehabilitation
intervention called CN-NINM may eliminate these negative factors, making it a
promising tool for clinicians and participants. CN-NINM combines targeted
training activities with mild, portable, electrical stimulation of the tongue to
facilitate learning. It was created after repeated clinical observations and
functional improvements were noted in related research. However, a great deal is
not known about the intervention mechanisms. To date, no negative
consequences have been documented.
Methods: An A-B-A-B-A single case experimental design five week
intensive protocol was implemented with one participant with a TBI. Seven
measures were collected including the Timed Up and Go, Romberg, Sharpened
Romberg, 4 components of the Dynamic Gait Index, 5 components of the
Community Balance & Mobility Scale, Gait Efficacy Scale-modified, Community
Integration Questionnaire, and Participation Objective, Participation Subjective.
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Results: While several assessments suggested improved function over
the study period, quantitative measures did not demonstrate statistically
significant improvement across phases of the study. No quantitative decline in
functional gait was evident during withdrawal phases. The participant reported
improvements during intervention weeks, including reduced tone and pain,
increased gait confidence, and increased activity tolerance.
Conclusion: CN-NINM warrants additional research. While this study
demonstrated no statistically significant effects during either intervention or
withdrawal phases, several qualitative observations suggest that the intervention
can potentially provide fast results with little to no risk and comparatively small
cost. Further research should involve multiple individuals with a number of
repeated baseline and outcome measures sufficient to attain pre- and posttreatment stability.
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Background
Therapeutic uses of neuromodulation is a relatively new field that is
expanding in scope and prescription. Neuromodulation is the suppression or
stimulation of the central or peripheral nervous system using pharmacological or
electrical techniques. Common techniques seen in rehabilitation vary widely and
can include baclofen pumps, deep brain stimulators, and transcranial magnetic
stimulation. Several show promise in improving function and quality of life for
users across many disabilities yet currently available techniques have several
undesirable characteristics or consequences. The following brief summary
highlights several of the limitations for current neuromodulation techniques.
Each technique presents different strengths and limitations. Intrathecal
baclofen, or baclofen pumps, can be effective at reducing severe spasticity,
particularly in traumatic brain injury (TBI), cerebral palsy, or spinal cord injuries
(Awaad et al., 2012). Deep brain stimulators decrease tremors as well as rigidity,
bradykinesia, and gait difficulties in participant’s with Parkinson’s Disease and
has shown positive benefits to patients (Perlmutter & Mink, 2006). However, both
are surgical interventions, introducing risks of infections and complications during
surgery (Perlmutter & Mink, 2006; Weaver et al., 2009). Both require training on
precautions and care of the devices. Maintenance or malfunctions require
medical attention and can be costly (Awaad et al., 2012). In addition, both lack
research documenting carry-over effects. The devices are intended for long term
use and symptoms may return when the devices are not “on” (Cooper, McIntyre,
Fernandez, & Vitek, 2013; Kern & Kumar, 2007).
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Transcranial magnetic stimulation (TMS) is gaining popularity as treatment
for depression that is unresponsive to conventional treatments; however,
limitations are inherent in this as well. Each session requires medical expertise
thereby increasing the cost. The intervention is unable to target specific, small
structures or isolate deep structures, instead stimulating large areas of the brain.
In some cases, repetitive TMS has had harmful side effects, such as seizures, in
healthy participants (Cramer et al., 2011; O'Malley, Ro, & Levin, 2006).
Cranial Nerve Non-Invasive Neuromodulation (CN-NINM), a therapeutic
intervention created in 2006 at the Tactile Communication & Neurorehabilitation
Laboratory (TCNL) at the University of Wisconsin Madison, appears to avoid the
limitations and risks of preceding techniques. CN-NINM, explained in detail
below, uses non-surgical oral electrical stimulation through a participant
controlled device paired with customized training activities, thereby avoiding the
risks associated with surgeries and medical stays and potentially reducing the
overall cost. CN-NINM requires an initial training period by a trained therapist, but
participants can use the devices independently after demonstrating a satisfactory
level of understanding of the intervention and device maintenance (TCNL, 2012).
This independence reduces the overall costs of the intervention. If a device
malfunctions, a new one can replace the old without additional therapy, training
or treatment, and requires very limited expert time or participant interaction.
Although the stimulation is provided orally and does not stimulate specific
targeted sections of the brain, the stimulation utilizes existing neural pathways,
and changes noted in previous studies appear related to the trainings activities
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provided during the studies (TCNL, 2012). CN-NINM may prime the brain for
learning and therefore specific results are targeted based on what is practiced
during the intervention. Case reports lead researchers to believe CN-NINM may
have lasting effects depending on the diagnosis and length of time using the
intervention (TCNL, personal communication, 2012-2013). These benefits make
CN-NINM a feasible complement to rehabilitation, particularly neurorehabilitation.
Cranial Nerve Non-Invasive Neuromodulation (CN-NINM)
The CN-NINM intervention and protocols were created after sensory
substitution and biofeedback studies observed improved function that was not
anticipated based on the treatment. During sensory substitution (Bach-y-Rita,
Collins, Saunders, White, & Scadden, 1969; Bach-y-Rita, Kaczmarek, Tyler, &
Garcia-Lara, 1998; Bach-y-Rita & Kercel, 2003) and electrical stimulation
biofeedback work (Barros, Bittar, & Danilov, 2010; Danilov, Tyler, Skinner, Hogle,
& Bach-y-Rita, 2007; Tyler, Danilov, & Bach-y-Rita, 2003), participants reported
improvements in sleep, vision, coordination, mood, pain, concentration, balance
and gait. These reports were not initially expected. A research team involved in
both lines of work began to explore the effect of information-free oral electrical
stimulation, (i.e. not used for sensory substitution or biofeedback) combined with
targeted training activities (TCNL, 2012).
The CN-NINM intervention has two components: 1) Targeted Training
Activity Sessions, combined simultaneously with 2) oral, electrical stimulation
provided by the Portable Neuromodulation Stimulator (PoNS™) device to create
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one CN-NINM session (See Figure 1). Each CN-NINM session is 20 minutes to
maximize learning and functional gain (TCNL, 2012). Targeted Training Activity
Figure 1: Overview of CN-NINM terms

Sessions are
individualized training
sessions specific to the
participant’s goals and
dependent on his/her
abilities and limitations
to provide the “just

right challenge” (Yerxa, 1990). For example, a participant with a balance
impairment receives customized balance trainings, often utilizing yoga balls,
balance foam, or challenging floor foot placements, depending on ability.
Previous research has studied balance and gait; initial protocols included CNNINM Sessions for balance, gait, and relaxation.
Portable Neuromodulation Stimulator (PoNS™) Device
The PoNS™ is a “T” shaped device

Figure 2: PoNS™ Device

(See Figure 2) with an oral tab slightly
larger than a quarter that rests on the
anterior third of the tongue. The device is
held lightly in place by the lips and is small
and light enough participants can complete
other tasks while using it (See Figure 3).
Participants are always in charge of the device and stimulation intensity. (For
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more detail on the PoNS™, see Appendix A.) The PoNS™ has not yet received
Food and Drug Administration (FDA) approval, but it is FDA recognized as a
nonsignificant risk device. Currently no negative
effects have been reported from using the PoNS™.

Figure 3: Participant
using the PoNS™
device during gait
CN-NINM session

The PoNS™ device provides oral stimulation
based on the documented benefits and results of
previous research (Fabien, Nicolas, Orliaguet, &
Payan, 2007; Kaczmarek, 2011; Ptito, Moesgaard,
Gjedde, & Kupers, 2005; Vuillerme & Cuisinier,
2009; Wildenberg, Tyler, Danilov, Kaczmarek, &
Meyerand, 2010). In addition, the tongue provides
access to branches of the trigeminal and facial
cranial nerves (CN V and VII, respectively). The cranial nerves provide a
figurative freeway into the brain and intersect the central nervous system in
centers in the brainstem responsible for sensory integration and movement
coordination (Twenty Eleven Theme, 2011).
Prior CN-NINM Research
CN-NINM has been tested in small studies across multiple diagnostic
groups with balance and gait deficits. None of these studies have been published
yet. All studies have had positive results. Individuals with chronic balance
dysfunctions and TBIs demonstrated large, fast improvements in balance and
gait tasks. Individuals with Multiple Sclerosis (MS) experienced gains in balance
and gait tasks that took longer to observe. Although there have been randomized
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controlled trials, much of CN-NINM research is still exploratory (TCNL, personal
communication, 2012-2013). Preliminary descriptive research is appropriate and
informative for the design of later studies (Portney & Watkins, 2009). No journal
articles have been published yet directly on the CN-NINM intervention. The
following is a brief summary of three areas of study from prior research.
1. Chronic Balance Dysfunction
To better understand the changes in the brain, fMRI studies looked at the
nine participants with chronic balance dysfunctions before and after 19 CN-NINM
balance sessions. fMRI scans showed activations in the right vestibular nucleus,
right superior colliculus, and multiple cerebellar structures. After the CN-NINM
intervention, the right trigeminal nucleus, the origin site for neuromodulation in
behavioral and subjective measures improvement, showed increased responses
(Wildenberg, Tyler, Danilov, Kaczmarek, & Meyerand, 2011). After prolonged
activation, the circuits can undergo neuronal reorganization, thus leading to an
increased ability to learn or relearn tasks and demonstrating the brain’s plasticity,
which is also known to occur in the absence of neuromodulation.
Balance testing was also evaluated before and after the CN-NINM
balance sessions. Seven participants had an improvement on the Sensory
Organization Test (SOT) scores. Scores increased an average of 15.75 points
(SE=5.59, p=0.026, paired Student’s t-test) (Wildenberg et al., 2011) with
changes greater than 8 points indicating a true change (Wrisley et al., 2007).
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2. Multiple Sclerosis
During a two week, ten person pilot study on Multiple Sclerosis (MS), all
ten participants showed clinically significant improvements on the Dynamic Gait
Index (DGI), a clinical measure of functional gait quality (Huang et al., 2011).
However, eight participants’ functional levels returned to baseline after the study.
After receiving additional funding, the participants were able to participate in a
longitudinal study, and all the participants regained the improvements they had
lost (Tyler, 2010).
Danilov and colleagues (N.D.) studied balance and gait changes from CNNINM in a randomized controlled trial with twenty participants with MS randomly
assigned to either the control or active group. The study consisted of an initial
assessment of the DGI, two weeks of laboratory training followed by 12 weeks
completed independently in the participant’s home and additional DGI
assessments at week 2, 6, 10 and 14. Each group received training activities to
complete, the control group received a PoNS™ device that provide stimulation
too light to detect and the active group received a PoNS™ device that provided
detectable stimulation controllable by the participant. All participants completed
the study. By the end of the two week laboratory training, the experimental group
reached twice the improvement on the DGI than the control group. At 10- and 14week assessments, the difference between groups was statistically significant. At
the 10 week assessment, the active group reached 80% improvement; the
control group reached 40% improvement. This is a difference of four points of
improvement on the raw score. Scores for the active group improved slightly at
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week 14 and decreased for the control group. Analysis of the groups showed the
only difference in group demographics was the length of time since diagnosis of
MS; the experimental group generally had a longer time since diagnosis.
Typically, a longer time would suggest poorer functioning, however, in this study,
the participants performed significantly better on the DGI (Danilov et al., N.D.).
3. Traumatic Brain Injury Case Studies
Two individuals with TBIs greater than 5 years prior used the CN-NINM
intervention in a pilot study. Both had had concussive, non-penetrating injuries.
Participants completed a 2-week protocol, five days per week. The DGI and SOT
were assessed before and after the 2-week session. Each participant had
clinically improved scores on both, with DGI scores improving from 10 to 24 for
one participant and 9 to 23 for the other. SOT composite scores increased from
55 to 77 and from 41 to 88. In addition, the participants reported improved
memory and mood elevation (Danilov et al., 2013).
Both participants saw improvements from the CN-NINM intervention very
quickly. Researchers believe the otherwise unprecedented speed in the changes
may be because a TBI is a one-time, external injury rather than progressive
disorder. The participants noted improvements in gait quality, increased ability to
multitask such as walking and looking, and improved balance, and reduced pain,
among other improvements. After the initial study, one participant’s device broke,
causing a circumstantial withdrawal phase. Researchers noted a decrease in
function almost back to her baseline that was evident within days (TCNL,
personal communication, 2012).
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CN-NINM Theory
The CN-NINM intervention was initially discovered as a result of numerous
observations of functional improvements while using oral electrical stimulation for
other purposes such as sensory substitution. However, the neurological basis of
how the intervention works is not yet thoroughly understood. Studies that have
examined the effects of CN-NINM have been of case study format and focus
primarily on observing functional changes in participants. These small studies
have included several diagnostic categories to determine which types of
individuals may receive the most benefit. No published research has been
completed to understand the biological or neurological changes. The two fMRI
case studies previously mentioned again provide some general conceptual
support, but are not conclusive.
CN-NINM investigators believe that the large amounts of constant
stimulation to the brain from the PoNS™ device floods the brain and primes it for
learning. The priming effect makes the training activities particularly important to
maximize the learning of intended tasks. In the fMRI case studies, the stimulation
particularly appeared to affect the brainstem and cerebellum as the cranial
nerves conducting the stimulation lead directly into the brainstem. Moreover, this
form of nervous system stimulation uses naturally existing neural pathways as
opposed to providing external stimulation to large areas of tissue (such as in
TMS). The sensory input travels along the internal cranial nerves so is exactly
targeted as input to the brain through normal nerve physiology. This contrasts the
more artificially injected stimulation provided directly to the brain without normal
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nerve and brainstem mediation. Affected centers appear to be those responsible
for movement coordination and sensory integration which is likely a component
of why balance and gait improvements have been noted in many participants.
As the stimulation follows normal pathways, it also may influence the rest
of the brain through its network of normal interconnections both synaptic and
extrasynpatic circuitries (again with the stimulation from “the inside out”, not
“outside in”). Because of the extensive amount of stimulation and the brain’s
neuroplasticity, the information processing and connections for functional tasks
increase in efficiency and effectiveness (personal communication, TCNL, 201213, unpublished manuscripts, 2013). Additional research is required to fully
understand the neurological changes related to the CN-NINM intervention.
Traumatic Brain Injuries
Individuals with TBIs often experience permanent gait impairments. Gait
abnormalities common after TBIs, changes in step lengths and stance times on
affected limbs and slow gait, may contribute to an increased risks of falls and
reinjury as well as limited community access (Williams, Morris, Schache, &
McCrory, 2009). In addition to gait changes, many individuals note increased
impulsivity, decreased problem solving, and reduced ability to multitask
(McCulloch, Buxton, Hackney, & Lowers, 2010). These impairments amplify the
physical limitations and would be expected to further increase the risk of reinjury.
The lasting impairments are particularly significant when considering the
scope and cost of TBIs. At least 1.7 million people are affected by a TBI in the
United States each year (CDC, 2010). A 2000 CDC report estimated the total
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cost of mild TBIs was $12 billion; each person with a severe TBI costs between
$600,000 and $1,870,000 in his or her lifetime (CDC, N.D.; Rezai & Corrigan,
N.D.). Traumatic brain injuries are a large scale, expensive problem causing
permanent disabilities or reductions in function. Currently rehabilitation does not
have a practical, effective solution for addressing most lasting TBI effects.
The study described in this paper used participants with TBIs to determine
if quick effects and withdrawal effects of CN-NINM could be detected. This paper
describes the first study to systematically document a withdrawal phase.
Research Questions
The research team was interested in several aspects of the CN-NINM
intervention. This research is exploratory and attempts to observe effects and
side effects of CN-NINM and to observe and measure changes it may produce or
augment in a person with a TBI. Since withdrawal effects from the CN-NINM
intervention are potentially possible, this study chose to include a formal
withdrawal phase. Research questions included asking how long it would take to
see results, how long the results would last, and how long any improvements
would last after ceasing the intervention. The research team developed four
hypotheses: 1) Participants’ functional gait quality will increase during each
intervention week. 2) Participants’ confidence with gait tasks will increase during
each intervention week. 3) Participants’ functional gait quality will decrease
during each withdrawal week. 4) Participants’ confidence with gait tasks will
decrease slightly during each withdrawal week.
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Methods
Research Design and Participant
This single case study implemented a classical A-B-A-B-A experimental
design with five day phases, Monday-Friday. The participant, referred to as DS,
was an individual with a TBI 27 years prior secondary to a motor vehicle accident
that resulted in a severe TBI requiring approximately a year of rehabilitation
training, and multiple, lasting orthopedic injuries. Because of these injuries, DS
used a left Ankle Foot Orthosis (AFO), had a flat, metal plate for support in his
right shoe, and had a cane he could use if he felt unstable or was walking long
distances. DS works full-time in the community.
For the past 21 years, DS has been going to a local fitness center each
weekday morning to stretch his heel cords and routinely exercise his upper body.
He reported avoiding substantial physical activity involving balance or his lower
extremities because that type of increased activity caused pain in his lower
extremity and lower back and increased spasticity. He reported he has avoided
using treadmills since 1992 as he did not feel safe using them. DS had been
receiving Botox injections in his left lower extremity for two and a half years prior
to the study to reduce pain, tone and improve the fit of his AFO.
Inclusion and Exclusion Criteria
DS lived in the community, was not receiving any rehabilitation services,
and self-identified as having a balance and gait impairment caused by his brain
injury. He did not use tobacco products. DS did not have a contagious mouth
disease, an electrical device/implant such as a pacemaker, nor a major change
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in medication type or dosage within three months of enrollment. Participants had
to be very motivated, as the study used an intensive, five-week protocol which
required significant time and physical and mental effort.
Instrumentation
Seven standardized measures were used during this study. Two
balance/gait assessments were used in their entirety, components of two
functional gait assessments were used, and three self-report assessments. Two
self-report assessments, the Community Integration Questionnaire and
Participation Objective, Participation Subjective, were collected to evaluate
changes over a longitudinal study and will not be discussed in this paper. The
remaining assessments are listed in the order completed.
Timed Up and Go
The Timed Up and Go (TUG) assesses a participant’s speed rising from a
chair, walking 3 meters, turning, returning to the chair and sitting (Podsiadlo &
Richardson, 1991). The primary researcher recorded the time to complete the
task; qualitative information was not used. Shorter times indicate better
performance. A study of community dwelling adults found cut-off scores to be
times below 13.5 seconds for risk of falls (Shumway-Cook, Brauer, & Woollacott,
2000). The Timed Up and Go has not been extensively tested for populations
with TBIs. However, a study of children with TBI found excellent test retest
reliability (ICC= .86) (Katz-Leurer, Rotem, Lewitus, Keren, & Meyer, 2008).

25
Romberg and Sharpened Romberg Test
The Romberg and Sharpened
Romberg tests assessed the participant’s
balance with and without vision.

Figure 4:
Romberg
Stance

Figure 5:
Sharpened
Romberg
Stance

Participants complete the Romberg with
their feet together (see Figure 4) and
Sharpened Romberg (see Figure 5) in a
tandem stance. The participant has up to
three trials to stand for a maximum of 60
seconds in each condition; longer times
indicate better performance (Callegari,
2009). The Romberg and Sharpened
Romberg have not been normed for TBI.
Minimal detectable change scores with a confidence interval of 95% for the
Sharpened Romberg with eyes closed ranged from 3-9 seconds and with eyes
open ranged from 9-10 seconds. Test retest reliability values (ICC) for volunteers
aged 55-75 years old were 0.72 and 0.76 for eyes closed and 0.90 with eyes
open (Steffen & Seney, 2008).
Dynamic Gait Index
The DGI assesses functional gait tasks on a 4 point scale (0-3). Higher
scores indicate better performance. Four components from the DGI were used
for this study. The tasks were: 1) Gait with horizontal head turns, 2) Gait with
vertical head turns, 3) Step over an obstacle (See Figure 6), and 4) Step around
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obstacles. Normative data for people in the
same age bracket as DS includes a mean

Figure 6: Participant
completing the DGI task
“Step over an Obstacle”

score of 23.9 with a range of 22-24 and a
standard deviation of 0.4 (Vereeck, Wuyts,
Truijen, & Heyning, 2008).
Community Balance and Mobility
Scale
The Community Balance and Mobility
(CB&M) Scale was created for high
functioning, community dwelling patients after
a TBI to assess lasting effects in functional
gait and balance tasks using a 6 point scale
(0-5). Higher scores indicate better performance. The minimal detectable
change, determined by using a 90% confidence interval, was 8 points (Howe,
Inness, & Wright, 2011). Overall the CB&M Scale has high reliability for intra-,
inter- and test-retest reliability with intraclass correlation coefficients of 0.977,
0.977, and 0.898-0.975 (for immediate and 5 days later test-retest), respectively.
A Cronbach’s alpha for internal consistency was 0.96 and 0.95, indicating a high
correlation among items. All but one task met a priori inclusion criteria for content
validity when scored by a focus group of physical therapists. (Howe, Inness,
Venturini, Williams, & Verrier, 2006). Importantly, it correlates well with
community integration scores (Howe & Inness, 2011).
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This study completed the following 5 of 13 tasks: 1) Unilateral Stance (on
right and left foot, timed), 2) Tandem Walking, 3) Crouch and Walk (timed), 4)
Forward to Backward Walking (timed),
5) Step ups onto a single stair

Figure 7: Participant completing
CB&M Scale task “Step- Ups”

(beginning with right foot and left foot,
timed; see Figure 7). The reliability and
validity scores described are for the
assessment completed in its entirety
and may not be accurate for the
components used in this study. The
entire assessment was not completed
as several tasks caused the participant pain; this is described in detail in the
Procedure section below.
Modified Gait Efficacy Scale
The Gait Efficacy Scale assesses self-reported confidence completing
common daily activities. A 2011 modified Gait Efficacy Scale (mGES) added
tasks commonly experienced in daily activities. The mGES has a test retest
reliability ICC of .93 (CI 0.85-0.97) after one month with a Cronbach’s alpha of
0.94 (Newell, VanSwearingen, Hile, & Brach, 2012). The 10 item scale uses a 10
point Likert-like rating scale (1-10). Higher scores indicate more confidence with
the task; a change of 6 points indicates a “true” change in confidence (Newell et
al., 2012). The mGES was not normed for participants with TBIs and the
assessment was modified further for the current study (GES-m) to include two
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additional tasks that may be difficult for individuals with a TBI. The tasks assess
confidence walking in a crowd and walking down aisles. (See Appendix B for the
GES-m.)
Procedure
This study based its protocol on similar protocols established at TCNL
where the primary researcher received training. The protocol was an intensive,
five-week protocol with daily visits and twice daily visits during intervention
weeks. After receiving approval through the University of Wisconsin Milwaukee’s
Institutional Review Board, participants were recruited primarily at local TBI
support groups. Three participants completed a phone screening. One participant
(DS) was eligible for and completed the study. Prior to beginning data collection,
DS met with the primary researcher to review and sign the informed consent. DS
then completed the POPS, CIQ, GES-m, and CB&M Scale. Per the protocol, the
data from this day would be thrown out and the day was intended to familiarize
DS with the assessments to eliminate a one time learning effect due to comfort
with the assessments and anticipation of questions.
During the completion of seven components of the CB&M Scale, DS
experienced pain in his lower back and left lower extremity that persisted
approximately 48 hours. The pain appeared to be musculoskeletal and caused
by his orthopedic injuries and avoidance of these tasks for the previous 20 years.
After further discussion, he expressed interest in continuing the study with the
tasks that did not cause pain, thus the addition of the TUG, Romberg, Sharpened
Romberg, and tasks from the DGI. These tasks were chosen to assess similar
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constructs as the CB&M Scale in a graded manner to eliminate the pain
experienced.
Weeks 1, 3, & 5: Baseline and Withdrawal Weeks
During non-intervention weeks, DS completed the balance and gait tasks
each afternoon (Monday-Friday) and the self-report scales on Friday afternoon
after the gait tasks. He returned the PoNS™ device during withdrawal weeks,
and was encouraged to try to maintain his same routine as prior to the study, not
continuing to complete the training activities he learned. The researcher
encouraged DS to complete subjective, unstructured journaling throughout the
study regarding his experiences, any changes he noted, and what he attributed
the changes to. Each day the participant and researcher discussed any changes
or questions he had. These activities remained consistent during intervention
weeks as well.
Weeks 2 and 4: Intervention
During intervention weeks, DS completed two Intervention Sessions, one
in the morning and one in the afternoon. The afternoon session was completed
after finishing the same tasks as the baseline week. Each Intervention Session
included three CN-NINM sessions; each CN-NINM session includes a 20-minute
personalized Targeted Training Activity Session and concurrent use of the
PoNS™ device. The CN-NINM sessions consisted of balance, relaxation, and
gait training sessions. Balance trainings consisted of static standing on foam
balance pads or sitting on a yoga ball with eyes closed. Relaxation trainings,
completed between the other sessions, did not use the PoNS™ device. The
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sessions focused on body and breathing awareness during quiet sitting to reduce
distractibility and improve focus and attention to task. DS initially completed gait
training sessions on a treadmill, expanding to over-ground walking to integrate
skills mastered on the treadmill. Gait tasks included maintaining upright posture
in the middle of the treadmill, reducing instances of toe drag, initiating reciprocal
arm swing, taking even step lengths etc...
On the first day of Week 2, the participant was provided with a PoNS™
device and educated on the use and care of the device. He explored the device
and discussed questions with the researcher until he expressed a high comfort
level with the device, stimulation, and maintenance.
DS completed two additional CN-NINM sessions at home each day.
These sessions involved similar activities as what was practiced during the day
but with less intensity to ensure participant safety. Example sessions included
using the PoNS™ when stretching his left heel cord and walking over ground as
well as while completing standing balance tasks at the kitchen sink.
Subjective Reports
During each Intervention Session, the primary researcher documented
observations and changes noted and reported. During withdrawal weeks, the
primary researcher documented observations and changes once each day. Selfreported changes were obtained from the ten single spaced typed notes pages
and are included if they were reported more than once.
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Data Analyses
All assessments were videotaped for later analysis. The primary
researcher recorded times for the time-based assessments. Data were graphed
using Excel. Comparisons across phases were evaluated and analyzed using a
combination of visual and statistical methods. Visual analyses included trend,
level, variability, and immediacy of effect. Statistical analyses used percentages
of data overlap including percentage of non-overlapping data (PND), percentage
exceeding the mean (PEAv) and median (PEM), and pairwise data overlap
(PDO).
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Results
Results are described in terms of: 1) timed scores, 2) data rated by trained
assessors, 3) self-report scale responses, and 4) self-reported changes.
One of the study’s hypotheses was that there would be a difference in
functional gait between intervention and withdrawal weeks. This was not
consistently supported by any of the measures. A second hypothesis indicated
that gait confidence would also change during intervention and withdrawal
weeks. Several of the participant’s confidence scores support this hypothesis.
To analyze results, 35 graphs were created and analyzed (see Appendix
C). Each graph was analyzed within and across adjacent and like phases. 16
graphs visually supported the hypotheses at least mildly. However, most of these
provided mild support of the hypotheses; some lightly trended toward expected
results. It is not clear that the changes are stably greater than minimal detectable
change values for the measures applied. The graphs depicted in this section are
representative samples from the full set of graphs to highlight results.
1) Timed Scores
Timed scores included the Timed Up and Go, Romberg, and Sharpened
Romberg, not the timed components of the CB&M Scale.
Timed Up and Go Scores
Each trial time was below the 13.5 seconds cut-off time for fall risk in
community dwelling adults (Shumway-Cook et al., 2000) indicating DS was a low
fall risk according to the Timed Up and Go. DS’s scores remained fairly stable,
with a slight trend toward decreasing times across the study. The only phases
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with significantly different times was between the baseline and first intervention
phase, with 96% of data being outside the PDO and 100% of data points being
different than the PEM and PEAv.
Romberg and Sharpened Romberg Scores
The participant reached 60 seconds, the maximum time for the Romberg
Test, on each trial during each phase both with eyes open and eyes closed.
Since no change was evident, the Romberg will not be discussed further.
Traditionally, Romberg and Sharpened Romberg scores are evaluated
using the best time from the three trials. Figure 8 shows the best time for the
Sharpened Romberg scores with eyes open. Between both the first intervention
and first withdrawal and the first withdrawal and second intervention there was
80% PDO. Between the first intervention and first withdrawal there was an 80%
difference in the PEM,
PEAv, and PND as well as

Figure 8: Sharpened Romberg Best Time with
Eyes Open
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but 100% PEM and PEAv.
Eyes closed Sharpened Romberg scores were evaluated three ways due
to each phase’s increased variability when using the best time scores. Graphs
were: 1) best time (see Figure 9), 2) average time, and 3) all raw data points (see

34
Figure 10). The most notable changes in scores occurred between the baseline
and first intervention phase with 60% PEM and PEAv. The final three phases
show a substantial amount of variability in scores in each phase.
Figure 9: Best time on
Sharpened Romberg with eyes
closed

Figure 10: All scores from the Sharpened
Romberg with eyes closed
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2) Data rated by trained assessors
Two raters were trained together on the DGI and CB&M Scale. Rater 1
was unfamiliar with the study design and scored all data from the participant;
Rater 2 scored 40% of the data (10 out of 25 days). Both used randomly ordered
videotapes when scoring the data. Inter-rater reliability was analyzed using SPSS
(SPSS Version 19). Data was ran as a two way random test. The Intraclass
Correlation Coefficient (ICC) for the average measures of the DGI was .731
(which matched the Cronbach’s Alpha). The ICC for the average measures of the
CB&M Scale was .798 (which also matched the Cronbach’s Alpha).
Each task of the assessments was graphed separately based on the
scores provided by Rater 1. The total score was then determined for both the
DGI and CB&M Scale by adding the component scores for each day.
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Dynamic Gait Index Scores
Total DGI scores data display a slight increasing trend across each phase
(see Figure 11); no decrease in scores was noted during withdrawal weeks.
No significant

Figure 11: Dynamic Gait Index Combined Scores
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looked similar to the
combined scores (the fourth showed no change due to a ceiling effect). Graphs
of individual tasks showed variability similar to the combined scores.
Community Balance & Mobility Scale Scores
The total CB&M Scale scores display a stable/slightly increasing trend
across phases. No decrease in scores is noted during withdrawal weeks.
Substantial differences were noted between the baseline and first intervention
week, with 100% PEM and PEAv, and 80% PDO. However, because the
baseline trend is steadily increasing and there is not a change in the intervention
week level, these differences may not indicate a change in function.
Four of the seven CB&M Scale task graphs showed similar trends as the
combined score graphs. Three of the component tasks showed no change over
the study. Unilateral stance while standing on his left foot showed a floor effect,
only scoring one point out of five on two days of the study. Step-ups onto and off
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a single step also showed no change throughout the study, scoring a “3” each
day except one when initiating with the right and left foot.
3) Modified Gait Efficacy Scale
Self-report scores were collected once per phase. Graphs were made for
each question as well as the average score. Self-reported confidence in the final
phase was not less than the first phase for any question. Typically, the individual
graphs showed an increase in confidence during one or both intervention weeks,
some decrease in confidence during the first withdrawal week, and either stable
or increasing confidence during the final withdrawal week (see Figure 12). Two
graphs did not fit this pattern, including confidence going down stairs not holding
onto a railing and confidence
walking long distances. On each

Figure 12: Confidence Walking on Grass
Q2: Confidence Walking on Grass
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greater than initial confidence.
4) Self-Reported Observations
Throughout the study, DS remarked through journaling and to the primary
researcher on several changes he attributed to the intervention that were not
measured by assessments during the study. Key observations are listed below.
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•

A reduction in tone of his left lower extremity allowing his AFO to fit more
securely. This was noted to the researcher on the afternoon visit of the first
day of the intervention and often repeated during both intervention weeks.

•

An increased tolerance for exercise without negative consequences such
as pain or unsafe movements. Although DS was initially skeptical of his
ability to complete 20 minutes of gait training on a treadmill, he began
remarking by the middle of the first intervention week that he felt very good
after the treadmill activities and wanted to keep walking.

•

An increase in confidence in his walking abilities. Because his AFO fit
better, DS felt more confident in the AFO supporting his foot and therefore his
walking ability. He noted he had better toe clearance and tripped less during
the day. DS also noted at the end of the first intervention week and several
times during the second intervention week that his walking had not felt so
“good” since his injury. He indicated being interested in going for long walks
and being more physically active because of this new positive feeling he
experienced when walking during and after the gait training sessions.

•

A reduction in and elimination of pain. DS indicated when he “overdoes”
physical activity, he experiences pain in his left lower extremity, particularly in
his foot. By the middle of the first intervention week, he indicated he was not
experiencing pain with increased physical activity. By the end of the second
week of intervention, he had a reduction in overall pain, elimination of pain
from activities that previously would have caused pain, and a significant
reduction in pain duration when he did feel pain related to physical activity.
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•

In addition to balance and gait changes, DS also indicated that he used his
left arm/hand more frequently and with less feelings of awkwardness.
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Discussion
DS reported several changes over the course of the study, but they were
not confirmed by the a priori chosen assessment measures. Nonetheless, the
results are informative to researchers and clinicians planning future CN-NINM
research or treatment. The primary researcher believes less change was evident
during the videotaped assessments than normal walking; this difference may be
attributed to the short duration of the assessment tasks and/or the attention and
focus provided for the assessment tasks. Consistent across all phases, the
participant’s gait looked substantially different when walking to and from locations
and while talking to the researcher than it did during the taped assessments.
Overall results on the assessment measures showed slight trends toward
improvement on balance and gait tasks. Several factors could influence this
finding. It is possible the intervention facilitated greater learning of the training
tasks. Some improvement would be expected from the training even without the
PoNS™ device. It was hypothesized that participant scores would decrease
during the withdrawal. This was not the case. It is very possible that the new
skills were learned and integrated during the intervention phases and therefore
not able to be withdrawn. Although a learning effect is likely, the tasks used were
chosen for their functional implications; tasks were common daily activities, like
walking and looking vertically or horizontally, or picking an object up off the floor.
1) Timed Scores
The Timed Up and Go data were all within the accepted range for
community dwelling adults, therefore, any differences noted are not as
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meaningful. Sharpened Romberg with eyes closed scores showed a great deal of
variability. Reasons for the variability may be related to DS’s attention and focus
on the task. He found it difficult to attend to tasks without becoming distracted. It
is also possible his orthopedic injuries and compensation strategies may have
influenced his scores. Much of the variability is not accounted for on this task.
2) Data rated by trained assessors
Neither the DGI nor CB&M Scale showed significant change in the DS’s
function during the study. One rater observed changes in DS’s function that were
not reflected in the scores due to the assessment criteria. For example, to pick
up an object from the ground, DS typically stopped walking and went down onto
his right knee. Several days he paused, lowered his knee, but did not touch his
knee to the floor or use the floor to push himself up. However, because forward
momentum was stopped, the days were scored the same. Similarly, during a
forward to backward walking task, the rater noted DS usually took four steps to
turn, securing a consistent test score, although the quality of the backward
walking showed changes. These observations indicate the assessments may not
have been sensitive enough or appropriate to detect the changes.
3) Self-Report Scale Responses
Scores on the GES-m followed trends similar to those hypothesized. The
differences observed did not reach the level set to determine a true change in
confidence. Decreases in confidence, particularly at the first withdrawal week
may be due to DS’s greater awareness of his gait deviations. DS remarked
several times during the intervention weeks that he believed his gait to be
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significantly better than it had been in years or possibly since the injury. During
the first withdrawal week, the participant noted several negative aspects
returning. When his gait felt worse, due to factors like the return of high tone, DS
was more observant about his strategies to work around his limitations, such as
hip-hiking to provide greater toe clearance rather than increasing hip and knee
flexion. The increase or maintenance of confidence during the second withdrawal
phase may be attributed to increased exposure to many of the GES-m tasks
during gait trainings like walking outside on grass and walking long distances.
4) Self-Reported Observations
The self-reported observations include observations from the participant
and primary researcher and are discussed separately below.
Participant Observations
DS attributed several changes to the CN-NINM intervention including a
reduction in tone, which returned during the withdrawal weeks, a reduction in
pain, which came back to a degree during the withdrawal weeks, and a more
natural feeling gait, which returned to baseline during withdrawal weeks. During
the first withdrawal week, DS indicated not being sure if he was functioning
worse than he had prior to the study, or if he were simply more aware of his
limitations and maladaptive behaviors. By the 3rd day of the intervention (out of
ten total intervention days), DS remarked he considered the study a success.
Prior to the study, DS could participate in physical activity for limited
amounts of time without developing pain in his left foot. While using the device,
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he was able to complete 20 minutes of strenuous activity for the participant on
the treadmill without having pain or feeling “tight” or poor after the activity.
Researcher Observations
Several observations about DS’s changes were made by the primary
researcher. During initial treadmill gait trainings, DS needed maximum cueing to
stay in the center of the treadmill. By the second day of the intervention, he
required minimum cueing to stay in the center. Several tasks were mastered with
similar speed, including reducing the number of times his left foot did not clear on
the swing thru. This was addressed the first two days of the intervention, then
integrated into remaining treadmill and over-ground walking with the researcher.
In addition to improvements during training sessions, the researcher noted
a slight change in gait when walking within the testing site. Particularly during the
second intervention week, DS appeared to integrate training tasks well. He took
more even step lengths, occasionally integrated unconscious, slight left arm
swing, and did not twist his body as greatly to walk leading with his right side.
On the first day before the protocol began, 7 out of 13 CB&M Scale tasks
caused the participant significant, lasting pain. On the last day of the second
intervention week, after the regular assessments, the researcher asked DS if he
wanted to try the whole CB&M Scale. He agreed and was able to complete six of
the seven tasks pain-free. The primary researcher noted that the tasks on the
first day looked uncontrolled, unsafe, and impulsive. On the last intervention day,
the tasks looked safe and more controlled. Although decrements in quality were
still noted, the researcher did not have to stabilize DS during any of the tasks nor
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was the researcher concerned for his safety. The only task he did not feel
comfortable trying was running, which he attributes to his orthopedic injuries.
Monthly Follow-up
If participants experienced positive functional changes, researchers did
not want to remove the PoNS™ device and potentially lose any functional gain.
DS accepted the opportunity to participate in up to a three-year longitudinal
study, with the option to drop out whenever he no longer wanted to use the
PoNS™. The longitudinal study includes monthly contact (phone or email) and
an in-person visit every 6 months to complete the assessments that were used
throughout the study. In the meantime, DS uses the device independently and
records the number of times each day he uses the device.
In the four months since the first study ended, DS made five key
observations. 1) His tone continues to be reduced. He is able to achieve a quality
stretch and his AFO continues to feel like it is fitting well. 2) His left hand
continues to feel more natural to use, although it requires additional conscious
thought, and he is crossing midline with his right hand less. 3) He is able to
complete more physical activity with less pain. He has started to use the treadmill
when exercising, increasing both speed and incline. He noted being overall pain
free since using the PoNS™ device, and when he did experience pain, the pain
had reduced duration. 4) DS mentioned several times during the study his
interest in volunteering more. Since the study ended, he began three new
volunteer opportunities and was maintaining two at last discussion. 5) Perhaps
the largest indicator of change since the study is that the participant cancelled his
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upcoming Botox injection for the left lower extremity. He indicated that his leg
feels as good as it did before he began Botox injections. He indicated preferring
an intervention that did not include injecting himself with chemicals.
Limitations
Four limitations to this study were identified. First, only one participant was
eligible for and completed the study. Although the study provides valuable
information regarding his experience, results and conclusions from this study are
not generalizable to a larger population. Second, participant was not an ideal
candidate because of his orthopedic injuries, presentation of symptoms and
strong compensation strategies that may have limited progress. Compensation
strategies included taking large left steps for greater heel strike, hip-hiking to
achieve toe clearance, and putting his right knee on the ground to pick up an
object from the floor. Participants with vestibular impairments may observe more
significant benefit from the intervention, although more research is required.
Third, the primary researcher completed the intervention and data
collection and neither the primary researcher or participant was blinded to the
study. As subjective outcomes can be influenced without blinding, the primary
researcher was cognizant of what she said and to follow established protocols.
Another attempt to reduce bias was the use of randomized video assessments
scored by reviewers unfamiliar with the study. Last, the measures selected,
though sensitive to small changes, may not have been sensitive enough or
appropriate to detect observed changes. However, the changes were reported
and some of the measures showed trends similar to the observations noted.
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Implications for Occupational Therapy
CN-NINM shows promise as a technology based rehabilitation
intervention. The positive changes DS noted after the first intervention session
had significant implications on his motivation to continue the protocols. With
additional research, CN-NINM may facilitate greater gains in rehabilitation. Once
trained, participants can use the CN-NINM intervention independently, which
may allow patients to master skills more quickly and integrate more skills
independently so each session with an occupational therapist can focus on
learning new skills or integrating and mastering more complex skills.
In this study, DS noted a decrease in tone and pain. As both can be
severe limitations to occupational therapy, reduction in both can of great benefit
for rehabilitation. Often a therapist must manage pain and tone prior to
addressing other aspects of function. It is also becoming more popular to look for
alternative treatment options to pharmaceuticals; the CN-NINM intervention
provides an option for a non-invasive option that does not rely on medications.
Future Research
Future research could address several areas of study. Additional
participants with TBI should be studied to determine the type of participants that
may benefit most from the intervention. Future participants with TBI may include
those with vestibular impairments and not those with tone. Studies should include
longer phases to determine if phase lengths correlate to the intensity of changes.
Studies should include a formal withdrawal period to determine any carry-over
effects. Future studies may also test whether the device increases rapidity of
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learning or level of performance. Last, additional research should study the
effectiveness of home programs to reduce the time commitment for researchers
and increase the feasibility of the study for participants.
Conclusions
Changes were observed in the participant’s functioning, even though the
assessment scores did not show a significant difference. Two changes were
noted. First, DS indicated an almost immediate change in the tone of his left
lower extremity, mentioning this change before the second intervention session
on the first day. He indicated being pleased with the changes and that the
intervention did not use medications. Second, DS reported decreased pain as
well as reduced the duration of pain when pain was experienced.
The intervention was clearly acceptable to the client, preferred to
pharmacologic interventions, and potentially practical because it does not require
constant direct supervision, is not expensive, and appears to lack negative side
effects. The CN-NINM intervention warrants additional research.
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Supplement:

Investigation of Brain Plasticity in Response
to Noninvasive Neuromodulation
I. Description of the Portable Neuromodulation Stimulator (PoNS)

The 'PoNSTM' system (ver. 2.0) has operational limits of 19 V (max) and 6 mA (nominally) on the
tongue. The biphasic waveform is specifically designed to ensure zero net direct current to minimize
the potential for tissue irritation. The system delivers triplets of pulses at 5 ms intervals (i.e. 200 Hz)
every 20 ms (50 Hz) to a hexagonally patterned array of gold electroplated circular electrodes created
by a photolithographic process used to make printed circuit boards. While the voltage and pulse timing
to each electrode is programmed in the device and cannot be altered, the subject can adjust the pulsewidth (0.4 - 60 µs) by manipulating a pair of push buttons to directly control the stimulus intensity. At
any instant in time, only one of the electrodes in each of the 16 sectors on the array is delivering
stimulation. The remaining electrodes serve as the current return path to ground. Additionally, the
stimulus intensity is mapped uniquely to each region of the tongue to insure that the perceived
sensation is uniform across the entire array. This form of tongue stimulation has been used in our
research for the last 13 years under multiple UW Health Sciences -IRB protocols for studies in balance,
vision, and speech substitution (H2000-527, H2001-364, H2004-0375, H2000-0192, H2005-0222,
H2007-0251), and for neuromodulation (H2008-0057, H2008-0252), with no adverse events [1-4].

Figure 1. Image of the PoNS_v2.0 device.
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Physically, the 32 mm wide by 0.84 mm thick oral tab is designed to fit into the upper cavity of the
mouth, and contains the tongue stimulation array of 143 electrodes (1.50 mm diam., on 2.34 mm
centers). The case of the T-shaped PoNS device measures 68 mm wide x 45 mm long x 15 mm thick,
with a total mass of 56 gm1. The user has complete control of the device, which has waterproof case,
power and intensity control buttons, and status indicator lights (see Figure 1).
The PoNS fabrication is based on Class-II medical device design principles. It is powered by a
rechargeable lithium-ion battery with built-in current-protection circuitry. Both the charging circuitry
and the power connector are specifically designed to prevent device use while it is being charged,
thereby preventing the possibility of electrical shock. An FDA approved USP Class VI biocompatible
polymer is used to encapsulate the tab (excluding the electrodes) prevent saliva from harming the
electronics. Array cleaning is accomplished with commercially available isopropyl alcohol.
II. Device Operation.

Procedurally, for each CN-NINM training session, subjects place the end of the tab containing the
electrode array approximately 45 mm into the mouth so that it contacts the superior anterior surface of
the tongue. The tab is held lightly in place by the lips and teeth. During CN-NINM training the
recommended stimulation intensity, Se, for each subject is defined as: Se = Ss + k[Sm – Ss], where Ss
and Sm are the minimum threshold and maximum-comfortable sensation levels, respectively, and k =
0.3 - 0.7, i.e. the recommended intensity level is between 30% and 70% of the usable sensation range.
If at any time the subject wants to stop the stimulation they may press the "Down" intensity control,
press the "Off" button, or simply remove the device from their mouth.
Controls and features
•

Power: "On" and "Off" pushbuttons. The device will remain on until "Off" is pressed or the battery
is exhausted. The device will automatically shutoff when plugged into the charger.

•

Intensity: “Up” button increases intensity, “Down” button decreases intensity. The buttons can
either be used by individual presses, or held down to adjust intensity levels. To achieve the
maximum intensity 63 individual presses are required, or the button can be held down for 8
seconds. Note: When the device turns on, it automatically starts at the lowest possible intensity,
and the step sizes increase uniquely. The user may not experience desired stimulation levels until
they reach the upper end of the intensity spectrum.
Charge indicators: The lights surrounding the OFF button indicate charge status. Red means
charging, green means charge is complete. The device can be used before charge is complete, but
with reduced operating time.
Operating indicators: The lights surrounding the ON button indicate battery status during operation.
Green means normal operation. Yellow indicates the battery is low, but the device is still operating
within specifications. When the battery charge is too low the device will turn off automatically.
Charger jack: Connect only the supplied charger to this jack. Use of any other charger may damage
the device or the charger. When charging, the red charge light will turn on. When fully charged the
green charge complete light will come on. For safety, the device cannot be used while charging.

•

•

•

1

The PoNS is designed and developed in the Tactile Communication and NeuroRehabilitation Laboratory (TCNL). The PC
board and electrodes are fabricated by Advance Circuits (Aurora, CO), and surface-mounted IC components assembled by
Prairie Digital (Sauk City, WI). Final inspection, verification and encapsulation performed at the TCNL by the investigators.
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III. Rationale for designation as a non-significant risk (NSR) device.

A predicate technology, the commercially available BrainPort Balance device (Wicab, Inc), and
developed by the investigators, received the NSR designation in 2006.
The PoNS device uses the same electrotactile waveform as the predicate BrainPort. It can also be
considered non-significant risk device because, under 21 CFR 812.3(m), (summarized in [5]), a
significant risk (SR) device is defined as one that:
(1) is intended as an implant and presents a potential for serious risk to the health, safety, or welfare
of a subject;
(2) is purported or represented to be for use supporting or sustaining human life and presents a
potential for serious risk to the health, safety, or welfare of a subject;
(3) is for a use of substantial importance in diagnosing, curing, mitigating, or treating disease, or
otherwise preventing impairment of human health;
(4) otherwise presents a potential for serious risk to the health, safety, or welfare of a subject.
Given the technical and functional considerations identified above, the PoNS can be considered a nonsignificant risk (NSR) device because it:
(1) is not an implant device: the recommended use is only for periodic non-invasive placement on
the tongue that is controlled by the user;
(2) will not be used to support or sustain human life: the recommended use is for periodic
application twice or three times each day for approximately 45 minutes each;
(3) will not be used for substantial importance in diagnosing, curing, mitigating, or treating disease;
only to address symptoms of neurologic disorders affecting movement control;
(4) is intentionally designed to not present a potential for serious risk to the health, safety or welfare
of a subject.
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Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Mr. John Comerford
Vice President, General Counsel and Secretary
Wicab, Inc.
8476 Greenway Boulevard
Middleton, WI 53562
Re:

1040581
Electrotactile signal stimulation of the tongue to treat patients with Bilateraf Vestibular
Dysfunction ("BVD").

Dear Mr. Comerford:
The Food and Drug Administration (FDA) has reviewed your PIDE submission, dated December
23, 2004, proposing a study using your BrainportTMBalance Device to treat in patients with
Bilateral Vestibular Dysfunction ("BVD").
FDA has determined that YOllrpropo~edclin.icalip.yestigationis a nonsigniticantrisk (NSR)
device study because it does not meet the definition of a significant risk (SR) device under §
812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812, available on

the internetat

.

.

http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/showCFR.cfm?CFRPart=812).
An IDE application is not required to be submitted to, or approved by, FDA for a NSR study. 'A
NSR study is, however, subject to the abbreviated requirements described in § 812.2(b) of the
IDE regulation. The abbreviated requirements stipulate that the sponsor of the investigation must
label the device in accordance with § 812.5; obtain institutional review board approval of the
investigation as a NSR study; ensure that each investigator obtains informed consent from each
subject under the investigator's care; comply with the monitoring requirements of § 812.46;
maintain records required under § 812.140(b)(4) and (5) and file the reports required under §
812.150(b)(1) through (3) and (5) through (10); and ensure that participating investigators
maintain the records required by § 812.140(a)(3)(i) and file the reports required under
§ 812.150(a)(1), (2), (5) and (7).
Unqer the abbreviated IDE r~quireh1~nts,'\.sponsor musJalso comply ~ith the prohibitions
against promotion and other practices as identified in § 812.7. According to this section of the
regulation, the sponsor of a NSR study, investigator, or any person acting for or on behalf of the
sponsor or investigator is prohibited from promoting or test-marketing the investigational device
until after FDA has approved the device for commercial distribution; commercializing the device
by charging a price greater than that necessary to recover the cost of manufacture, research,
development, and handling; unduly prolonging the investigation; and representing the
investigational device as being safe or effective for the purposes for which it is being
investigated.
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Page 2 - Mr. John Comerford

If you have any questions regarding our NSR determination or the abbreviated IDE requirements,
please contact Mr. Neil R.P. Ogden at (301) 594-1307.

--

- --

-

-

---

;:;:;~
Mark-N. Melkerson

-

---

Acting Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and Radiological Health
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Modified Gait Efficacy Scale
Please answer the following questions regarding your confidence completing the
following activities WITHOUT an assistive device (without a cane, walker, or
wheelchair).
1. How much confidence do you have that you would be able to safely walk on a level
surface such as a hardwood floor?
1
2
3
4
5
6
7
8
9
10
No Confidence

Complete Confidence

2. How much confidence do you have that you would be able to safely walk on grass?
1
2
3
4
5
6
7
8
9
10
No Confidence

Complete Confidence

3. How much confidence do you have that you would be able to safely walk over an
obstacle in your path?
1
2
3
4
5
6
7
8
9
10
No Confidence

Complete Confidence

4. How much confidence do you have that you would be able to safely step down from
a curb?
1
2
3
4
5
6
7
8
9
10
No Confidence

Complete Confidence

5. How much confidence do you have that you would be able to safely step up onto a
curb?
1
2
3
4
5
6
7
8
9
10
No Confidence

Complete Confidence

6. How much confidence do you have that you would be able to safely walk up stairs if
you are NOT holding on to a railing?
1
2
3
4
5
6
7
8
9
10
No Confidence

Complete Confidence
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7. How much confidence do you have that you would be able to safely walk down stairs
if you are NOT holding on to a railing?
1
2
3
4
5
6
7
8
9
10
No Confidence

Complete Confidence

8. How much confidence do you have that you would be able to safely walk in a large
crowd?
1
2
3
4
5
6
7
8
9
10
No Confidence

Complete Confidence

9. How much confidence do you have that you would be able to safely walk down
aisles in a store such as a grocery store?
1
2
3
4
5
6
7
8
9
10
No Confidence

Complete Confidence

10. How much confidence do you have that you would be able to safely walk a long
distance such as ½ mile?
1
2
3
4
5
6
7
8
9
10
No Confidence

Complete Confidence
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Protocol Used for Data Presentation
The following section presents the graphs and analyses for the data collected
during this study. Graphs that are used in the research manuscript are
designated with an asterisk (*). Each graph is assessed in the same manner.
Prior to collecting data, proposed analysis techniques to look at the data included
visual analyses, basic trend lines using split middle celeration lines, percentage
data overlap techniques, and two standard deviation band method analyses.
Visual analysis methods included examining level, trend, variability, immediacy of
effect, overlap, and consistency across similar phases. On the analyses below,
consistency is included in Phase 4, comparing Phase 2 and 4, and in Phase 3
comparing Phase 1 and 3, and in Phase 5 comparing Phase 3 to 5. Four
percentage data overlap techniques were utilized: percentage non-overlapping
data, percentage exceeding the median, percentage exceeding the mean, and
pairwise data overlap. Each of these techniques evaluate the data based on the
trends expected from the hypotheses. For example, for percentage nonoverlapping data, the highest score is used for baseline and withdrawal phases
and counts only data points higher in the intervention. The lowest score is used
for intervention phases and counts include only lower points in the withdrawal
weeks. These follow the hypotheses that the participant would have better scores
during intervention weeks and worse scores during the baseline and withdrawal
phases.
After graphing the data, two observations altered the analyses completed. First,
several tasks and assessments had high variability and few phases stabilized.
This often made basic trend lines misleading and uninformative. Because the
trend lines were not deemed to be accurate or representative, there were not
used for the data collected and are not shown below. Subsequent studies may
considered lengthening each phase to provide a more accurate celeration line. A
second observation made was that the each phase scores were relatively
consistent, that is, there were no noticeable level differences in data. This makes
the use of the two standard deviation band method unnecessary, as no change
was noted that would be close to showing significance with this method.
Therefore, the two standard deviation band method was not completed for the
data and is not included below.
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Timed Up and Go
Timed Up and Go Scores
14

Time (in seconds)

12
10
8
6
4
2
0
1

3

5

7

9

11

13

15

17

19

21

23

25

Days

The black dashed line represents the cut-off scores for community dwelling
adults for risk of falls (13.5 seconds). All data points for the participant fall below
this, indicating he is at low risk for falls according to this assessment.
Consistency: Low
Phase 1: Baseline
Phase 4: Intervention
Level: Low/Medium
Trend: Increasing
Level: Low/Medium
Variability: Stable
Trend: N/A due to variability
Phase 2: Intervention
Variability: Medium
Level: Low
Immediacy of effect: N/A
Trend: Decreasing very slightly
Data overlap (phase 3 to 4):
Variability: Stable
PND: 20%
Immediacy of effect: N/A
PEM: 40%
Data overlap (phase 1 to 2):
PEAv: 40%
PND: 0%
PDO: (2+2+2+1+2/25) 36%
PEM: 100%
Consistency: None
PEAv: 100%
Phase 5: Withdrawal
PDO: (4+5+5+5+5/25) 96%
Level: Low
Phase 3: Withdrawal
Trend: Stable/slightly decreasing
Level: Low
Variability: Low
Trend: N/A
Immediacy of effect: N/A
Variability: Low/medium
Data overlap (phase 4 to 5):
Immediacy of effect: N/A
PND: 0%
Data overlap (phase 2 to 3):
PEM: 0%
PND: 20%
PEAv: 0%
PEM: 60%
PDO: (0+3+0+0+1/25) 16%
PEAv: 80%
Consistency: Moderate
PDO: (1+3+5+5+3/25) 68%
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Romberg

Eyes Open Romberg
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Eyes Closed Romberg
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Phase 1
Level: Stable
Trend: Stable
Variability: None
All Subsequent Phases
Level: Stable
Trend: Stable
Variability: None
Immediacy of effect: None
Data overlap: 0%
Consistency across phases:
Complete consistency

Additional Analyses
No changes were noted in ability due
to a strong (complete) ceiling effect
at each session. Therefore, no
additional analyses were deemed
appropriate.
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*Eyes Open Sharpened Romberg

Sharpened Romberg Best Time with Eyes Open

Time (in seconds)
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Phase 1
Level: High
Trend: Relatively stable
Variability: Low
Phase 2
Level: High
Trend: Stable
Variability: Very little
Immediacy of effect: N/A (ceiling
effect)
Data overlap (phase 1 to 2):
PND: 0%
PEM: 0%
PEAv: 100%
PDO: (5+0+5+0+0/25) 40%
Phase 3
Level: Medium to high
Trend: stable, increasing
Variability: Slight
Immediacy of effect: Immediate
notable decrease
Data overlap (phase 2 to 3):
PND: 80%
PEM: 80%
PEAv: 80%
PDO: (4+4+4+4+4/25) 80%
Consistency: None

Phase 4
Level: High
Trend: Stable
Variability: None
Immediacy of effect: N/A (ceiling
effect)
Data overlap (phase 3 to 4)
PND: 0%
PEM: 100%
PEAv: 100%
PDO: (5+5+5+5+0/25) 80%
Consistency: Very high
Phase 5
Level: High
Trend: Stable
Variability: Low
Immediacy of effect: None
Data overlap (phase 4 to 5):
PND: 20%
PEM: 20%
PEAv: 20%
PDO: (1+1+1+1+1/25) 20%
Consistency: None
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*Eyes Closed Sharpened Romberg

Sharpened Romberg Best Time with Eyes Closed
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Phase 1
Level: Low to medium
Trend: N/A
Variability: Medium/low
Phase 2
Level: Medium to low
Trend: Decreasing
Variability: Slight
Immediacy of effect: None
Data overlap (phase 1 to 2):
PND: 0%
PEM: 60%
PEAv: 60%
PDO: (3+3+3+0+3/25) 48%
Phase 3
Level: Medium to low
Trend: N/A due to instability
Variability: High
Immediacy of effect: None
Data overlap (phase 2 to 3):
PND: 0%
PEM: 40%
PEAv: 40%
PDO: (3+2+3+0+0/25) 32%
Consistency: None

Phase 4
Level: Medium to low
Trend: Curvilinear
Variability: Curvilinear
Immediacy of effect: None
Data overlap (phase 3 to4):
PND: 0%
PEM: 40%
PEAv: 40%
PDO: (2+0+4+3+0/25) 36%
Consistency: None
Phase 5
Level: Medium to high
Trend: N/A due to instability
Variability: High
Immediacy of effect: None
Data overlap (phase 4 to 5):
PND: 0%
PEM: 0%
PEAv: 20%
PDO: (3+0+0+0+3/25) 24%
Consistency: Moderate
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Average Eyes Closed Sharpened Romberg Scores

Average Time on Eyes Closed Tandem Romberg
Time (in secods)
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Phase 1
Level: Low
Trend: Stable
Variability: Slight
Phase 2
Level: Low
Trend: Decreasing slightly
Variability: Low to moderate
Immediacy of effect: None
Data overlap (phase 1 to 2):
PND: 0%
PEM: 60%
PEAv: 60%
PDO: (3+3+3+0+3/25) 48%
Phase 3
Level: Low
Trend: N/A due to instability
Variability: Moderate
Immediacy of effect: None
Data overlap (phase 2 to 3):
PND: 0%
PEM: 60%
PEAv: 40%
PDO: (3+3+3+0+0/25) 36%
Consistency: Moderate

Phase 4
Level: Low
Trend: Curvilinear
Variability: Curvilinear
Immediacy of effect: None
Data overlap (phase 3 to 4):
PND: 0%
PEM: 40%
PEAv: 40%
PDO: (2+0+4+3+1/25) 40%
Consistency: None
Phase 5
Level: Medium to low
Trend: N/A due to instability
Variability: High
Immediacy of effect: None
Data overlap (phase 4 to 5):
PND: 0%
PEM: 0%
PEAv: 20%
PDO: (1+0+0+1+3/25) 20%
Consistency: None
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*All Scores from Eyes Closed Sharpened Romberg

All Sharpened Romberg Eyes Closed Scores
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The raw data for the Sharpened Romberg with eyes closed was included as an
additional way to view and understand the data. Formal analyses were not
completed on this graph. Trends noted appear to include an increase in
variability of the data, particularly in the final phase.
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*Combined Dynamic Gait Index Scores

DGI Score (12 max possible)

Combined DGI Scores
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Phase 1
Level: Medium to high
Trend: N/A due to instability,
decreasing slightly
Variability: Medium to high
Phase 2
Level: Medium to high
Trend: N/A
Variability: Medium
Immediacy of effect: N/A
Data overlap (phase 1 to 2):
PND: 20%
PEM: 20%
PEAv: 40%
PDO: (1+1+5+1+5/25) 52%
Phase 3
Level: Medium to high
Trend: N/A due to instability
Variability: High
Immediacy of effect: N/A
Data overlap (phase 2 to 3):
PND: 0%
PEM: 0%
PEAv: 0%
PDO: (5+0+0+2+0/25) 28%
Consistency: Moderate

Phase 4
Level: N/A
Trend: Curvilinear
Variability: Curvilinear
Immediacy of effect: N/A
Data overlap (phase 3 to 4):
PND: 40%
PEM: 40%
PEAv: 80%
PDO: (2+5+2+5+2/25) 64%
Consistency: Very low
Phase 5
Level: High
Trend: Stable
Variability: Low
Immediacy of effect: N/A
Data overlap (phase 4 to 5):
PND: 0%
PEM: 0%
PEAv: 80%
PDO: (4+0+0+0+4/25) 32%
Consistency: Low
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Dynamic Gait Index Individual Task Scores

DGI Score (max 3 possible)

DGI Task 3 Scores: Horizontal Head Turn
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For the analysis of individual DGI tasks, there is a three point scale, therefore,
any change in rating indicates higher variability than on the combined DGI scores
with a greater possible overall score where a difference of 1 is not as significant.
It is possible that a change of one point on individual tasks indicates a change in
function. If a modified scale had been used to rate the DGI tasks there may have
been less variability in scores and trends may have been easier to identify.
Phase 1
Consistency: Moderate/High
Level: N/A due to instability
Phase 4
Trend: N/A due to instability
Level: Moderate/High
Variability: High
Trend: N/A
Phase 2
Variability: Moderate
Level: Moderate/High
Immediacy of effect: N/A
Trend: Stable
Data overlap (phase 3 to 4):
Variability: Low
PND: 0%
Immediacy of effect: N/A
PEM: 0%
Data overlap (phase 1 to 2):
PEAv: 40%
PND: 0%
PDO: (0+2+0+2+0/25) 16%
PEM: 20%
Consistency: High
PEAv: 20%
Phase 5
PDO: (1+0+5+0+1/25) 28%
Level: High
Phase 3
Trend: Stable
Level: High/Moderate
Variability: None
Trend: N/A due to instability
Immediacy of effect: N/A
Variability: High
Data overlap (phase 2 to 3):
Immediacy of effect: N/A
PND: 0%
Data overlap (phase 2 to 3):
PEM: 0%
PND: 0%
PEAv: 0%
PEM: 0%
PDO: (0+0+0+0+0/25) 0%
PEAv: 40%
Consistency: Low
PDO: (2+0+0+0+0/25) 8%
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DGI Score (max 3 possible)

DGI Task 4 Scores: Vertical Head Turn
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Phase 1
Level: High/Moderate
Trend: N/A
Variability: High
Phase 2
Level: Moderate/High
Trend: N/A
Variability: High
Immediacy of effect: N/A
Data overlap (phase 1 to 2):
PND: 0%
PEM: 0%
PEAv: 40%
PDO: (0+0+2+0+2/25) 16%
Phase 3
Level: High/Moderate
Trend: N/A
Variability: High
Immediacy of effect: N/A
Data overlap (phase 2 to 3):
PND: 0%
PEM: 0%
PEAv: 40%
PDO: (2+0+0+2+0/25) 16%
Consistency across phases: High
consistency, both have similar
variability and patterns

Phase 4
Level: High
Trend: Stable
Variability: None
Immediacy of effect: N/A
Data overlap (phase 3 to 4):
PND: 0%
PEM: 0%
PEAv: 100%
PDO: (0+5+0+5+0/25) 40%
Consistency across phases: Low
Phase 5
Level: High/Moderate
Trend: N/A
Variability: High
Immediacy of effect: N/A
Data overlap (phase 4 to 5):
PND: 0%
PEM: 40%
PEAv: 40%
PDO: (2+2+2+2+2/25) 40%
Consistency: Complete
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DGI Score (max 3 possible)

DGI Task 6 Scores: Step over Obstacle
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Phase 1
Level: Moderate/Low
Trend: N/A
Variability: Moderate
Phase 2
Level: Moderate/High
Trend: Stable
Variability: Low
Immediacy of effect: Mild
Data overlap (phase 1 to 2):
PND: 20%
PEM: 100%
PEAv: 100%
PDO: (1+1+5+5+5/25) 68%
Phase 3
Level: Moderate
Trend: Stable
Variability: None
Immediacy of effect: N/A
Data overlap (phase 2 to 3):
PND: 0%
PEM: 0%
PEAv: 100%
PDO: (5+0+0+0+0/25) 20%
Consistency across phases: Low

Phase 4
Level: High
Trend: Stable
Variability: Low
Immediacy of effect: Mild
Data overlap (phase 3 to 4):
PND: 80%
PEM: 80%
PEAv: 80%
PDO: (4+4+4+4+4/25) 80%
Consistency: N/A to low
Phase 5
Level: High/Moderate
Trend: N/A
Variability: High
Immediacy of effect: N/A
Data overlap (phase 4 to 5):
PND: 0%
PEM: 40%
PEAv: 40%
PDO: (2+2+0+2+2/25) 32%
Consistency: Low
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DGI Score (max 3 possible)

DGI Task 7 Scores: Walk around
Obstacles
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All data points for Task 7 of the DGI (walking around obstacles) reached the
maximum score on each day of the study (3 out of 3). Therefore, no data
analysis was completed or necessary.
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Combined Community Balance & Mobility Scale Scores

CB&MS Score (35 max possible)

Combined CB&M Scale Scores
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Phase 1
Level: Moderate
Trend: Increasing slightly
Variability: Low
Phase 2
Level: Moderate
Trend: None
Variability: Moderate
Immediacy of effect: None
Data overlap (phase 1 to 2):
PND: 20%
PEM: 100%
PEAv: 100%
PDO: (5+5+5+4+1/25) 80%
Phase 3
Level: Moderate
Trend: Stable
Variability: Low
Immediacy of effect: None
Data overlap (phase 2 to 3):
PND: 0%
PEM: 20%
PEAv: 20%
PDO: (1+1+1+5+0/25) 32%
Consistency: None

Phase 4
Level: Moderate
Trend: Increasing slightly
Variability: Low
Immediacy of effect: None
Data overlap (phase 3 to 4):
PND: 0%
PEM: 0%
PEAv: 20%
PDO: (1+0+3+0+0/25) 16%
Consistency: Moderate
Phase 5
Level: Moderate
Trend: None
Variability: Moderate
Immediacy of effect: None
Data overlap (phase 4 to 5):
PND: 0%
PEM: 0%
PEAv: 0%
PDO: (0+0+0+0+0/25) 0%
Consistency: Low
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CB&M Score (max 5 possible)

Community Balance & Mobility Scale Individual Task Scores

CB&M Scale Task 1L: Standing on Left
Foot
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All data points for the first task on the CB&M Scale (Standing on the left foot)
were the lowest possible score, indicating an inability to complete the task, each
day of the study except two. Further analysis was not completed or necessary for
this data.
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CB&MS (max 5 possible)

CB&M Scale Task 1R: Standing on Right Foot
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Phase 1
Level: N/A
Trend: Increasing
Variability: Low
Phase 2
Level: Moderate
Trend: Stable
Variability: Moderate
Immediacy of effect: N/A
Data overlap (phase 1 to 2):
PND: 0%
PEM: 0%
PEAv: 60%
PDO: (5+3+0+0+0/25) 32%
Phase 3
Level: Moderate
Trend: N/A
Variability: High
Immediacy of effect: N/A
Data overlap (phase 2 to 3):
PND: 20%
PEM: 0%
PEAv: 60%
PDO: (3+1+3+3+1/25) 44%
Consistency: None

Days

Phase 4
Level: N/A
Trend: N/A
Variability: High
Immediacy of effect: N/A
Data overlap (phase 3 to 4):
PND: 0%
PEM: 40%
PEAv: 40%
PDO: (0+2+4+0+2/25) 32%
Consistency: None
Phase 5
Level: High/Moderate
Trend: Stable
Variability: Low
Immediacy of effect: N/A
Data overlap (phase 4 to 5):
PND: 0%
PEM: 0%
PEAv: 0%
PDO: (0+0+0+0+0/25) 0%
Consistency: None
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CB&M Scale Task 2: Tandem Walking
CB&MS Score (max 5 possible)

5
4
3
2
1
0
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
Days

Phase 1
Level: N/A
Trend: N/A
Variability: High
Phase 2
Level: Moderate
Trend: Stable
Variability: Low
Immediacy of effect: N/A
Data overlap (phase 1 to 2):
PND: 0%
PEM: 100%
PEAv: 100%
PDO: (0+5+5+5+1/25) 64%
Phase 3
Level: Moderate
Trend: Stable
Variability: Moderate
Immediacy of effect: N/A
Data overlap (phase 2 to 3):
PND: 20%
PEM: 20%
PEAv: 80%
PDO: (1+1+1+4+1/25) 32%
Consistency: None

Phase 4
Level: Moderate
Trend: Stable
Variability: Moderate
Immediacy of effect: N/A
Data overlap (phase 3 to 4):
PND: 0%
PEM: 20%
PEAv: 20%
PDO: (1+0+4+1+1/25) 28%
Consistency: Moderate
Phase 5
Level: Moderate
Trend: Stable
Variability: Moderate
Immediacy of effect: N/A
Data overlap (phase 4 to 5):
PND: 0%
PEM: 0%
PEAv: 0%
PDO: (0+0+0+0+2/25) 8%
Consistency: Low
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CB&MS Score (max 5
possible)

CB&M Scale Task 6: Crouch and Walk
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Phase 1
Level: Low
Trend: Stable
Variability: Low/Moderate
Phase 2
Level: Low
Trend: Stable
Variability: None
Immediacy of effect: N/A
Data overlap (phase 1 to 2):
PND: 0%
PEM: 100%
PEAv: 100%
PDO: (5+5+0+5+0/25) 60%
Phase 3
Level: Low
Trend: Stable
Variability: None
Immediacy of effect: N/A
Data overlap (phase 2 to 3):
PND: 0%
PEM: 0%
PEAv: 0%
PDO: (0+0+0+0+0/25) 0%
Consistency: Low

Phase 4
Level: Low
Trend: Stable
Variability: Low
Immediacy of effect: N/A
Data overlap (phase 3 to 4):
PND: 0%
PEM: 0%
PEAv: 0%
PDO: (0+0+0+0+0/25) 0%
Consistency across phases: High
Phase 5
Level: Low
Trend: Stable
Variability: Moderate
Immediacy of effect: N/A
Data overlap (phase4 to 5):
PND: 0%
PEM: 0%
PEAv: 0%
PDO: (0+0+0+0+0/25) 0%
Consistency: High
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CB&MS Score (max 5
possible)

CB&M Scale Task 10: Forward to Backward Walking
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Phase 1
Level: Low/Moderate
Trend: Stable
Variability: Low
Phase 2
Level: Moderate
Trend: Stable
Variability: Moderate
Immediacy of effect: N/A
Data overlap (phase 1 to 2):
PND: 20%
PEM: 80%
PEAv: 80%
PDO: (4+4+4+1+4/25) 68%
Phase 3
Level: Moderate
Trend: Stable
Variability: Low
Immediacy of effect: N/A
Data overlap (phase 2 to 3):
PND: 0%
PEM: 0%
PEAv: 0%
PDO: (0+0+0+1+0/25) 8%
Consistency across phases: Low

Phase 4
Level: Moderate
Trend: Stable
Variability: Moderate
Immediacy of effect: N/A
Data overlap (phase 3 to 4):
PND: 0%
PEM: 0%
PEAv: 60%
PDO: (3+0+0+0+0/25) 12%
Consistency: Moderate
Phase 5
Level: Moderate/High
Trend: Stable
Variability: Low
Immediacy of effect: N/A
Data overlap (phase 4 to 5):
PND: 0%
PEM: 0%
PEAv: 0%
PDO: (0+0+0+0+0/25) 0%
Consistency : High
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CB&M Score (max 5
possible)

CB&M Scale Task 13R: Step Ups
starting with Right Foot
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CB&M Score (max 5
possible)

CB&M Scale Task 13L: Step Ups
starting with Left Foot
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All data points for Task 13 of the CB&M Scale (Step Ups onto a single stair)
received a 3 out of 5 on each day of the study when leading with the right foot.
When leading with the left foot, each day after the first day was scored the same
at 3 out of 5. Therefore, no data analysis was completed or necessary as the
data had no changes.
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Average Modified Gait Efficacy Scale Scores

Modified Gait Efficacy Scale Score (max
10)

Average Modified Gait Efficacy Scale Scores
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The average score on the ten question modified Gait Efficacy Scale for each
week was plotted. The participant’s average confidence on the GES-m remained
stable the first two weeks, increased very slightly the third week then increased
one point in the second intervention phase and increased one point in the second
withdrawal phase.
None of the changes in scores for the average GES-m or individual questions
were significant based on the true change scores for the mGES (6 points).
No statistical analyses were completed on the modified Gait Efficacy Scale
questions as they were only completed once weekly. Trends in scores can be
observed visually.
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GES-m Score (max 10)

Q1: Confidence Walking on Level Surfaces
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*
Q2: Confidence Walking on Grass
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Confidence on the first question (walking on level surfaces) increased during the
both intervention weeks to maximum possible confidence, decreased during the
first withdrawal week, and stayed at the maximum confidence for the second
withdrawal week.
*The second question (walking on grass) shows the same pattern as the first,
with confidence increasing during the first intervention week, decreasing back to
the baseline for the first withdrawal, increasing again in the second intervention
week, and increasing further during the second withdrawal week.
.
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Q3: Confidence Walking over an Obstacle
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GES-m Score (max 10)

Q4: Confidence Stepping Down from a Curb
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Confidence on the third question (walking over an obstacle) remained constant
for the first three weeks, increased two points after the second intervention week,
and increased another point after the second withdrawal week.
Confidence on the fourth question (stepping down from a curb) also remained
stable the first three weeks before increasing two points after the second
intervention week and remaining stable there after the second withdrawal week.
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GES-m Score (max 10)

Q5: Confidence Stepping Up onto a Curb
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GES-m Score (max 10)

Q6: Confidence Going Up Stairs Not Holding On
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Confidence on the fifth question (stepping up onto a curb) increased one point
after the first intervention week, remained stable there for three weeks, then
increase one more point after the second withdrawal week.
Confidence on the sixth question (going up stairs without holding on) remained
stable during the first two weeks, increased three points after the first withdrawal
week and remained stable there the rest of the study.
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GES-m Score (max 10)

Q7: Confidence Going Down Stairs Not Holding On
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GES-m Score (max 10)

Q8: Confidence Walking in a Large Crowd
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Confidence on the seventh task (going down stairs without holding on)
decreased two points after the first intervention week, decreased another point
after the first withdrawal week, remained stable after the second intervention
week, and increased three points after the second withdrawal week (returning to
baseline confidence level).
Confidence on the eighth task (walking in a large crowd) remained stable the first
two weeks, increased one point after the first withdrawal week, increased another
point after the second intervention week, and remained stable there after the
second withdrawal week.

89

GES-m Score (max 10)

Q9: Confidence Walking Down Aisles in a Store
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GES-m Score (max 10)

Q10: Confidence Walking Long Distances (1/2 Mile)
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Confidence on the ninth task (walking down aisles in a store) remained constant
the first three weeks, increased one point after the second intervention week, and
increased another point after the second withdrawal week.
Confidence on the tenth task (walking long distances like ½ mile) decreased one
point after the first intervention session, increased two points after the first
withdrawal week, decreased one point after the second intervention week, and
increased two points after the second withdrawal week. The responses to this
question are particularly interesting as they do not correlate with the statements
made by the participant throughout the study. The participant indicated several
times during intervention weeks that walking had not felt as natural or confident
in years, and he noted he usually experienced pain when walking long distances
prior to the study. However, when he was completing the treadmill activities, he
often remarked that the walking felt very good and he wanted to continue walking
either on the treadmill or around the office building.
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Community Integration Questionnaire
Community Integration Questionnaire Total Scores
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The CIQ and POPS assessments were included largely to determine change
over the longitudinal portion of the study, should the participants decide to
continue using the PoNS™ device. The graphs of the CIQ are shown and
described here. However, it must be acknowledged that the time between each
assessment was only one week. It would be very difficult for the participant to
experience a true change in the level of community integration in one week.
The participant’s CIQ scores were plotted as total scores for the assessment,
and as Home, Social and Productive Subsection.
The maximum score on the CIQ is 29 points. The participant’s CIQ total score
increased one point after the first intervention week, decreased three points after
the first withdrawal week, increased four points after the second intervention
week and increased one more point after the second withdrawal week.
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CIQ: Home Scores
CIQ Score (max 10)
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The maximum score on the Home subsection is 10 points. The participant had
the maximum score on the home subsection of the CIQ after each phase.

CIQ: Social Scores
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The maximum score for the Social subsection is 12 points. The participant’s
scores on the social subsection varied the most of the subsections. The
participant’s score increased by one point after the first intervention week,
decreased three points after the first withdrawal week, increased five points after
the second intervention week and remained at that level after the second
withdrawal week.

92

CIQ: Productive Scores
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The maximum score on the Productive subsection is 7 points. The participant’s
scores were constant the first three weeks of the study, decreased one point
after the second intervention week, and increased one point after the second
withdrawal week.
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Appendix D: Research Proposal
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Introduction
The brain is constantly interpreting information, making and strengthening
connections, and can restructure itself, to some degree, to meet these needs
most effectively. This ability to change and mold is referred to as neuroplasticity.
In the event of brain trauma and injury, the brain is able to adapt to some
impairments, particularly with beneficial interventions and training.
Neurorehabilitation capitalizes on the brain’s ability to restructure and relearn
information for individuals with neurotrauma; most commonly treated are
individuals with strokes, traumatic brain injuries and spinal cord injuries.
Neurorehabilitation focuses on reinforcing, creating and continuing
neuroplasticity using various intervention theories and techniques. However,
impairments from each of these diagnoses are often long lasting or permanent
and the impairments decrease the individual’s functional abilities, even after
rehabilitation services are completed.
Neuromodulation, a related field of study, uses electricity or medications to
alter the nervous system. Unlike neuroplasticity, this may not be equated to
learning, rather the interventions either suppress or enhance the nervous system.
While neuroplasticity is a restructuring or reorganization, neuromodulation effects
can be dependent on the intervention being present; without the intervention, the
effects are eliminated. Many neuromodulation interventions are invasive and
costly and results are not permanent without the medication or electricity.
A new neuromodulation intervention called Cranial Nerve Non-Invasive
NeuroModulation (CN-NINM) provides a promising intervention for
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neuromodulation in various impairments. It was created based on observational
results from sensory substitution interventions and the biofeedback device called
BrainPort™. Each of these will be described briefly in the context of information
learned for the development of the CN-NINM intervention. It eliminates the risks
associated with an invasive or implanted device and has shown promise for
improving a wide range of impairments that remained after standard
rehabilitation. In comparison to existing interventions, the CN-NINM intervention
is less expensive, has shown positive results in several patient populations, and
may require less time from medical professionals. Although the intervention has
shown great promise for improving various abilities, no research has documented
the withdrawal effects or carryover. This is a critical branch of research to
understanding how the intervention works and how it may be best used as a
clinical tool.
Due to the nature of the injury and exploratory results found with the CNNINM intervention, this study will test the withdrawal effects on individuals with
past traumatic brain injuries (TBIs) who have a functional gait impairment. A TBI
population was selected because the impairment is in a more centralized
location; the brain is impaired but the periphery nerves have not been damaged.
Observational results of past CN-NINM use have indicated that individuals with
traumatic brain injuries respond well and quickly to the intervention, making it
feasible and ideal for a single subject withdrawal study.
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Neuroplasticity
Although neuroplasticity occurs automatically, advances in science have
led to better understandings of it and how it could be facilitated and utilized.
Coined in the 1940’s, neuroplasticity refers to the nervous system’s ability to
respond to stimuli by reorganizing its structure, function, and connections by
modifying, strengthening, creating, and eliminating synaptic connections (Cramer
et al., 2011; DeFina et al., 2009). In addition to changes in neural pathways and
synapses, neuroplasticity can also be from neurochemical, synaptic, receptor,
and neuronal changes (Bach-y-Rita & Kercel, 2003). Neuroplasticity occurs due
to habituation, learning and memory, and cellular recovery after injury (StehnoBittel, 2002). According to Cramer et al. (2011), neuroplasticity can occur “during
development, in response to the environment, in support of learning, in response
to disease, or in relation to therapy”. It is a natural process, occurring, to some
degree, automatically given appropriate environments. Once thought to cease as
people aged, neuroplasticity is now known to occur throughout the lifespan.
Research supports, however, that the brain appears most plastic at a young age.
This can be demonstrated by the success in surgeries such as
hemispherectomies, which are most successful in children under age six for
regaining normal function, or comparative success of cochlear implants in
children under three and a half (Cramer et al., 2011).
Although it can occur automatically and across the lifespan in normal
development, many factors can influence the brain’s plasticity. Some factors
cannot be controlled or manipulated. For example, neuroplasticity may gradually
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decrease with age (Dimyan & Cohen, 2011). After an injury or damage to the
brain, the length of time since the injury can influence neuroplasticity. Motivation
and attention, partially controllable variables, greatly impact neuroplasticity.
Although the brain is capable of reorganization, it acts most effectively when the
individual is motivated to complete a task, master an objective, or closely attuned
to the stimulus. Other variables can be and often are manipulated to produce
desired effects. The most commonly manipulated variable to increase
neuroplasticity is repetition. Repetition can cause restructuring of the central
nervous system, and is often a primary component of interventions used in
rehabilitation as discussed later. The repetition should also be experience or task
specific; repeating a task will increase the ability to complete that task, but may
not transfer to a similar task as effectively. Increased exposure to and repetition
of information causes a refining of the neural pathways, thus making the paths
more efficient. Pharmacotherapies can be used to facilitate neuroplasticity after
an injury or impairment. The best results with pharmacotherapies occur when
coupled with targeted interventions or behavioral reinforcement. When
attempting to increase neuroplasticity, almost all interventions include a great
deal of repetition and a focus on completing functional tasks as opposed to
fractured components of a task (Cramer et al., 2011; Dimyan & Cohen, 2011;
O’Malley, Ro, & Levin, 2006).
In addition to natural reorganizing due to the environment and common
stimuli or regaining function lost after a trauma, neuroplasticity can be used to
train the brain to interpret novel information in a specific manner. Possible
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because of the ability to reorganize and restructure, the intention of training the
brain to interpret information in a specific manner is not always to relearn skills
previously mastered but rather to process information presented in a different
format. Sensory substitution and biofeedback measures are specific examples
detailed below of using neuroplasticity for learning information presented in a
different format.
Sensory Substitution
A current research area exploring the uses and benefits of neuroplasticity
is the use of sensory substitution. In this approach, individuals with a sensory
impairment are provided equivalent information in a different format. There are
many forms of sensory substitution. Reading Braille uses sensory substitution;
visual information is provided and interpreted through a tactile medium, similarly
to that of a cane used by individuals with visual impairments (Bach-y-Rita &
Kercel, 2003). The brain only receives information via electrical impulses; it
cannot “see” or “feel” items for example, rather, it interprets electrical signals into
the perception of the sensation. This simple premise is the basis for sensory
substitution. When there is an impairment in the transmission of information, it is
theoretically possible to be able to use the sense again, were the electric signal
able to bypass the impairment. For example, individuals who are blind may be
unable to see secondary to an impairment within the eye structure. If the
electrical impulses from the impaired eye could reach the brain, the brain could
interpret the information and the individual would have the perception of seeing.
Sensory substitution attempts to circumvent the impairment and provide electrical
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impulses to the brain that can be practiced and learned to be interpreted as
information from the impaired sense (Ptito, Moesgaard, Gjedde, & Kupers, 2005).
Previous research with sensory substitution has explored the use of
various means of information input, such as patterns of tactile pressure, audio
information, or small amounts of electrical stimulation. Electrical stimulation has
become one of the most widely used form of sensory substitution (Ptito et al.,
2005). Studies have attempted to provide stimulation to the hands, forehead,
abdomen, and tongue, with the best overall results occurring from electrical
stimulation to the tongue. The individual, with training and practice, is able to
adapt and interpret the information similarly as when information came from the
original source. This process ultimately modifies the nervous system and is only
possible due to neuroplasticity (Bach-y-Rita & Kercel, 2003; Lozano, Kaczmarek,
& Santello, 2009; Tyler, Braun, & Danilov, 2009).
Research from sensory substitution indicates the tongue is an optimal
location to provide input and stimulation for multiple reasons. The mouth provides
a secure, discreet, and isolated environment for the stimulation. Unlike the
abdomen, hands, and forehead which are influenced by the outside environment,
the mouth maintains a relatively constant temperature and typically is not
stimulated by things like a breeze whereas the skin readily picks up
environmental stimuli. Saliva’s composition makes it a useful component in the
provision of electrical information because it maintains a constant pH+. Saliva
also reduces the stimulation required for perception and interpretation. When
electrical stimulation is provided on the skin, it must reach a threshold perceptible
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to the individual. This varies based on location of nerve receptors, requiring less
in the fingers than on the abdomen, but the tongue requires less stimuli to
respond than even the fingers. The tongue and mouth are very sensitive to
information yet capable of interpreting a great deal of information. In addition to
the benefits of using the tongue, research has not indicated negative effects or
negative perceptions of providing electrical stimulation to the tongue. The
intensity required for interpretation is not near the pain level, and patients
generally have not described the experience as unpleasant (Fabien, Nicolas,
Orliaguet, & Payan, 2007; Kaczmarek, 2011; Vuillerme & Cuisinier, 2009;
Wildenberg, Tyler, Danilov, Kaczmarek, & Meyerand, 2010).
Sensory substitution research has provided a solid foundation and support
for the use of therapeutic electrical stimulation of the tongue. Not only has the
research been successful in training participants to interpret the stimuli, little to
no negative effects have been documented as a result of providing stimulation of
the tongue. Observational results during sensory substitution studies have led
researchers to believe tongue stimulation could be beneficial in additional areas
beyond object recognition.
BrainPort™: A Biofeedback Approach
According to Vuillerme et al. (Vuillerme, et al., 2008), biofeedback
provides individuals with “additional artificial information about body orientation
and motion to substitute or supplement the natural visual, somatosensory and
vestibular sensory cues”. Biofeedback can provide positioning information using
visual or proprioceptive cues, and increase body awareness. A Cochrane review

101
from 2004 found that visual and auditory feedback did not improve functional
balance (Badke, Sherman, Boyne, Page, & Dunning, 2011).
The BrainPort™ device was created for individuals with balance
impairments to provide real-time cues on head positioning (Badke et al., 2011). It
contains an accelerometer, and when movement from the center is detected, the
BrainPort™ transmits the signal to electrotactile stimulation of the tongue. For
example, if the head moves/leans to the right, the electrotactile stimulus will be
felt on the right side of the tongue (Danilov, Tyler, Skinner, Hogle, & Bach-y-Rita,
2007).
This device has been used with populations with chronic balance
dysfunction due to peripheral or central etiologies (Danilov et al., 2007), stroke
(Badke et al., 2011), and healthy populations with vision occluded (Vuillerme &
Cuisinier, 2009). After the initial time required to learn how the device works and
what each condition felt like, each population tested was able to successfully
improve balance scores after using the BrainPort™ device.
A 2009 study (Vuillerme & Cuisinier, 2009) used nine healthy young males
with no vision or balance impairments. When tested without feedback from the
BrainPort™, participants had significant differences in head displacement scores
when vision was available than when it was not. When feedback from the
BrainPort™ was provided, there were no differences noted depending on the
vision condition. Testing was completed after practice trials to become familiar
with the device. The order of presentation of conditions was randomized for
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participants. There were no mentions of participants feeling uncomfortable with
or disliking the stimulus (Vuillerme & Cuisinier, 2009).
A 2011 study on the effects of an 8-week intervention with BrainPort™ on
29 individuals post-rehabilitation following a stroke found clinically significant
results for most participants on some combination of assessments. Although
numerous assessments and results were reported, only a brief summary
designed to show the magnitude of clinically significant findings are reported
here. Participants were tested on five assessments. Of these assessments, 27 of
29 participants improved more than the minimal clinically important difference
(MCID) on at least one assessment and 3 participants improved more than the
MCID on all five assessments. Two participants’ scores decreased more than the
MDIC, one on the Timed Up and Go, and the other on the Stoke Impact Scale –
Mobility score. Overall improvements showed great promise for the vast majority
of the population studied (Badke et al., 2011).
A 2007 study’s population included 28 individuals with many types of
chronic balance dysfunction. Participants were post-rehabilitation, and used the
BrainPort™ device for 3-4½ days. Observational results report all participants
with impaired gait had notably improved gait. All participants reported
improvements in balance-challenging tasks, and all participants improved on the
SOT with an average improvement of 42% (Danilov et al., 2007).
Overall, the BrainPort™ has demonstrated significant improvements in
balance for various population groups and the effects were noted to have some
carryover. However, methodologically strong studies have not been completed
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and a great deal more research on this topic is needed. No formal documentation
of withdrawal effects was indicated. Some descriptive information from involved
authors indicates additional benefits aside from anticipated balance
improvements. Although uncertain as to the rationale or physiology of the
changes, participants reported improved quality of life (Badke et al., 2011),
balance, gait, sleep, concentration, coordination, multitasking, and mood. These
findings, in part, led to the design and exploration of the CN-NINM intervention
(Tactile Communication & Neurorehabilitation Laboratory, 2007).
Neurorehabilitation
The brain’s ability to relearn and restructure has led to the growing field of
neurorehabilitation, which aims to increase function and reduce impairments
caused by a neurotrauma. Neurorehabilitation can benefit individuals with a
multitude of injuries, and neurotraumas can include any trauma to the nervous
system, however the primary diagnoses treated in these fields are stroke,
traumatic brain injury, and spinal cord injury. Since the brain is the body’s control
center, injury to the brain could cause any number of countless impairments and
depend on the location and cause of injury. Most individuals with traumatic brain
injuries or strokes have motor impairments along with potential cognitive and
psychosocial impairments. Many medical facilities have neurorehabilitation
specialists, as treatment approaches and interventions may vary from other
specialty areas. Primary members of the rehabilitation component of the team
include both physical and occupational therapists. Both therapists aim to
increase functioning of the patient, facilitate relearning, and increase mastery of
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skills to help return patients to their prior level of functioning (American Society of
Neurorehabilitation, 2012).
Neurorehabilitation specialists can use a wide variety of interventions to
facilitate neuro-reeducation and neuroplasticity, both traditional and innovative.
Neuro-reeducation is the primary intervention objective and attempts to succeed
in relearning tasks. Techniques used in conventional neurorehabilitation can
include gait training, aerobic training, biofeedback, and, increasing in popularity,
the use of robotic or robot-assisted therapies. All the listed interventions utilize a
great deal of repetition to be successful, and all require a learning period,
significant practice and time to see results. In addition, they typically are
completed under the observation of a rehabilitation specialist such as an
occupational or physical therapist. Innovative intervention ideas for
neurorehabilitation include the use of neuroprostheses and devices for
neuromodulation such as pharmacological approaches, invasive, or non-invasive
electrical stimulation, as described in more detail below (Cramer et al., 2011;
Dimyan & Cohen, 2011; O’Malley et al., 2006).
Neuromodulation
Neuromodulation is the therapeutic alteration of the nervous system,
either pharmacologically or electrically. It can be used to enhance or suppress
electrical activity in any section of the nervous system. Examples include
baclofen pumps, spinal cord stimulators, deep brain stimulators, and transcranial
magnetic stimulation. These interventions have begun to gain more widespread
acceptance and have positive results, but many are invasive procedures that
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require a highly trained surgeon and specialist, have a risk of complications, and
are ultimately costly. New interventions are exploring the use of non-invasive
techniques; one in particular is called Cranial Nerve Non-Invasive
NeuroModulation (CN-NINM). Three neuromodulation techniques will be briefly
explored and compared.
Electricity has been intentionally introduced to the brain and body to study
the effects since the 1870s. Initially used to help map function and identify
structures, it was not until the 1960’s that the idea of using electrical stimulation
as a therapeutic intervention began to emerge. This novel idea was perpetuated
by documentation of positive phenomena that occurred from brain stimulation,
such as a reduction in tremors for individuals with Parkinson’s Disease
(Perlmutter & Mink, 2006).
Deep Brain Stimulators
Deep brain stimulators are a type of neuromodulator that use electrical
stimulation to alter the nervous system. Although not used until the 1990’s, deep
brain stimulators (DBS) have quickly gained favor in the medical community.
DBS consist of an electrode surgically implanted into the brain with a wire
connector to a pulse generator device surgically implanted under the clavicle.
The electrode can be implanted numerous locations in the brain, depending on
the reason for the device and effects noted during the surgical insertion. The
most common use of DBS is to alleviate Parkinson’s Disease symptoms,
particularly tremors. Research has not indicated that the device has any effect on
disease prognosis; rather, it is intended to reduce or eliminate symptoms to
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increase the individual’s functional abilities while receiving the stimulation. The
DBS device located below the clavicle can be adjusted to different intensities
based on symptoms, and can be turned off and on, and fine-tuned over time. The
effects of the DBS can be almost immediate; turning off the device allows a
return of the symptoms, like tremor from Parkinson’s Disease, within seconds
through several hours for other symptoms such as freezing gait (Kern & Kumar,
2007).
Transcranial Magnetic Stimulation
Transcranial Magnetic Stimulation (TMS) also uses electrical stimulation
for neuromodulation, but is a non-invasive approach. It utilizes a stimulating coil,
held directly next to the head, to send an electrical impulse into the brain. This
stimulation however can only influence the surface of the brain because the
intensity of the stimulation decreases very quickly in relation to the distance from
the coil. Depending on the type of stimulation provided, effects of the stimulation
can be a decrease in brain stimulation in the area, an increase in stimulation,
and, when using repetitive TMS, the effects may have some type of carryover.
O’Malley, Ro, and Levin (2006) report that using the repetitive TMS for 15
minutes can decrease the cortical excitability for up to 15 minutes. Individuals
after a stroke often have decreased cortical excitability on the hemisphere of the
incident, and increased excitability on the contralateral hemisphere. Because
changing the frequencies of the stimulation change whether the effects of the
TMS are generally excitatory or inhibitory, TMS may be beneficial to some
individuals with a stroke, depending in what part of the brain the incident
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occurred. TMS has also been used to stimulate the prefrontal cortex to reduce
depression. With each of the interventions TMS is used for, targeting training
activities are very important to promote relearning along with the
neuromodulation. Overall, although promising particularly in stroke intervention,
TMS may be limited due to the difficulty with providing stimulation to an exact
brain location, limited area of the brain affected, and unknown lasting effects
(Cramer et al., 2011; O’Malley et al., 2006).
Cranial Nerve Non-Invasive NeuroModulation (CN-NINM)
The CN-NINM intervention was established after repeated observations
made while completing sensory substitution and electrical biofeedback balance
research with the BrainPort™. Some of the common effects noted in multiple
patients were improved balance, gait, sleep, concentration, coordination,
multitasking, and mood (Tactile Communication & Neurorehabilitation
Laboratory, 2011). After working closely with other neuromodulation and
neuroplasticity concepts and research, a team of researchers at the Tactile
Communication and Neurorehabilitation Laboratory (TCNL) created a device with
features based on the BrainPort™ device. However, unlike the other
interventions that use electrical stimulation, the CN-NINM couples individualized
targeted training activities with information-free stimulation to the tongue as
opposed to providing information specific to a component of the environment that
must be interpreted (Wildenberg, Tyler, Danilov, Kaczmarek, & Meyerand, 2010,
2011). As mentioned previously, completing activity-specific interventions while
providing neuromodulation or increasing neuroplasticity is important to increase
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the relearning and efficiency of desired activities (Cramer et al., 2011; Dimyan &
Cohen, 2011; O’Malley et al., 2006).
The CN-NINM intervention consists of two primary components, electrical
stimulation of the tongue using a Portable Neuromodulation Stimulator (PoNS™)
device, paired with targeted training activities, which vary based on diagnosis
and what impairment is being studied. Protocols for the intervention have been
established, each customized slightly depending on diagnoses and targeted
impairments (See Appendix 2 for a sample protocol for a previous MS study). For
example, fatigue is a common concern for patients with Multiple Sclerosis, so
more options for rest periods were integrated into the protocol, depending on
energy levels, whereas populations with central balance impairments followed a
more routine intervention. Each component of the CN-NINM intervention is
described in greater detail, followed by an overview of the literature regarding
CN-NINM and decision to study a population with traumatic brain injury on
withdrawal effects.
Portable Neuromodulation Stimulator (PoNS™) device
Research on and work with the predicate BrainPort™ device led to the
design and basis for the PoNS™ device currently used in CN-NINM
interventions. This device continues to use the tongue as the stimulation receptor
for the reasons indicated previously. In addition to the protected, electrically
beneficial environment, and sensitivity of the tongue, the tongue also provides
access to branches of two cranial nerves, the Lingual nerve, part of the trigeminal
nerve (CN V) and the Chorda tympani, part of the facial nerve (CN VII). The
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activation and excitation of both cranial nerves as well as the great number of
other nerves in the mouth and tongue provide comparatively direct connections
to the central nervous system compared to previously studied human interface
locations (Tyler, Braun, & Danilov, 2009; Wildenberg et al., 2011)
The PoNS™ device is a T-shaped, battery powered, portable device. The
oral tab that provides the stimulation is 32mm wide and .84mm thick, and the
device case measures 68mm wide,

Figure 1: The PoNS™ device

45mm long, and 15mm thick (see
Figure 1). When recharging, the
charging circuitry and power
connector are designed to prevent
device use, thereby eliminating the
possibility of electrical shock while
charging.
When in use, the PoNS™ device delivers 5 ms of stimulation every 20 ms.
The voltage and pulse timing for each device are established and not able to be
altered, however, device users can adjust the pulse-width to alter the intensity by
pressing either the “Decrease Intensity” or “Increase Intensity” buttons on the
device. Each time the device is turned on the intensity starts at the lowest level
(.4Us) and can be adjusted up to 60Us, the highest intensity possible. The device
has a maximum of 19 V and 6 mA. The PoNS™ device consists of 16 electrodes,
of which only one is active, and the rest ground the stimulation to minimize the
potential for negative side effects. The amount of stimulation used is described
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as feeling like drinking a carbonated beverage and should not be a noxious
stimulus (Wildenberg et al., 2011). The PoNS™ device is recognized as a
nonsignificant risk (NSR) device by the Food and Drug Administration (See
Appendix 3 for a copy of the FDA NSR designation). At the current time, it has
not yet received FDA approval. To date, there have not been any documented
negative effects as a result of the use of the PoNS™ device or the BrainPort™.
Similar intervention stimulus used in sensory substitution similarly does not
indicate negative side effects when using electrical stimulation of the tongue. (For
more specific information regarding the PoNS™ device, see Appendix 1.)
The results of the CN-NINM intervention are believed to be caused by a
large influx of tongue stimulation, stimulating the brainstem and cerebellum
through the cranial nerve tracts. Additional research needs to be completed to
confirm or correct inconsistencies in this theory. This significant activation
proceeds through other interneuron circuitry as well as through direct collateral
connections. This stimulation is believed to “prime” the brain for learning
activities, thus justifying the use of targeted training activities in addition to the
stimulation (Wildenberg et al., 2010, 2011).
A 2011 study by Wildenberg et al. used fMRI to discover how the brain
was affected by the CN-NINM with balance training. Nine participants with
chronic balance dysfunction underwent fMRIs before and after 19 sessions of
stimulation, each 20 minutes long and paired with standing balance activities with
feet together and eyes closed. Seven of the nine participants had improved
sensory organization testing (SOT) scores, with an average improvement of
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15.75 points (SE=5.59, p=.026, paired Student’s t-test), possible SOT scores
range from 0-100. High resolution scans showed activations of optic flow in the
right vestibular nucleus and right superior colliculus as well as multiple cerebellar
structures. After CN-NINM, the right trigeminal nucleus, the site of origin for the
neuromodulation in behavioral and subjective measures improvement, showed
increased response to optic flow. This supports the idea that the
neuromodulation is task dependent (Wildenberg et al., 2011). After prolonged
activation, the circuits can undergo neuronal reorganization, thus leading to an
increased ability to learn or relearn tasks and demonstrating the plasticity of the
brain.
Targeted Training Activities
The stimulation from the PoNS™ device is believed to prime the central
nervous system for learning. Thus, it is important to pair the stimulation received
with personalized, appropriately challenged activities, specific to the impairment
targeted. If the intended goal is improved gait, targeted training on gait tasks
should be included while using the PoNS™ device for best results. The targeted
training activities are completed at a maximal challenge level for participants so
they are difficult but not impossible tasks. Targeted training activities can be very
difficult and require a great deal of motivation from the participant. Because of
the specialization, they also require a learning period where the interventions
occur under the supervision of a trained researcher (see Procedures for
additional information regarding the researcher training prior to patient contact).
Once the patient is competent in the intervention, depending on the type and
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length of study, it may be possible to allow them to continue the interventions at
home independently. Although the stimulation facilitates learning, the targeted
training is important to focus the primed nervous system to learn the intended
task or activity (Tactile Communication & Neurorehabilitation Laboratory, 2011).
Initial CN-NINM Research
The TCNL team initially began research using the CN-NINM intervention
on populations with balance impairments and disorders. Targeted training
therapeutic activities while using the PoNS™ device included trainings on
balance, gait, and relaxation. Individuals with balance impairments showed a
decrease in overall sway and sway in response to optic flow after one week of
CN-NINM training as detected on fMRIs. After the week of CN-NINM, there was
no longer a significant difference noted between controls and participants in optic
flow. Changes in balance and gait after the CN-NINM intervention are believed to
have some carry-over since the participants were not tested while using the
PoNS™ device (Wildenberg et al., 2010, 2011). This is in contrast to most
electrical neurostimulation, like deep brain stimulators, which are believed to only
produce behavioral effects when active or very shortly thereafter. Research
specific to exploring the carry-over or withdrawal was not found.
Recent CN-NINM research.
In 2011, Danilov, et al., studied the balance and gait effects of
neuromodulation on individuals with multiple sclerosis (MS) using the CN-NINM
intervention. Twenty participants with MS completed a 14-week protocol and
after a 2-week in-laboratory training were provided a PoNS™ device to use at
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home. Results found that individuals in the active group who had completed the
CN-NINM training improved in functional gait as measured by the DGI more
quickly than the control group and reached twice the improvement of the control
group by the end of the first two weeks. At the 10- and 14-week assessments,
this difference was highly statistically significant. The only difference between
group demographics was found to be number of years with MS; the greater the
length of time since diagnosis with MS typically reflects poorer functioning. In this
study, although the active group generally had a longer time since diagnosis,
they improved on the Dynamic Gait Index at a faster rate than the control group.
Statistically significant differences on the SOT were not found (Danilov, Tyler,
Rust, Kaczmarek, & Subbotin, N. D.).
Overall Quality of Research Available on CN-NINM Intervention
Although there is relatively little published on the effects of CN-NINM, over
300 participants have been studied across multiple impairment categories using
the BrainPort™ and PoNS™ devices (Dr. Yuri Danilov & Kathy Rust, personal
communication). These participants have provided and continue to provide
qualitative and quantitative information and results that have helped create and
improve the protocols used for future research. Research has indicated that a
rigorous training protocol, paired with electrical stimulation, may slow or improve
certain aspects of function for impairments that are systemic and progressive
such as MS (Danilov et al., N.D.). Research has also demonstrated favorable
results for individuals with various sorts of central and peripheral balance
impairments. Impairments that are progressive and neurodegenerative may take
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longer to show effects or show a slowing of progression, whereas individuals with
impairments secondary to a brain injury likely show faster and more significant
improvement due to the nature of the injuries. In observational research
completed at TCNL with individuals with a brain injury, effects of the CN-NINM
intervention showed tremendous results very quickly upon beginning the
intervention (personal communications).
Traumatic Brain Injuries
Traumatic Brain Injuries (TBIs) are a significant and growing public health
problem defined as any injury that “disrupts the normal function of the brain”
(CDC, 2012). Each year at least 1.7 million people in the United States are
affected by a TBI (CDC, 2010). TBIs can vary in intensity, and are classified as
either mild, moderate or severe. Young adult males and elderly populations are
the two groups most likely to sustain a TBI. Due to the recent wars and increased
military actions, more soldiers are being diagnosed with brain injuries; from 20002011, 220,000 service members were diagnosed with a TBI (Pellerin, 2012).
TBIs can result in lasting functional impairments. The combination of
impairments often experienced by an individual after a TBI increases the risk of
falls, which can lead to reinjury, other injuries, and amplification of symptoms
(CDC, N.D.). The increased risk comes from impairments in balance and gait, as
well as increased impulsivity, decreased problem solving and a reduction in the
ability to multitask, whether the multitasking involves physical tasks (carrying
something while walking) or cognitive demands (answering a question or being
distracted by something) (CDC, N.D.; Dijkers, 2004; Kashluba, Hanks, Casey,&
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Millis, 2008; McCulloch, Buxton, Hackey, & Lowers, 2010; McFadyen et al.,
2009; Rezai & Corrigan, N.D.). Gait impairments after a moderate and severe
TBI are a common complaint (Basford et al., 2003; McFadyen et al., 2009;
Williams, Morris, Schache, & McCrory, 2009).
It is common for a primary rehabilitation focus to be regaining ambulation,
if possible (McFadyen et al., 2009; Williams et al., 2009). Independent mobility
requires a great deal of skills aside from strictly physical abilities. For example,
mobility requires the coordination of various systems, the ability to process
sensory information, the ability to navigate in the environment and back to the
intended destination, and being aware of the surroundings. Independent mobility
can often provide the individual with control and a great deal of improvement in
multiple domains (McFadyen et al., 2009). Because of this, impairments in
balance and gait can lead to decreased independence, physical fitness,
community participation, and quality of life, and an increased risk of falls and
reinjury (Betker, Szturm, Moussavi, & Nett, 2006). However, the ability to walk
does not imply the individual does not have gait impairments that will decrease
function and independence since high-level gait activities are often necessary,
such as picking something up from the floor while walking, or turning his/her
head while walking. These impairments, compounded by the additional long-term
impairments that may be present like impulsivity and poor problem solving, may
decrease the independent functional ability and community integration of an
individual with a TBI long after he/she is physically able to ambulate in the
community or increase the risk of reinjury (CDC, N.D.).
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Connection of TBI to CN-NINM
The proposed study will use a population of individuals who have had a
traumatic brain injury. TBIs will be recruited for several reasons. First, individuals
with TBIs often have a high level mobility impairment. Although able to live in the
community, they may have difficulty completing tasks such as walking in a crowd
or turning their head while walking. The CN-NINM has been used previously for
balance and gait impairments. This study will provide additional information for a
protocol very similar to the protocol used previously. Second, one of the two most
affected age groups is young adult males. The proposed study will be excluding
participants if they are over the age of 65 to reduce confounding variables of
natural decrements in balance with age. Young individuals with a static gait
impairment will likely have to compensate for the impairment all of his/her life,
which may end up detrimental for independence and functioning, overall medical
costs, and psychosocial adjustments. Third, the proposed study will begin to
document the withdrawal effect of the CN-NINM intervention. To keep the study
feasible and practical it is necessary be able to see results quickly. Previous
patients with TBI have responded quickly to the CN-NINM intervention (personal
communication). By using participants with TBI, the study will be able to study
two intervention periods and two withdrawal periods per participant, thus
strengthening the design of the study.
Significance to Occupational Therapy
Occupational therapists are a primary rehabilitation provider in
neurorehabilitation, a field that works primarily with TBI, spinal cord injury, and
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stroke. Many patients after a traumatic brain injury have lasting impairments
when they return to the community, including balance and gait impairments; this
increases the cost of care for that individual if they are not independent. A
reliance on other people for assistance can also decrease self-confidence.
Occupational therapists often work in rehabilitation to improve functional abilities
and functional mobility. Functional mobility is critical for being able to complete
self-cares, for completing Instrumental Activities of Daily Living (IADLs), and
often for obtaining and maintaining leisure and work activities. Impairments in
these domains can cause a decrease in community integration and feelings of
confidence. A lack of community integration can increase isolation and decrease
independence. Occupational therapists attempt to speak to all of these needs,
addressing physical, emotional, and psychosocial domains. Improving high level
functioning may increase community participation, confidence completing gait
activities, and independence. This intervention particularly shows significant
promise in rehabilitation due to its relative inexpense, ease of use, and lack of
complete dependence on trained rehabilitation professionals to achieve
significant gains.
Hypotheses
1. During each of the two, 5-day CN-NINM intervention phases, participants’ gait
performance scores will significantly increase when compared to their
baseline scores (as measured by the Community Balance & Mobility Scale).
2. During each of the two, 5-day CN-NINM intervention phases, participants’
confidence in gait activities will significantly increase when compared to their
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baseline confidence scores (as measured by the modified Gait Efficacy
Scale).
3. During each of the two, 5-day withdrawal phases, participants’ functional gait
performance will show a decrease in function until reaching baseline function
(as measured by the Community Balance and Mobility Scale).
4. During each of the two, 5-day withdrawal phases, participants’ confidence in
gait activities will show a slight decreasing trend but will not reach previous
baseline levels (as measured by the modified Gait Efficacy Scale).
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Methods
Research Design
This study used a single subject experimental design with five data points
collected in each phase. The participant followed an A-B-A-B-A design. ‘A’
indicates a baseline phase with no intervention and the two subsequent ‘A’
phases are withdrawal phases with no intervention. ‘B’ indicates the CN-NINM
intervention. Each phase lasted one week, with participants completing the
protocol Monday through Friday. No interventions were completed on the
weekends. One week interventions were chosen based on previous laboratory
observations from a researcher and clinician trained in the CN-NINM intervention
and gait assessments.
Variables
The independent variable in this study is the CN-NINM intervention. The
intervention is explained in detail in Procedures. The two dependent variables
are 1) quality of functional gait tasks, as measured by the Timed Up and Go,
Romberg and Sharpened Romberg and components of the Community Balance
& Mobility Scale and Dynamic Gait Index, and 2) confidence completing
common gait tasks, as measured by a modified version of the Gait Efficacy
Scale.
Participants
One community dwelling participant with a closed TBI completed the
study. The study had extensive inclusion and exclusion criteria to provide the
best chance of the intervention being appropriate and participants showing
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results in a short period of time. Extensive criteria also ensured all participants
were sufficiently similar so they might react similarly to the intervention.
Inclusion Criteria
Participants must:
•

be between the ages of 18-65

•

speak English fluently

•

must be their own legal guardian, be able to understand and give informed
consent

•

have a clinically detectable gait impairment secondary to a closed traumatic
brain injury

•

live in the community

•

no longer be receiving rehabilitation or balance training programs of any kind

•

be able to maintain upright posture for 20 minutes

•

be able to ambulate 10 meters without resting with or without assistive
devices

•

must indicate gait is an impairment they hope to improve
Exclusion Criteria
Participants will be excluded from the current study if they:

•

have electrical devices/implants

Multiple Sclerosis or Parkinson’s

such as pacemakers

Disease

•

have a biomechanical prosthetic

•

have a comorbid diagnosis that
could affect balance such as

•

are pregnant or trying to become
pregnant

•

use tobacco products
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have contagious mouth diseases,

•

have guillan barre

sores, piercings or abrasions

•

have fibromyalgia

•

have tongue neuropathies

•

have hypertension

•

have receptive aphasia

•

have diabetes

•

have uncontrolled pain

•

have chronic fatigue syndrome

•

have uncontrolled mental health

•

are on medications and have had a

•

conditions

major change in type or dosage

•

have a history of seizures

within three months of enrollment

•

have vision below 20/40

•

have myasthenia gravis

•

have Charcot-Marie tooth disease

•

have post-polio

•

lack the motivation necessary to
complete the tasks

•

lack the cognition to understand and
complete the protocols as directed

The participant who completed the study was 35 years post injury. His
injury was caused by a motor vehicle accident and resulted in a severe head
injury and multiple orthopedic injuries. As a result, the participant used an AFO
on his left lower extremity, had a metal plate for support in his right shoe, and
used a cane on occasion when he felt unstable or was walking long distances.
Instrumentation
Phone Screening
The phone screening consisted of basic demographic information,
background on impairment, and a brief overall impairment list to determine
appropriateness for the study. (See Appendix 4 for the phone screening in its
entirety.)
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Community Balance and Mobility Scale
The primary measure used to evaluate participants is the Community
Balance and Mobility (CB&M) Scale. Created in 2002, this tool assesses the
function of higher functioning populations of individuals with previous traumatic
brain injuries. The 13 tasks assess multitasking, sequencing of movement
components, and complex motor skills. Eight of the 13 tasks are timed, as gait
impairments can manifest as increased time and caution used to complete tasks;
using timed tasks can increase sensitivity to detect these impairments. (See
Appendix 5 for the assessment in its entirety.) The CB&M Scale requires
approximately half an hour to complete and uses an eight-meter track.
Participants are scored on a 0-5 scale with 0 indicating a complete inability to
complete task, and 5 indicating the most successful completion of the task
(Howe, Inness, Venturini, Williams, & Verrier, 2006).
As described earlier, functional mobility can influence community
involvement and independence with tasks. Aware of this during the creation and
validation of the CB&M Scale, the authors collected Community Integration
Scores throughout their research. Using the results of 47 participants,
researchers found an association between the CB&M Scale and Community
Integration Scores (r=0.54, p<0.001). Individuals with a CB&M Scale score of
less than 45 (out of a possible 65) had lower scores on the Community
Integration Measure. A score of 45 is an appropriate threshold for decreased
community participation and integration (Howe, Inness, & Wright, 2011)(Howe,
Inness, & Wright, 2011).
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The minimal detectable change indicated for the CB&M Scale is 8 points.
This will be used as a determinant in the proposed study of true change that is
not caused by measurement error. The minimal detectable change was
determined using a 90% confidence interval (Howe et al., 2011)(Howe et al.,
2011).
Although not extensively documented, the reliability and validity of the
CB&M Scale are overall high. The CB&M Scale has high reliability for intra-,
inter- and test-retest reliability with intraclass correlation coefficients of 0.977,
0.977, and 0.898-0.975 (for immediate and 5 days later test-retest), respectively.
A Cronbach’s alpha for internal consistency was 0.96 and 0.95, indicating a high
correlation among items. Content validity was assessed in a focus group of
physical therapists. All but one task met a priori inclusion criteria. The CB&M
Scale appears to have high content validity. Last, construct validity was assessed
by comparing it with other related measures. A significant correlation was found
with self-paced gait velocity (r=0.53, p=0.001) and maximal gait velocity (r=0.64,
p<0.001). The CB&M scale has strong validity and reliability when used with a
population of individuals with brain injuries (Howe et al., 2006)(Howe et al.,
2006).
Protocol Modification
Initially, participants were expected to complete the Community Balance
and Mobility Scale as the sole gait measure in the study. On the first day working
with the participant, the participant completed all tasks from the study as an
exposure round to eliminate a one-time, initial learning effect due to anticipation
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of questions and comfort with the assessments. On this day, the participant
completed tasks from the CB&M Scale but remarked that several of the tasks
caused increased pain (which lasted two full days) and were tasks he avoided at
all costs in daily life (such as running, walking and looking horizontally, etc…).
Many of the tasks he attempted to completed appeared to be too complex for him
to complete. The participant expressed interest in continuing the study if he was
able to complete variations of the tasks that did not cause pain. To accommodate
his pain-free ability level while obtaining information similar to what would have
been acquired, the participant completed components of 4 balance and gait
assessments. These included completing the Timed Up and Go, Romberg and
Sharpened Romberg, four tasks from the Dynamic Gait Index, and five
components of the CB&M Scale.
Due to the inability to use the assessment in its entirety, the reliability and
validity of the CB&M Scale and Dynamic Gait Index are no longer possible to be
assumed. Data is therefore examined to look for trends and patterns but the
scores cannot be standardized or compared to norms.
Timed Up and Go
The Timed Up and Go assesses a participant’s mobility and speed rising
from a chair. The primary researcher recorded the time to complete the task;
qualitative information was not used. Shorter times indicate better performance.
The Timed Up and Go has not been extensively tested for populations
with TBIs. A study of children with TBI found excellent test retest reliability (ICC=
.86) (Katz-Leurer, Rotem, Lewitus, Keren, & Meyer, 2008). Other studies on
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community dwelling adults found cut-off scores to be times below 13.5 seconds
for risk of falls (Shumway-Cook, Brauer, & Woollacott, 2000).
Romberg and Sharpened Romberg
The Romberg and Sharpened Romberg assessed the participant’s
balance with and without vision. Participants complete the Romberg with their
feet together and Sharpened Romberg in a tandem stance. The participant has
up to three trials to stand for a maximum of 60 seconds in each condition; longer
times indicate better performance (Callegari, 2009). The Romberg and
Sharpened Romberg have not been normed for TBI. Minimal detectable change
scores with a confidence interval of 95% for the Sharpened Romberg with eyes
closed ranged from 3-9 seconds and with eyes open ranged from 9-10 seconds.
Test retest reliability values (ICC) for volunteers aged 55-75 years old were .72
and .76 for eyes closed and .90 with eyes open (Steffen & Seney, 2008).
Dynamic Gait Index
The DGI assesses functional gait tasks on a 4 point scale (0-3). Higher
scores indicate better performance. Four components from the DGI were used
for this study. The tasks were: 1) Gait with horizontal head turns, 2) Gait with
vertical head turns, 3) Step over an obstacle, and 4) Step around obstacles.
Normative data for people in the same age bracket as DS includes a mean score
of 23.9 with a range of 22-24 and a standard deviation of 0.4 (Vereeck, Wuyts,
Truijen, & Heyning, 2008).
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Community Balance and Mobility Scale
The participant was able to complete five components of the CB&MS.
These tasks included unilateral stance, tandem walking, crouch and walk,
forward to backward walking, and step-ups x 1 step.
Modified Gait Efficacy Scale
The Gait Efficacy Scale was created to assess how confident an individual
was in performing select gait tasks. Confidence is an important component to
function, as a lack of confidence completing a task will likely lead to a decrease
in task performance. A modified Gait Efficacy Scale (mGES), published in 2011,
modified the Gait Efficacy Scale to include tasks that were more commonly
experienced in daily activities (Newell, VanSwearingen, Hile, Brach, 2012). For
the proposed study, the mGES will be further modified to include tasks
specifically difficult for individuals after a traumatic brain injury. The assessment
used in the proposed study, GES-m, eliminates tasks assessing confidence
ascending and descending stairs using a railing, since additional questions
remain to assess confidence with these tasks without using a railing. Two
additional tasks will be added to assess confidence walking in a crowd and
walking through isles, such as at a grocery store.
Although tested for older adult populations, the GES-m assesses tasks
that will likely be affected in the proposed study and tasks that individuals with a
traumatic brain injury may find difficult. This assessment demonstrates a low
likelihood of a ceiling effect which was an important consideration for the
assessment used in the proposed study. The GES-m is a ten item measure that
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uses a 1-10 Likert-like rating scale with a 1 indicating no confidence completing
the task and a 10 indicating complete confidence completing the task. The GESm takes approximately five minutes to complete (Newell et al., 2012). See
Appendix 6 for the complete assessment.
A change of six points appears to indicate a “true” change in that a change
of six points indicates confidence that the score changes reflects a change in
confidence (Newell et al., 2012). A six point change will be used in the proposed
study to indicate a change in confidence.
The mGES has strong reliability and validity. Test-retest reliability after
one month had an intraclass correlation coefficient of 0.93 (CI 0.85-0.97). The
Cronbach alpha was 0.94. The mGES correlated strongly with the Activityspecific Balance Confidence assessment (r=0.88), Falls Efficacy Scale (r=-0.80)
and the Late Life Function and Disability Instrument (r=0.88) (Newell et al.,
2012)(Newell et al., 2012)
Procedures
Completion of the study was completely voluntary, and subjects could
withdrawal from the study or choose not to answer any questions at any point
without negative consequences. To further strengthen the proposed study and
produce as reputable and usable results as possible, guidelines set by
Kratochwill et al., in 2010 were used as a guide and reference as much as
possible (Kratochwill, Hitchcock, Horner, Levin, Odom, Rindskopf, & Shadish,
2010.)
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Researcher Training
The primary researcher for the study received training on the CN-NINM
intervention from the Tactile Communication and Neurorehabilitation Laboratory
(TCNL) at the University of Wisconsin Madison prior to contact with any potential
participants. The training consisted of observation and hands on experience with
the device and intervention. Training continued until the primary researcher and
expert were confident in the ability of the primary researcher to understand and
follow the protocol and apply it to participants.
Phone Screening
Prior to the study, interested participants completed a phone screening. At
this time, the study was explained in detail, including a brief background of the
intervention, what was expected of the participant, and the study time
commitments. Participants were screened to ensure they met inclusion and
exclusion criteria. The primary researcher collected basic demographic
information and a brief impairment list. The only eligible participant set up a time
to begin the study. (See Appendix 4 for the phone screening in its entirety.)
Subjective, free-response journaling
Throughout the study, the participant was encouraged to document his
experiences with each phase in the study in an informal, unstructured journal.
The information was discussed daily to ensure the participant was following the
protocols as directed and address and document any changes he noted.
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First Visit
Prior to beginning data collection, the participant received an informed
consent approved by the Institutional Review Board at the University of
Wisconsin-Milwaukee. The researcher again explained the study and clarified the
expectations for the participant. The participant was provided time to read the
document and ask any questions prior to signing. After signing the informed
consent, the participant completed the self-report surveys, the GES-m, and the
CB&M Scale. According to the protocol established, the scores on these
measures were thrown out and the day was used as practice and awareness of
the assessment components.
While completing several of the CB&M Scale components (running,
walking and looking, etc…), the participant experienced pain in his lower back
and left lower extremity that persisted approximately 48 hours. After further
discussion and prior to beginning the study, the participant expressed an interest
in completing the study if he could complete tasks that did not cause pain. The
primary researcher chose to include the Timed Up and Go, Romberg and
Sharpened Romberg, four components of the Dynamic Gait Index, and five
components of the Community Balance and Mobility Scale to incorporate many
of the variables addressed in the CB&M Scale at a graded intensity level. The
participant agreed to completing the tasks and all were at a level appropriate to
the participant’s abilities. Due to time and financial constraints, the participants
will not be blinded to the study conditions and the study will not employ any sort
of randomization.
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Week One: Baseline Function
During the first week of the study, the participant was tested once daily in
the afternoon, Monday through Friday, under the observation and direction of the
primary researcher. The participant completed the balance and gait tasks to
establish a baseline for functional gait ability. On Friday, the participant
completed the GES-m, POPS, and CIQ to establish a baseline of confidence with
gait activities and perceived community integration.
The primary researcher encouraged the participant to complete periodic
subjective journal entries to document their experiences throughout the study.
The participant made short notes regarding his experience, and the primary
researcher and participant discussed changes and observations each day during
the study to document the experience as well as ensure the participant was
complying with the established protocols. The primary researcher encouraged
the participant to ask questions at any point throughout the study.
Weeks Two and Four: Intervention Weeks
During weeks two and four, the participant completed two training
intervention sessions each day (Monday through Friday), once in the late
morning and again approximately three hours later in the afternoon. At the first
Intervention Session on Monday of week 2, prior to beginning the general
protocol, the participant received his Portable Neuromodulation Stimulator
(PoNS™) device and education on the wear, care, and use of the device. The
primary researcher answered the participant’s questions and the participant
explored the device to be comfortable and familiar with it prior to beginning the
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protocol followed for the intervention weeks. After the participant expressed
feeling comfortable with the device and had no further questions, the Intervention
Sessions and following of the protocol began.
Each morning and afternoon Intervention Session included three 20minute Targeted Training Activity Sessions. The three session included balance
training, relaxation, and gait training. The participant used the PoNS™ device
concurrently with balance and gait targeted trainings; the PoNS™ device was not
used during the relaxation targeted training. All of the Targeted Training Activity
Session tasks were personalized to the participant and depended on his ability
levels each day as well as his limitations. As the participant mastered skills, the
primary researcher increased the difficult level of tasks to maintain the just-right
challenge. For example, once the participant was able to walk consistently in the
center of the treadmill, the participant worked on reducing the number of times he
dragged his left foot rather than clearing the treadmill surface. All targeted
training activities were completed under the instruction and observation of the
primary researcher.
Each day, prior to beginning the second Intervention Session, the
participant completed the balance and gait assessments. These assessments
were administered by the primary researcher and were videotaped and assessed
by clinicians blinded to the study protocols. The participant journaled about his
experiences. Each Friday, the participant also completed the GES-m, POPS, and
CIQ. After completing the assessments, the rest of the afternoon Intervention
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Session continued the same as the morning session with the three Targeted
Training Activity Sessions for gait, relaxation, and balance.
Outside of the Intervention Sessions with the primary researcher, each
day the participant completed two additional 20-minute CN-NINM training, one in
the morning prior to work and one in the evening prior to bed. These sessions
included less rigorous activities to ensure the participant’s safety and increase
likelihood of compliance. No targeted training activities or use of the PoNS™
device occurred on the weekends.
The decision to use one week interventions was based on previous
laboratory observations of individuals with traumatic brain injuries. Often the
individuals with TBIs responded quickly to the intervention.
If a trend is not able to be established during the five data points for the
intervention, the intervention sessions for all following participants will be
increased to two week interventions. This will result in a seven week commitment
for participants instead of five weeks.
Weeks Three and Five: Withdrawal Weeks
During the third and fifth weeks, the participant did not use the PoNS™
device or complete any targeted training activities in order to document
withdrawal effects of the CN-NINM intervention. Each afternoon (Monday through
Friday), the participant completed the balance and gait assessments at
approximately the same time as the second Intervention Sessions the week prior.
On Friday afternoon, the participant completed the GES-m, POPS, and CIQ as
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well. The researcher continued to encourage the use of daily journaling about
changes noticed and experiences with the study.
Data Analysis
The principal guide and reference for completing data analyses came from
guidelines established by Kratochwill et al. in 2010. The authors provide
justification for each the methods of analysis, ensuring the results are evaluated
in an appropriate and meaningful manner (Kratochwill et al., 2010).
Four primary means were used to evaluate the data collected: 1) visual
analyses, also including; 2) basic trend lines using split middle celeration line; 3)
percentage of data overlap technique; and 4) two standard deviation band
analysis.
Visual Analyses
Data will be organized, graphed, and visually analyzed by the primary
researcher to assess visual differences or discrepancies. To strengthen these
results, an expert with a substantial single subject design analysis background
will also visually analyze the data collected. This will be important to strengthen
the observations made regarding the information since experts are recognized as
better at interpreting single subject design data (Ottenbacher, 1986). Visual
analyses can only reliably detect large effects in data (Parker & Hagan-Burke,
2007) and often have very poor inter-rater reliability and additional analyses
methods are encouraged (Zhan & Ottenbacher, 2001). For these reasons,
additional analyses will be completed as well.
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To complete the visual analyses, there are six components to be
evaluated within and between phases: 1) level; 2) trend; 3) variability; 4)
immediacy of the effect; 5) overlap; and 6) consistency of data patterns across
similar phases (Kratochwill et al., 2010).
Basic Trend Lines
Basic trend lines will be created for each phase of each participant and
one technique used will be the split middle celeration line technique. Trend lines
will be particularly beneficial in noting and explaining the trends during phases
and noting changes in direction or slope (Solanas, Manolov, & Onghena, 2010).
Percentage of Data Overlap
A type of percentage of data overlap analyses will be used to evaluate
adjacent phases (Parker, Vannest, & Davis, 2011). This form of analysis is able
to state a percentage of one phase outside the prior phase. For example, if a line
is drawn through the median of the baseline phase, and this line is below all the
data points in the first intervention phase, it is easy and appropriate to state that
100% of data points from the first intervention phase were higher than the
baseline phase.
Two standard deviation bands
The last type of analysis used will calculate the standard deviation in each
phase; a line representing two standard deviations will be drawn below and
above the data set. When continued into the adjacent phase, it is clear if any or
how much of the data is more than two standard deviations different than the first
phase. This analysis technique can be misleading if there is a great deal of

135
variability in the data, which further supports the use of several analysis
techniques. Two standard deviations, in quantitative group designs, represents
95% of the population and indicated a 95% confidence that if something is
outside of the two standard deviations it is truly different than the rest of the data,
not that the difference is due to chance (Nourbakhsh & Ottenbacher, 1994).
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Screening Questionnaire
We are doing this study to learn more about the effects of a new therapeutic
intervention tool (therapy aid). We want to study the immediate effects, what happens
when the device is taken away, and what happens over a longer period of time. The
intervention we are studying uses safe, mild electricity on your tongue to prepare your
brain for learning while you do therapy activities. People who have used this device and
completed other studies have had positive results. Almost all people have said they
noticed their walking and balance getting better, and many have commented on other
positive changes as well. A few people did not notice very much improvement in their
walking or balance. No one has mentioned negative changes they believe are from the
device.
If you want to be in this study, it will be a lot of work for you and a lot of time. You
will have to come to a lab at the University of Wisconsin-Milwaukee (UWM) every day
for 5 weeks to do a walking test and once a week you will do the same three additional
surveys. If you miss too many days or on the rare chance the researcher thinks it is
necessary, we might ask you to come an extra week, making the study a total of 6
weeks. Every other week, on the 1st, 3rd and 5th weeks, you will come to the lab every
day to do a walking test. Each visit should take about 45 minutes. On the other two
weeks, the 2nd and 4th, you will have to come to the lab twice every day, once in the
morning and once in the afternoon. During these weeks, you will use the new
intervention tool. Each appointment will be about an hour and a half so you will be in the
lab a total of 3 hours each day during the two intervention weeks. You will also use the
device at home two times per night, each time for 20 minutes. While you are using the
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device, we will be helping you work on improving your balance and walking. You will do
activities similar to what you did in rehabilitation in the hospital. For example you might
stand on foam with your eyes closed to improve your balance, or walk backwards in the
hallway to improve your walking. In both examples you would also keep the device on
your tongue so it is providing the electricity to the tongue during the activities.
If you decide you want to be in the study, you can change your mind and drop
out of the study at any time. There will not be any negative effects of you deciding not to
be in the study anymore, but you will have to return the device.
Do you have any questions?
If you decide to be part of the study, there are two parts to the study. Phase I is
the study I described to you before. It will last 5 weeks. If you finish that Phase and want
to keep using the device, Phase II studies long-term effects. You will be able to keep the
device and use it at home as much as you want, up to the amount you use it during the
first Phase. Every six months for three years we will ask you to come back to the lab so
we can see how your walking is and have you take three surveys. When you are using
the device at home, we will ask you to put a mark on a calendar we give you every time
you use the device. Again, you can stop participating in the study at any time. If you
decide to stop, you will have to return the device. At the end of the three years, you will
have to return the device.
Do you have any questions?
Are you interested in participating?
I am going to ask you several questions to make sure that you are an appropriate
fit to the study. Please answer the questions as honestly as you can.
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Questions
1.

How old are you?_____________________________________________

2.

What caused your head injury? __________________________________

3.

How long has it been since your injury? ___________________________

4.

How much therapy have you had since your injury? __________________

5.

What kinds of rehabilitation have you had since your injury? ___________

6.

Approximately how long has it been since you received rehabilitation services?

7.

Are you currently receiving any balance or walking (gait) training or in any
exercise programs? _____________________________________________

8.

Are you your own legal guardian? ________________________________

9.

Do you live in any type of assisted living facility? ____________________

10.

What type of support system do you have, who is your support system? __
__________________________________________________________

11.

How would you describe your living situation? ______________________

12.

Are you able to walk 30 feet[13] with or without an assistive device, such as a
cane, walker or holding on to someone? _____________________________

13.

Are you able to maintain an upright posture for 20 minutes? ___________

14.

Do you have any electronic devices/implants such as a pacemaker, deep brain
stimulator, biomechanical prosthetic? ________________________________

15.

Do you have any of the following conditions: a hard time understanding words
you hear (called receptive aphasia), uncontrolled pain, uncontrolled mental health
condition, another condition (or comorbid diagnosis) that affects balance such as
Multiple Sclerosis or Parkinson’s Disease, problems with your vision, myasthenia
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gravis, Charcot-Marie tooth disease, post-polio, guillan barre, fibromyalgia,
hypertension, diabetes, or chronic fatigue syndrome? ___________________
16.

Do you use tobacco products, have any contagious mouth diseases, sores,
piercings or abrasions or tongue neuropathies? ________________________

17.

Are you pregnant or trying to become pregnant? ____________________

18.

Have you had a major change in the type or amount (dosage) of medications
within the previous three months? __________________________________

19.

What kind of impairments to you still notice that you think are from your brain
injury? (Some common symptoms noted are decreased balance and gait, ability to
walk in a crowd, increased irritability, decreased short-term memory, decreased fine
motor control, vision changes or impairments). ________________________
__________________________________________________________

20.

Are balance or walking activities hard for you? Some people have a hard time
keeping their balance with their eyes closed, turning their head while walking,
changing speeds or directions, or walking in a crowd. ___________________

21.

Are you willing and able to come to the laboratory at the University of Wisconsin
Milwaukee every day for five concurrent weeks? _______________________

22.

Have you had any major life changes within the past month, or any events that
affect your daily functioning? ______________________________________

23.

In order to complete the longitudinal portion of the study, you must either have an
email address or be willing to create an email address for the study. You do NOT
need an email address to participate in the first phase. Do you have an email
address? _____________________________________________________
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Equivalent text descriptions (EqTDs) are provided for each figure used in
the research manuscript but are not included for the graphs created in Appendix
C. Each of these graphs are described in context for trends and changes noted
and will not be duplicated here.
Figure 1: Overview of CN-NINM terms
Brief Description: Flowchart defining terms intrinsic to the CN-NINM
intervention
Essential Description: The flowchart shows two equations and has five
components. The first equation is 20 minutes of Targeted Training Activity
Session plus 20 minutes PoNS™ stimulation equals 1 CN-NINM session. The
second equation is 3 CN-NINM sessions (gait, relaxation, balance) equals 1
Intervention session.
Figure 2: PoNS™ Device
Brief Description: Photograph of a PoNS™ device
Essential Description: The PoNS™ device has two main pieces. The first is a
small plastic box with four buttons labeled “Down”, “Up”, “Off”, and “On”. A sticker
labeling it PoNS™ is visible in the middle of the box. The second piece is a small
oral tab. There is a plastic piece that is labeled to be just over one centimeter
long and between one and two centimeters wide leading to an oral tab. The tab
looks to have several small circles on it.
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Figure 3: Participant using the PoNS™device during gait CN-NINM
session
Brief Description: Photograph of a woman walking backwards on a treadmill
with the PoNS™ device in her mouth
Essential Description: The woman in the photograph is completing a gait
training CN-NINM session with the PoNS™ device visible in her mouth. The
device is small and the woman does not appear to be working to keep the device
in her mouth, or focusing on the device or struggling to multitask. The device is
attached to a lanyard which is around the woman’s neck.
Figure 4: Romberg Stance
Brief Description: Photograph of a woman standing with her feet together
Essential Description: A woman is photographed standing with her feet next to
each other, her arms folded into an “x” across her chest, and her eyes closed.
This is the standardized position for completing the Romberg test.
Figure 5: Sharpened Romberg Stance
Brief Description: Photograph of a woman standing with one foot directly in
front of the other
Essential Description: A woman is photographed standing with her feet in
tandem (one in front of the other, with her heel touching her toes of the other
foot, her arms folded into an “x” across her chest, and her eyes closed. This is
the standardized position for completing the Sharpened Romberg test.
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Figure 6: Participant completing the DGI task “Step over an
Obstacle”
Brief Description: Photograph of a man stepping over a plaid covered shoebox
Essential Description: A man is stepping over a shoebox sized object covered
in a plaid design. He is leading with his left foot. Another person is visible
standing behind the man.
Figure 7: Participant completing CB&M Scale task “Step-Ups”
Brief Description: Photograph of a man stepping up onto a stair
Essential Description: A man is stepping up onto step. He appears to be
leading with his left foot. Another person is visible to the side of the man.
Figure 8: Sharpened Romberg Best Time with Eyes Open
Brief Description: Graph of time scores on the Romberg test with eyes open
showing five lines with alternating colors
Essential Description: Time scores for the Romberg test with eyes open are
graphed with five points in each of five lines. The first line has three points on the
highest point (60 seconds); the second line has four points at 60 seconds and the
fifth point slightly below 60 seconds. The third line starts at about the 40 second
line, drops slightly for the second point, then climbs steadily for the subsequent
points, reaching 60 seconds on the final point. Each point on the fourth line is at
60 seconds. The second point on the fifth line is the only point not at 60 seconds,
falling slightly above 50 seconds. Overall higher scores and greater stability is
noted on the second and fourth weeks.
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Figure 9: Best time on Sharpened Romberg with eyes closed
Brief Description: Graph of time scores on the Sharpened Romberg test with
eyes closed showing five lines with alternating colors
Essential Description: Time scores for the Sharpened Romberg test with eyes
closed are graphed with five points in each of five lines. The first line has four
points between five and fifteen seconds and the fourth point is around 25
seconds. The first three points of the second line are between 15 and 25
seconds and the last two points around 5 seconds. The third line shows increase
variability with a pattern similar to an “N” shape with scores ranging from 8-45
seconds, the second and fifth points near 45 seconds, and the first, third, and
fourth points below 20 seconds. The fourth line is shaped like a “V” or “U” with
scores ranging from 5-20 seconds. The fifth line has a pattern like an “M”, with
high scores of 60 and just over fifty, respectively, and low scores between ten
and twenty seconds. Overall trends show increasing variability over the five
phases.
Figure 10: All scores from the Sharpened Romberg with eyes closed
Brief Description: Graph of each data point for the Sharpened Romberg test
divided into Baseline, Intervention, Withdrawal, Intervention, and Withdrawal
sections
Essential Description: Time scores for each day are graphed and sections are
divided into baseline, intervention, withdrawal, intervention, and withdrawal. No
obvious trends are noted in the data, however, the last phase has the most
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variability and most of the data points for each phase are clustered at or under
ten seconds.
Figure 11: Dynamic Gait Index Combined Scores
Brief Description: Graph of combined scores from the Dynamic Gait Index
shown in five lines of alternating colors
Essential Description: Combined scores from the Dynamic Gait Index are
graphed in five lines. Overall, a slight increasing trend is noted. The first line has
high variability with scores ranging from 7-11 (with a maximum score of 12). The
first point of the second line reaches 12 points, the maximum for the scale, and
the last four points are 9 and 10 points. The third line scores have a “W” pattern
with scores of 9 and 11. Scores on the fourth line are shaped like a “V” and range
include scores of 12, 11, 10, 11, 12 respectively. The first point on the fifth line is
12 and all subsequent scores remain steady at 11.
Figure 12: Confidence Walking on Grass
Brief Description: Bar graph of Gait Efficacy Scale- modified scores with five
lines of alternating colors
Essential Description: Five lines are graphed to show scores on the Gait
Efficacy Scale-modified. Scores start at 4 points at the first line, increase one
point for the second line, decrease one point at the third line, increase three
points for at the fourth line, and increase one point at the fifth line.
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Department of University Safety & Assurances

Modification/Amendment - IRB Expedited Approval
Date:

April 29, 2013

To:
Dept:

Roger O. Smith, PhD
College of Health Sciences

Cc:

Kati Liegl

Jessica Rice
IRB Administrator
Institutional Review Board
Engelmann 270
P. O. Box 413
Milwaukee, WI 53201-0413
(414) 229-3182 phone
(414) 229-6729 fax
http://www.irb.uwm.edu
ricej@uwm.edu

IRB#: 13.136
Title: Beneficial and Withdrawal Effects of Cranial Nerve Non-Invasive Neuromodulation on
Functional Mobility for Individuals with Traumatic Brain Injury with Multiyear Followup
After review of your research protocol by the University of Wisconsin – Milwaukee Institutional
Review Board, your protocol has received modification/amendment approval for:
•
•
•

Addition of Independence First as a data collection site
Addition of asking participants to consent to videotaping the gait assessment
Revisions to consent forms to reflect the changes above

IRB approval will expire on December 6, 2013. If you plan to continue any research related
activities (e.g., enrollment of subjects, study interventions, data analysis, etc.) past the date of IRB
expiration, a Continuation for IRB Approval must be filed by the submission deadline. If the
study is closed or completed before the IRB expiration date, please notify the IRB by completing
and submitting the Continuing Review form found on the IRB website.
Unless specifically where the change is necessary to eliminate apparent immediate hazards to the
subjects, any proposed changes to the protocol must be reviewed by the Institutional Review
Board before implementation.
Please note that it is the principal investigator’s responsibility to adhere to the policies and
guidelines set forth by the University of Wisconsin – Milwaukee and its Institutional Review
Board. It is the principal investigator’s responsibility to maintain proper documentation of its
records and promptly report to the Institutional Review Board any adverse events which require
reporting.
Contact the IRB office if you have any further questions. Thank you for your cooperation and best
wishes for a successful project
Respectfully,

Jessica Rice
IRB Administrator

UW-Milwaukee
Institutional Review Board

IRBManager Protocol Form
v1.2

IRBManager Protocol Form
Instructions: Each Section must be completed unless directed otherwise. Incomplete forms will delay the IRB review process and may be returned to
you. Enter your information in the colored boxes or place an “X” in front of the appropriate response(s). If the question does not apply, write “N/A.”
SECTION A: Title
A1. Full Study Title:

Beneficial and Withdrawal Effects of Cranial Nerve Non-Invasive Neuromodulation on Functional Mobility for
Individuals with Traumatic Brain Injury with Multiyear Follow-up.

SECTION B: Study Duration
B1. What is the expected start date? Data collection, screening, recruitment, enrollment, or consenting activities may not begin until IRB approval has
been granted. Format: 07/05/2011
12/10/2012
B2. What is the expected end date? Expected end date should take into account data analysis, queries, and paper write-up. Format: 07/05/2014
09/30/2017
SECTION C: Summary
C1. Write a brief descriptive summary of this study in Layman Terms (non-technical language):
Functional recovery from neurological insult or disease remains compromised for many individuals. In the field of
neurorehabilitation, electrical stimulation of the brain has long been theorized as a potential mechanism to improve function.
Recently, researchers at the Tactile Communication and Neurorehabilitation Laboratory at the University of Wisconsin- Madison
(TCNL) have developed a method of delivering non-invasive electrical stimulation to the brain that, when paired with targeted
rehabilitation training (cranial nerve non-invasive neuromodulation, or CN-NINM), is showing remarkable benefits and promise for
rehabilitation. As a portable device to deliver the stimulation continues to be developed, observational, case study and proof of
concept investigations plus one randomized controlled trial (RCT) are reported. This study will use a single subject research design,
appropriate at this stage of concept development, to quantify the effect of CN-NINM in improving functional balance and gait in
individuals who have residual effects following a traumatic brain injury (TBI).
Background: Multiple studies have examined the effects of the CN-NINM intervention for multiple diagnostic groups, but this is the
first study that proposes to examine the withdrawal effects from the intervention as well as the immediate effects. The CN-NINM
October 15, 2012
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intervention, created by TCNL at the University of Wisconsin-Madison, combines non-invasive, safe doses of electricity, applied to
the tongue using a device called the Portable Neurostimulator (PoNS™), and personalized targeted training activities. All of the
completed research has looked specifically at individuals with balance and/or gait impairments and have focused targeted training
activities to reduce these impairments. fMRI research has demonstrated an increase in activation in the posterior aspect of the pons
varolli, superior medulla oblongata, and ventral cerebellum after a week of CN-NINM intervention; these areas are primary sensory
integration and movement control centers, thus making them prime targets for neuromodulation to improve balance and gait
impairments. Prior research has studied effects of this intervention for individuals with primary vestibular dysfunction, cerebellar
atrophy, traumatic brain injuries, strokes, and Multiple Sclerosis. This research has demonstrated significant positive results for
each population tested, and have yet to observe negative side effects from the intervention. Some of the results appeared to have a
carryover effect, lasting after the stimulation was stopped. The withdrawal effects have not been studied. This study will look at the
benefits and withdrawal effects of the CN-NINM intervention for individuals with a past traumatic brain injury as well as follow-up on
functional balance and gait changes every 6 months for three years.
Research utilizing electrical stimulation of the tongue has established the technique as safe and easy to administer. No negative
side effects have been recorded. Through research using sensory substitution and the BrainPort™, the predicate device to the
PoNS™, researchers observed improvements in participants’ function that did not appear related to the intervention received.
Examples of these improvements included improved balance and gait, improved mood, concentration, sleep, and a reduction in
expressive aphasia and reduction in pain. The CN-NINM intervention was established to explore the effects of using informationfree stimulus combined with targeted training specific to the individuals’ impairments.
Design: The proposed study will use a single subject design with four participants to study the benefits and withdrawal effects of
the CN-NINM intervention using an A-B-A-B-A design planned to last 5 weeks. CN-NINM involves targeted therapeutic interventions
paired with simultaneous non-invasive electrical stimulation. Within any phase, should two data points be greater or less than the
value of two minimal detectable changes (16 point change for the gait assessment) from the regression line, that phase will be
lengthened to two weeks. This is not anticipated unless the participant is unable to attend his/her appointments more than once in a
week. Therefore, phase lengths will be referred to as lasting one week, however it is possible that a phase may last a maximum of
two weeks in a rare event.
Following this, should the participant decide to continue with the second phase of the study, a longitudinal follow up every 6 months
for three years will provide descriptive information regarding functional status and voluntary use of the device outside of a structured
study environment. (See the timeline protocol for participant expectations and the overall study design.)
All researchers with participant contact have a formal education in therapeutic rehabilitation, as well as experience working with
people with disabilities including brain injuries. The primary researcher has 6 months of full time clinical experience with populations
in physical rehabilitation including working with individuals with brain injuries. In addition to the clinical experience, the primary
researcher has completed substantial formal education in rehabilitation areas. The primary researcher will be trained on the
intervention and participant interactions by a CN-NINM expert. The primary researcher will receive training at TCNL from a primary
researcher of a study using the CN-NINM intervention at TCNL. Training will continue until the primary researcher and expert reach
agreement in answering potential questions and completing appropriate targeted training activities. This training will occur prior to
any data collection with participants in the study. During the study, several experts from TCNL and the R2D2 Center will be available
for questions, should any arise.
Baseline: The initial baseline phase will contain 6 days of data collection. On the first data collection day, participants will read and
sign the Informed Consent, complete the Participant Objective Participation Subjective (POPS) Assessment, Community Integration
October 15, 2012
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Questionnaire (CIQ), modified Gait Efficacy Scale (GES-m), and Community Balance and Mobility (CB&M) Scale. Of the measures
used, all are self-report assessments which will be taken by the participant independently in the lab, except the CB&M Scale, which
will be administered by a trained researcher. The first day will take approximately 90 minutes. The subsequent five days of data
collection for the baseline will occur on a following Monday through Friday in the afternoons. Monday through Thursday, participants
will be assessed only with the CB&M Scale. On Friday, participants will complete the gait assessment as well as the three selfassessment surveys. The CB&M Scale will be videotaped contingent on participant consent to videotape. If the participant does not
consent to being videotaped, they may still participate in the study with no negative consequences. During the baseline phase,
participants will be instructed to continue with their normal daily routines and structures, trying not to change their habits in an
attempt to do better on the assessments. Each day, data collection will take approximately 45 minutes, except appointments that
include the self-assessment surveys, which will take approximately 90 minutes. All appointments will occur at a University of
Wisconsin – Milwaukee laboratory in the R2D2 Center or in the Occupational Sciences & Technology (OS&T) Department or in an
equivalent space at IndependenceFirst. These spaces are well-equipped and have been used previously for human subjects
research. They provide ample space to complete the balance, gait and relaxation training. The gait assessment will be completed
either inside the primary data collection areas or in the hallway directly outside.
Intervention: The “B” phases indicate the intervention phases. Each intervention phase lasts 5 days. On the first day of the
intervention phase, participants will receive a PoNS™ device and be instructed on proper wear, care, and use of the device. Each
day of the Intervention phases, participants will complete two intervention sessions in the laboratory under the direction of a trained
researcher, one in the morning, the other in the afternoon approximately two to three hours apart. Each intervention session will
include three 20 minute targeted training activities, one for balance, one for relaxation, and the third for gait (completed in the order
listed. See attachment of typical training activities for examples of typical training activities.). Participants will use the PoNS™ device
to provide electrical stimulation during the balance and gait targeted training activities. These targeted training activities are selected
to replicate the intervention used in earlier studies at the TCNL. Each targeted training activity session will be individualized based
on the functioning of the participant. Activities will be selected to be challenging but feasible for participants, and will change in
difficulty level as the participant’s ability level changes. The risk associated with completing the activities is no more than the risk in
clinic based outpatient neurorehabilitation. The CB&M Scale will be administered prior to beginning the second intervention session.
This assessment will be videotaped contingent on participant consent to videotape. If the participant does not consent to being
videotaped, they may still participate in the study with no negative consequences. Each intervention session will take approximately
90 minutes to complete. On the last day of the intervention phases, participants will also complete the self-assessment surveys after
the completion of the CB&M Scale. Participants will be encouraged to document their experiences with the intervention throughout
the study, but the journaling will not be structured or regulated. The journaling will be collected and reviewed weekly to ensure
compliance and identify any potential problems or confounding variables such as illnesses or major life changes.
Each day, participants will be asked about any adverse effects from the intervention.
In addition to the two intervention sessions in the laboratory, participants will use the PoNS™ device for two 20 minute sessions at
home in the evenings while completing more simplified tasks to ensure safety completing the tasks. The participants will select
which training activities they complete in the evenings.
Withdrawal: The “A” phases indicate withdrawal phases. Both withdrawal phases last five days. During the withdrawal phases,
participants will come to the laboratory in the afternoon. Each day, participants will be assessed using the CB&M Scale. This
assessment will be videotaped contingent on participant consent to videotape. If the participant does not consent to being
videotaped, they may still participate in the study with no negative consequences. On the last day of the withdrawal phases,
participants will also complete the GES-m, CIQ, and POPS after the CB&M Scale. Each appointment is expected to last
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approximately 45 minutes, with the visit on the last day lasting approximately 90 minutes. Participants will be encouraged to
maintain as similar a routine and habits as they had prior to admittance into the study.
After the last withdrawal period, participants will be allowed to choose if they would like to keep the device and participate in the
longitudinal portion of the study. If the participants decide not to continue with the research, they will be asked to return the device
and no additional information will be collected on that participant. If the participant chooses to keep the device and continue with the
study, they will complete the follow-up sessions described below. The longitudinal information collected will be used as descriptive
information.
Overall, the first, third, and fifth weeks will require 45 minute daily sessions Monday through Thursday, and 90 minute sessions on
Fridays. In addition, the first appointment will occur prior to starting the first full week; this appointment may take up to 90 minutes.
The second and fourth weeks require two laboratory sessions daily, each approximately 90 minutes, totaling approximately three
hours per day in the laboratory both weeks.
Longitudinal Follow-ups: After the completion of the ABABA protocol, subjects will be asked if they wish to continue use of the
PoNS™ device. If they want to continue using the device there will be no further formal intervention and minimal recording will
informally document use. Participants will be provided with monthly calendars. Each time they use the device, participants will
indicate this on the calendar by marking the day with an “x”. Participants will be informed that they can use the device daily up to the
amount they used during the initial phase of the study or rarely use the device; the amount of use is of no consequence so long as
they accurately record how often they choose to use the device. Participants will receive monthly email reminders to continue
tracking the use of the PoNS™ device. Monthly email reminders will also encourage and welcome periodic updates on functional
status and experience with the device. (See the sample monthly email in the supplemental information.) If participants choose to
stop using the device, they will be asked to return the device. Every six months for the following three years, participants will return
to the laboratory to complete the CB&M Scale, GES-m, CIQ, and POPS. Participants will also be instructed to bring their calendars
to the researchers in order to track voluntary usage and functional status changes. Subjective journaling as in the ABABA protocol
will be encouraged but not required; the back side of the calendar page will have room for subjective journaling or comments.
Each follow up visit will be expected to last for approximately 90 minutes.
Phase I will last until four subjects have completed the phase. This is expected to require up to approximately six months of data
collection. Phase II will be conducted for up to three years from the time the last (fourth) participant successfully completes Phase I.
Data Collection: All data collection will occur at a laboratory at UW-Milwaukee in the R2D2 Center or in the OS&T Department or at
IndependenceFirst. The UWM spaces have previously been used for human subjects data collection and both areas include spaces
that provide a quiet location for the balance and relaxation training. They also have space to complete the balance and gait
trainings. (1) The primary outcome measure is the Community Balance & Mobility Scale (CB&M Scale), a gait assessment created
for individuals with TBI who are ambulatory in the community and have gait impairments not detectable with other measures. (2) A
modified version of the Gait Efficacy Scale will be used after each phase and during follow-up visits to examine the effects of the
intervention on the confidence participants have completing routine functional gait tasks. (3 & 4) The POPS and CIQ will be
administered at the first visit, at the end of each phase, and at each follow-up visit. These measures will be used to examine
community integration. (5) Participants will also keep informal journals during the study to document their experiences with the
intervention. During intervention weeks, the assessments will be completed prior to beginning the afternoon intervention session.
During withdrawal weeks, participants will come to the laboratory in the afternoon to complete the assessments.
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If a participant completes the study at IndependenceFirst, the researcher will be in possession of the paper copies of data collected
at all times. After the completion of trainings or the assessments each day, the records collected will be taken directly to the secured
location at UWM. No additional personnel will have access to the information collected from IndependenceFirst or UWM.
The participant data (video-recorded) will be assessed by two trained raters, each with clinical experience. The two raters will
complete a training session together to become familiar with the assessments. The raters will score the assessments either at UWM
in the R2D2 Center or in their office with instructions for maintaining the confidentiality of the participant. If the rater chooses to
complete the scoring outside of UWM, a CD/DVD of the videos will be personally delivered to the rater. They will be expected to
return the CD/DVD upon completion of the scoring, up to one month after obtaining the CD/DVD and immediately after completing
the scoring. None of the scored information obtained from the raters will contain patient identifying data. The raters will be
compensated for their time scoring the data.
Participants: Four participants with a history of a closed traumatic brain injury will complete Phase I of the study. If a participant
drops out during Phase I of the study, that participant will be replaced until four participants successfully complete Phase I (up to a
maximum of 12 participants recruited). A maximum of the four participants that complete Phase I will be eligible to complete Phase
II; participants who drop out during Phase II will not be replaced and beginning Phase II is not required. Participants must live in a
community setting and no longer be receiving rehabilitation services or balance training. For inclusion and exclusion criteria, see
D3. Participants will be recruited through flyers hung in the community, referrals, word of mouth, and email flyers sent to targeted
brain injury support groups, (see recruitment flyers in attachments).
C2. Describe the purpose/objective and the significance of the research:
This research will evaluate the benefits and withdrawal effects of the CN-NINM intervention on functional gait for individuals with
TBI. The intervention protocol used in this study is based on the protocols and research of the PoNS™ device developers at TCNL.
Their work has demonstrated significant benefits, particularly improved balance and gait, through preliminary case study and proof
of concept studies, for individuals with diverse neurological diagnoses. One randomized controlled trial is completed with subjects
who have Multiple Sclerosis. To date, there have been no formal investigations looking at the effects of withdrawal. CN-NINM has
the potential to greatly impact rehabilitation, but it is critical to understand and document withdrawal effects. This is an important
component to understand prior to FDA trials. The longitudinal component to the study will provide structured, quantitative and
descriptive information on the longitudinal effects as well as track voluntary participant usage.
C3. Cite any relevant literature pertaining to the proposed research:
Bach-y-Rita, P., & Kercel, S. W. (2003). Sensory substitution and the human-machine interface. Trends in Cognitive Sciences,
7(12), 541-546. doi: 10.1016/j.tics.2003.10.013
Badke, M. B., Sherman, J., Boyne, P., Page, S., & Dunning, K. (2011). Tongue-based biofeedback for balance in stroke: Results of
an 8-week pilot study. Archives of Physical Medicine & Rehabilitation, 92, 1364-1370.
Cramer, S. C., Sur, M., Dobkin, B. H., O'Brien, C., Sanger, T. D., Trojanowski, J. Q., . . . Vinogradov, S. (2011). Harnessing
neuroplasticity for clinical applications. Brain, 134, 1591-1609. doi: 10.1093/brain/awr039
Danilov, Y. P., Tyler, M. E., Rust, K. L., Kaczmarek, K. A., & Subbotin, A. M. (N.D.). Non-invasive neuromodulation to improve gait
in chronic Multiple Sclerosis: A randomized controlled trial. Unpublished manuscript.
Danilov, Y. P., Tyler, M. E., Skinner, K. L., Hogle, R. A., & Bach-y-Rita, P. (2007). Efficacy of electrotactile vestibular substitution in
patients with peripheral and central vestibular loss. Journal of Vestibular Research, 17, 119-130.
Dimyan, M. A., & Cohen, L. G. (2011). Neuroplasticity in the context of motor rehabilitation after stroke. Nature Reviews Neurology,
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7, 76-85. doi: 10.1038/nmeurol.2010.200
Howe, J. A., Inness, E. L., Venturini, A., Williams, J. I., & Verrier, M. C. (2006). The Community Balance and Mobility Scale – A
balance measure for individuals with traumatic brain injury. Clinical Rehabilitation, 20, 885-895.
Howe, J., Inness, E. L., & Wright, V. (2011). The Community Balance & Mobility Scale. The Center for Outcome Measurement in
Brain Injury. Retrieved October 8, 2012, from http://www.tbims.org/combi/cbm.
Kaczmarek, K. A., Danilov, Y. P., & Tyler, M. E. (2009). Reducing symptoms of Multiple Sclerosis using non-invasive
neuromodulation. Final Report to Partnership for Cures Foundation. Hyperlink
“http://tcnl.med.wisc.edu/projects_PfC_MS.php”.
Newell, A. M., VanSwearingen, J. M., Hile, E., & Brach, J. S. (2012). The modified Gait Efficacy Scale: Establishing the
psychometric properties in older adults. Physical Therapy, 92, 318-328. doi: 10.2522/ptj.20110053
Ptito, M., Moesgaard, S. M., Gjedde, A., & Kupers, R. (2005). Cross-modal plasticity revealed by electrotactile stimulation of the
tongue in the congenitally blind. Brain, 128, 606-614.
Tactile Communication & Neurorehabilitation Laboratory. (2011). Manual: Balance and gait training for subjects with Multiple
Sclerosis. Reducing symptoms of MS using Cranial Nerve Noninvasive Neuromodulation (CN-NINM).
Tyler, M. E., Braun, J. G., & Danilov, Y. P. (2009). Spatial mapping of electrotactile sensation threshold and intensity range on the
human tongue: Initial results. Paper presented at the IEEE EMBS.
Tyler, M. E., & Meryerand, M. E. (2008). Investigation of brain plasticity in response to noninvasive neuromodulation. Final Report,
UW-Madison 2007-2008 Industrial & Economic Development Research Program. Retrieved on September 14, 2012 from
http://tcnl.med.wisc.edu/pioneer/IEDR.pdf.
Wildenberg, J. C., Tyler, M. E., Danilov, Y. P., Kaczmarek, K. A., & Meyerand, M. E. (2010). Sustained cortical and subcortical
neuromodulation induced by electrical tongue stimulation. Brain Imaging and Behavior, 4, 199-211. doi: 10.1007/s11682010-9099-7
Wildenberg, J. C., Tyler, M. E., Danilov, Y. P., Kaczmarek, K. A., & Meyerand, M. E. (2011). High-resolution fMRI detects
neuromodulation of individual brainstem nuclei by electrical tongue stimulation in balance-impaired individuals.
NeuroImage, 56, 2129-2137. doi: 10.1016/j.neuroimage.2011.03.074
SECTION D: Subject Population
Section Notes…
 D1. If this study involves analysis of de-identified data only (i.e., no human subject interaction), IRB submission/review may not be necessary.
Visit the Pre-Submission section in the IRB website for more information.
D1. Identify any population(s) that you will be specifically targeting for the study. Check all that apply: (Place an “X” in the
column next to the name of the special population.)
Institutionalized/ Nursing home residents recruited in the
Not Applicable (e.g., de-identified datasets)
nursing home
UWM Students of PI or study staff

Diagnosable Psychological Disorder/Psychiatrically impaired

Non-UWM students to be recruited in their educational
setting, i.e. in class or at school

Decisionally/Cognitively Impaired

October 15, 2012

161

Page 6 of 18

UW-Milwaukee
Institutional Review Board

X

IRBManager Protocol Form
v1.2

UWM Staff or Faculty

Economically/Educationally Disadvantaged

Pregnant Women/Neonates

Prisoners

Minors under 18 and ARE NOT wards of the State

Non-English Speaking

Minors under 18 and ARE wards of the State

Terminally ill

Other (Please identify): Individuals with a gait impairment secondary to a closed traumatic brain injury but not currently
receiving any type of balance intervention or therapy.

D2. Describe the subject group and enter the total number to be enrolled for each group. For example: teachers-50,
students-200, parents-25, parent’s children-25, student control-30, student experimental-30, medical charts-500, dataset of 1500,
etc. Enter the total number of subjects below.
Describe subject group:

Number:

Individuals with previous traumatic brain injury

12

TOTAL # OF SUBJECTS:

12

TOTAL # OF SUBJECTS (If UWM is a collaborating site):
D3. List any major inclusion and exclusion criteria (e.g., age, gender, health status/condition, ethnicity, location, English speaking, etc.) and
state the justification for the inclusion and exclusion:
Inclusion Criteria
 Have a clinically detectable gait impairment secondary to a closed traumatic brain injury
 Live in a community setting or facility that does not provide assistance
 No longer be receiving rehabilitation or balance training programs of any kind
 Be able to ambulate 10 meters without resting
 Be able to maintain upright posture for 20 minutes
 Be between the ages of 18-65
 Speak fluent English
 Must be their own legal guardian and able to understand instructions and give informed consent
Exclusion Criteria
Participants will be excluded from the study if they:
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have electrical devices/implants such as pacemakers
have a biomechanical prosthetic
have a comorbid diagnosis that could affect balance such as Multiple Sclerosis or Parkinson’s Disease
are pregnant or trying to become pregnant
use tobacco products
have contagious mouth diseases, sores, piercings or abrasions
have tongue neuropathies
have receptive aphasia
have uncontrolled pain
have uncontrolled mental health conditions
have a history of seizures, including a diagnosis of Epilepsy
self-report as having a vision impairment that is not corrected
are on medications and have had a major change in type or dosage within three months of enrollment
lack the motivation necessary to complete the tasks
lack the cognition to understand and complete the protocols as directed
do not have an email address and are unwilling to create one (this applies only if participants choose to complete Phase II
of the study. An email address is not required for the first phase.)

SECTION E: Informed Consent
Section Notes…
 E1. Make sure to attach any recruitment materials for IRB approval.
 E3. The privacy of the participants must be maintained throughout the consent process.
E1. Describe how the subjects will be recruited. (E.g., through flyers, beginning announcement for X class, referrals, random telephone sampling,
etc.). If this study involves secondary analysis of data/charts/specimens only, provide information on the source of the data, whether the data is publicly
available and whether the data contains direct or indirect identifiers.
Participants will be recruited through flyers distributed in public community locations as well as word of mouth and referrals. Emails
with flyers attached will be sent to targeted groups. These groups will include TBI support groups such as Dryhootch (a coffee shop
for veterans, ran by veterans that utilizes various peer-support support groups) and Brain Injury Alliance of Wisconsin. Recruitment
will continue until four participants complete the five week section of the study; if a participant drops out of the study, an additional
participant will be recruited to complete the study.
E2. Describe the forms that will be used for each subject group (e.g., short version, combined parent/child consent form, child assent form,
verbal script, information sheet): If data from failed eligibility screenings will be used as part of your “research data”, then these individuals are
considered research subjects and consent will need to be obtained. Copies of all forms should be attached for approval. If requesting to waive
documentation (not collecting subject’s signature) or to waive consent all together, state so and complete the “Waiver to Obtain-Document-Alter
Consent” and attach:
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Participants will complete an Informed Consent Form prior to participation. Prior to signing the consent form, information will be
explained to the participant orally by the primary researcher, a copy will be provided for the participant to keep, and the participant
will have time to read the document prior to signing, returning the document to the primary researcher and beginning the study.

E3. Describe who will obtain consent and where and when consent will be obtained. When appropriate (for higher risk and complex study
activities), a process should be mentioned to assure that participants understand the information. For example, in addition to the signed consent form,
describing the study procedures verbally or visually:
Participants interested in completing the study will contact the researchers. A phone screening will determine eligibility and provide
the opportunity for questions and answers. If eligible, the participant will schedule a time to begin the study at a University of
Wisconsin-Milwaukee laboratory or at IndependenceFirst. The primary researcher will again explain each section of the study and
Informed Consent for Phase I. After the explanation, the participant will be provided time to read and ask questions regarding the
Phase I consent form prior to signing the form, returning it to the primary researcher, and beginning the study. Each participant will
be provided a copy of the Informed Consent to keep. If the participant decides to continue to participant in Phase II of the study, the
Informed Consent for Phase II will be explained and provided to participants in the same manner as the Informed Consent for
Phase I. Both of the two phases in the study have a separate Informed Consent document.

SECTION F: Data Collection and Design
Section Notes…
 F1. Reminder, all data collection instruments should be attached for IRB review.
 F1. The IRB welcomes the use of flowcharts and tables in the consent form for complex/ multiple study activities.
F1. In the table below, chronologically describe all study activities where human subjects are involved.


In column A, give the activity a short name. E.g., Obtaining Dataset, Records Review, Recruiting, Consenting, Screening, Interview,
Online Survey, Lab Visit 1, 4 Week Follow-Up, Debriefing, etc.



In column B, describe in greater detail the activities (surveys, audiotaped interviews, tasks, etc.) research participants will be engaged
in. Address where, how long, and when each activity takes place.



In column C, describe any possible risks (e.g., physical, psychological, social, economic, legal, etc.) the subject may reasonably
encounter. Describe the safeguards that will be put into place to minimize possible risks (e.g., interviews are in a private location, data
is anonymous, assigning pseudonyms, where data is stored, coded data, etc.) and what happens if the participant gets hurt or upset
(e.g., referred to Norris Health Center, PI will stop the interview and assess, given referral, etc.).

A. Activity Name:
Screening

C. Activity Risks and Safeguards:

Interested participants will contact the researcher and a

Risks: Loss of confidentiality

preliminary phone screening will determine eligibility and detail

Safeguards: Screenings will be completed by the
October 15, 2012

164

Page 9 of 18

B. Activity Description:

UW-Milwaukee
Institutional Review Board

IRBManager Protocol Form
v1.2

requirements for the study.

primary researcher and information will be stored on a
password protected computer. Only the primary
researcher and project advisor will have access to the
information. Phone screen information of individuals
who do not qualify or do not wish to participate will be
destroyed.

At the UWM lab or IndependenceFirst research space, informed

Risks: Loss of confidentiality of information, risk of

consent will be obtained. After signing, the CB&M Scale, CIQ,

falling

POPS and GES-m will be given to document the current level of

Safeguards: Any identifying information for

gait function and other self-reported functional statuses. The first

participants will be accessed by only the primary

visit will take approximately 90 minutes.

researcher and administrators. If conducted at
IndependenceFirst, information will be taken to UWM
each day after the completion of the participant
interaction. Information will be stored on a password
protected computer. Subjects will be given a research
participant number for the study and only the number

First visit

will be used on data collection forms. All participant
information files will be encrypted upon storage on the
server. All assessments will be administered by a
trained researcher. Assessment tasks will only be
completed if they are felt to be safe for the participant.
Participants will be asked to wear a gait belt at the
researcher’s discretion to increase safety.
Researchers will maintain proximity to the participants
when completing the gait assessment and balance
and gait trainings, as appropriate.

Baseline visits

Participants will complete the gait assessment under the

Risks: Falls during the CB&M Scale, loss of

(visits during the

observation and direction of a trained researcher to ensure

confidentiality

first week)

safety. This will be videotaped if the participant consents.

Safeguards: The CB&M Scale will be completed
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Participants will also complete the GES-m, POPS, and CIQ on

under the supervision of a trained researcher to

the last day of the phase to assess confidence completing

ensure safety. Participants will be asked to wear a gait

various common routine tasks. Each baseline visit will take

belt at the researcher’s discretion to increase safety.

approximately 45 minutes.

Researchers will maintain proximity to the participants
when completing the gait assessment and balance
and gait trainings, as appropriate. Identifying
information will not be kept with data, and all
information will be stored on a password protected
computer and only the primary researchers and
administrators will have access to identifying
information. All participant information files will be
encrypted upon storage on the server.
™

Portable neurostimulator (PoNS ) devices will be provided to

Risks: Falls, discomfort, negative reaction to the

each participant and they will be instructed on proper wear,

PoNS™ device, decrease in function, loss of

care, and usage. Participants will complete the CB&M Scale

confidentiality

daily (which will be videotaped with participant consent) and the

Safeguards: Training activities will be personalized to

GES-m, POPS, and CIQ at the end of each intervention phase.

each participant to provide an appropriate challenge

Participants will complete two intervention sessions per day with

without increasing the risk of falls. Training will be

the assessment(s) completed at the beginning of each afternoon

done under the direction of a researcher. Participants

Intervention visits

session. Each intervention session will take approximately 90

will be asked to wear a gait belt at the researcher’s

(visits during the

minutes and will be under the direction of a trained researcher.

discretion to increase safety. Researchers will

2nd and 4th weeks)

maintain proximity to the participants when completing
the gait assessment and balance and gait trainings,
as appropriate. Participants will be educated on the
appropriate use and handling of the device to reduce
the likelihood of discomfort while using it. Should any
discomfort occur, participants will be asked to explain
to ensure it is caused from the device. Any discomfort
or negative effect from the device will be recorded and
October 15, 2012
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carefully observed. Any negative reactions will be
discussed with the project advisor, primary
researcher, participant, and intervention experts.
There have been no indications in any previous or
related research that participants will experience
negative effects. Similarly, there is no indication from
prior research that participants will observe a
decrease in function. All participant information files
will be encrypted upon storage on the server.
Participants will be free to withdraw from the study at
any time should they so decide.
Participants will be assessed on the CB&M Scale under the

Risks: Falls, loss of confidentiality, decrease in gait

direction of the trained researcher to ensure safety (this will be

function

videotaped with participant consent). On the last days of the

Safeguards: All gait measures will be completed

weekly phases, participants will complete the GES-m, CIQ, and

under the direction of a trained researcher to ensure

™

Withdrawal visits
(visits during the 3
th

and 5 weeks)

rd

POPS. Participants will not have the PoNS device during these

safety. Participants will be asked to wear a gait belt at

weeks and will be instructed not to modify their habits,

the researcher’s discretion to increase safety.

performing as they typically did prior to entering the study; they

Researchers will maintain proximity to the participants

will be instructed not to continue completing the targeted training

when completing the gait assessment and balance

activities. Each visit will take approximately 45 minutes.

and gait trainings, as appropriate. Identifying
information will not be kept with data, and all
information will be stored on a password protected
computer. All participant information files will be
encrypted upon storage on the server. No research
has documented withdrawal effects. However, if gait
function should decrease, participants will be allowed
to resume use of the device after the study should
they choose to do so.
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Participants will receive monthly emails to remind them to fill out

Risks: Loss of confidentiality, discomfort using the

their daily tracking log (indicating whether they used the device

device.

that day or not and how many times). The reminders will also

Safeguards: Identifying information will not be stored

encourage periodic informal updates on their experiences and

with participant data. All information collected will be

functioning or feedback regarding the device and any questions

stored on a password protected computer. Should any

they may have.

negative side effects or discomfort occur, participants
are free to ask questions to the researchers as well as

reminders

stop using the device with no negative consequences.
Negative effects from the intervention will be
documented and discussed with the participant,
primary researcher, project advisor and intervention
experts.

6 month follow-ups

Participants will return to the laboratory to complete the same

Risks: Loss of confidentiality, risk of falls,

assessments they completed on the first day of the study (the

Safeguards: All information will be collected by a

CB&M Scale, GES-m, POPS, and CIQ). This session should

trained researcher and identifying information will not

take approximately 90 minutes to complete. Participants will be

be stored with participant data. All information

asked to bring any subjective journaling they completed during

collected will be stored on a password protected

the 6 month period as well as the monthly calendars tracking

computer. All assessments will be completed under

™

their usage of the PoNS device.

the direction of a trained researcher. Participants will
be asked to wear a gait belt at the researcher’s
discretion to increase safety. Researchers maintain
proximity to the participants when completing the gait
assessment and balance and gait trainings, as
appropriate.

Participants will be asked to return the device. If, after three

Risks: Loss of confidentiality, discomfort returning the

Last 6 month

years, in the unlikely event that the device is not FDA approved

device.

follow-up visit at

and a participant remains dependent on using the device,

Safeguards: Identifying information will not be stored

three years

researchers will consider extending the study to continue

with participant data. As noted in description, if a

tracking the individual.

participant remains dependent on the device after 3
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years, researchers will consider extending the study to
continue tracking use.
F2. Explain how the privacy and confidentiality of the participants' data will be maintained after study closure:
All data will be initially collected on paper forms, which will be stored in a locked cabinet in a locked room the researcher’s lab. If
participants complete the study at IndependenceFirst, the forms and video from the assessment will be taken directly to UWM daily
after the completion of the trainings or assessments for each day. The forms will remain in the possession of the researcher until
they are secured in the locked cabinet at UWM. Information will be coded into spreadsheet forms and stored confidentially on a
password protected server. In addition, all documents that are stored on the server as well as backup data will be encrypted using a
virtual encryption disk as the documents are being saved to the secure server. All information will be destroyed five years after the
completion of data collection for the study. All information will be stored confidentially and no identifying information will be
associated with information gathered from the study. All participants will be assigned a number, and information will use the
participant’s number rather than identifying information. Only the lead researchers and administrators will have access to identifying
information.
F3. Explain how the data will be analyzed or studied (i.e. quantitatively or qualitatively) and how the data will be reported (i.e. aggregated,
anonymously, pseudonyms for participants, etc.):
Data analyses will follow the Kratochwill standards and analysis methods may include visual analyses, trend lines, split middle
celebration lines, and the percentage of overlap techniques. Qualitative information will also use thematic identification methods. All
information will remain confidential and identifying information will not be published or distributed. Any publication or presentation of
the information will be deidentified.
Two trained raters, each with clinical experience and human subjects training, will evaluate the data. Raters will review the video
data at their office or at UWM. Raters will be provided with a CD/DVD of the data if they choose to rate the data outside of UWM.
The video will contain the participants face, but the raters will not receive any information about the participant and none of the data
they score involves sensitive information. The CD/DVD will be returned upon completion of the scoring, no more than one month
after obtaining the CD/DVD. The scored data obtained from the rater will not have any sensitive information, including any
demographic information. The raters will be instructed on methods for maintaining confidentiality of the participant during the
viewing and possession of the video data. Raters will be instructed to score data when they are alone in an area and store the
information in a locked, protected location. All raters will have human subjects training and the DVD will be personally returned to
the student researcher.
SECTION G: Benefits and Risk/Benefit Analysis
Section Notes…
 Do not include Incentives/ Compensations in this section.
G1. Describe any benefits to the individual participants. If there are no anticipated benefits to the subject directly, state so. Describe potential
benefits to society (i.e., further knowledge to the area of study) or a specific group of individuals (i.e., teachers, foster children). Describe the
ratio of risks to benefits.
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Potential benefits for participants include an improvement in functional gait during the intervention weeks which may lead to
carryover past the intervention weeks. Participants will be allowed to choose the amount they use the device during the longitudinal
section of the study, and may experience improved function with increased carryover time. In previous research, many participants
noted improvements in other areas in addition to improvements in balance and gait. This is possible for individuals in the current
study and previous improvements appear to be dependent on the other limitations the individual has. By participating in the study,
participants are contributing to further knowledge regarding the withdrawal and longitudinal effects of the CN-NINM intervention,
and potentially leading to significant discoveries and more effective interventions for individuals with gait impairments. The potential
benefits of the study outweigh the risks.
G2. Risks to research participants should be justified by the anticipated benefits to the participants or society. Provide your assessment of
how the anticipated risks to participants and steps taken to minimize these risks, balance against anticipated benefits to the individual or to
society.
Potential risks to participants are minimal. Previous research has demonstrated the safety of the PoNS™ neuromodulation device
and has used the protocol proposed. The FDA has determined that the predecessor for the current device, the BrainPort™, is a
nonsignificant risk device. The risk of discomfort or harm from the use of electricity is very slim. There have been 14 IRB protocols
approved at the University of Wisconsin-Madison using the PoNS™ device or predicate device, the BrainPort™. The device
development has been ongoing for the previous 14 years. (See supplemental information for a listing of all the approved IRB
protocols, additional information regarding technical details of the PoNS™, and the nonsignificant risk letter from the FDA for the
BrainPort™) The device is battery powered, thereby ensuring the discharge of a regulated amount of electricity at a time. When
recharging the device, the device is not capable of discharging stimulation. Each time the device is turned off, the intensity resets;
when the device is turned on it is always at the lowest intensity setting (below perception level) and participants control setting the
intensity each time they begin to use the device. Participants are in control of the device and the intensity of the stimulation at all
times during the study. If the stimulation for any reason becomes uncomfortable, participants will be encouraged to reduce the
intensity, turn the device off, and/or remove the device from their mouth at any point.
Participants will use the PoNS™ device independently and without supervision during intervention weeks as well during the
longitudinal component of the study. Participants will receive thorough training as to the proper use, care, and handling of the
device. There have been no previous reports of any negative effects due to overuse or misuse of the device. Participants will be
instructed to not let anyone else use their device, as the devices are not intended to share between people and the other individual
may not meet inclusion and exclusion criteria. Aside from misuse due to sharing the device, there is no other known risk to using
the device without supervision after the initial training.
Participants may face a slight risk of falling during interventions and assessments. This risk is no more than in a clinical
neurorehabilitation setting. This study will be conducted under the direction of a licensed occupational therapist, and participants will
be under the direct direction of a trained researcher to ensure they are following safety instructions during treatments. All
researchers with participant contact have a formal education in a therapeutic rehabilitation and background, as well as experience,
working with people with disabilities. A researcher will be near the participants during trainings and the gait assessment to provide
safety instructions and hands-on stabilization if necessary. Researchers will use clinical judgment to avoid unsafe activities that may
increase the risk of falls. Participants will wear a safety/gait belt as necessary during gait or balance tasks if the researcher feels
he/she needs additional hands on support during tasks. Not all participants are expected to require the use of a gait belt, as the
participants will all be able to ambulate independently and training tasks will be customized to meet their ability level.
In the unlikely event that a participant falls during the time in the laboratory, the test or training will stop immediately and the
October 15, 2012

170

Page 15 of 18

UW-Milwaukee
Institutional Review Board

IRBManager Protocol Form
v1.2

situation will be assessed. If the participant is injured in any way, emergency care will be called. The participants will be responsible
for any costs accrued as a result of the emergency care. This study and UW-Milwaukee make no commitment to provide
compensation for a research-related injury. Participants may contact the study advisor with questions or further concerns.
In addition, if at any time there are indications that the patient is in distress, the training session will be stopped immediately, and
both the circumstances and the plans for progression will be evaluated and discussed with the participant, study advisor, and
experts from TCNL, as appropriate. Participants are free to withdraw from the study at any time without penalty or explanation.
Participation in this study will not interfere with insurance coverage for the participant. No harmful effects have been observed in
any participants who have used the PoNS™ or BrainPort™ devices for individuals receiving additional medical treatments. Several
medical conditions that may require medical treatment (such as MS and Parkinson’s Disease) are exclusion criteria. However, there
is no indication that the therapeutic intervention using the PoNS™ device with targeted training will negatively impact individuals who
are receiving additional medical treatment.
Any adverse event will be reported to the IRB in writing within five working days. Any serious adverse event (an event that is lifethreatening regardless if associated with the study) will be reported immediately to the IRB. All adverse events, serious and nonserious, will be fully documented on the appropriate report forms. The primary researcher or study advisor will report all potential
adverse events, For each adverse event, the PI will provide the onset, duration, intensity, treatment required, outcome, and action
taken.
Any new complications not already reported that may impact willingness to participate will be reported to participants.
SECTION H: Subject Incentives/ Compensations
Section Notes…
 H2 & H3. The IRB recognizes the potential for undue influence and coercion when extra credit is offered. The UWM IRB, as also
recommended by OHRP and APA Code of Ethics, agrees when extra credit is offered or required, prospective subjects should be given
the choice of an equitable alternative. In instances where the researcher does not know whether extra credit will be accepted and its
worth, such information should be conveyed to the subject in the recruitment materials and the consent form. For example, "The
awarding of extra credit and its amount is dependent upon your instructor. Please contact your instructor before participating if you have
any questions. If extra credit is awarded and you choose to not participate, the instructor will offer an equitable alternative."
 H4. If you intend to submit to the Travel Management Office for reimbursement purposes make sure you understand what each level of
payment confidentiality means (click here for additional information).
H1. Does this study involve incentives or compensation to the subjects? For example cash, class extra credit, gift cards, or items.
[_X_] Yes
[__] No [SKIP THIS SECTION]
H2. Explain what (a) the item is, (b) the amount or approximate value of the item, and (c) when it will be given. For extra credit, state the
number of credit hours and/or points. (e.g., $5 after completing each survey, subject will receive [item] even if they do not complete the procedure,
extra credit will be award at the end of the semester):
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Upon completion of the first phase of the study, participants will be allowed to keep the PoNS™ device they used throughout the first
phase if they agree to continue into Phase II, the longitudinal component to the study. If they do not choose to continue into Phase
II, they will be asked to return the device. If they choose to withdraw at any point, they will be asked to return the device. After the
completion of the 3 year follow-up, participants will be asked to return the device. If, after three years, in the unlikely event that the
device is not FDA approved and a participant remains dependent on using the device, researchers will consider extending the study
to continue tracking the individual.
H3. If extra credit is offered as compensation/incentive, an alternative activity (which can be another research study or class assignment) should be
offered. The alternative activity (either class assignment or another research study) should be similar in the amount of time involved to complete and
worth the same extra credit.
NA
H4. If cash or gift cards, select the appropriate confidentiality level for payments (see section notes):
[__] Level 1 indicates that confidentiality of the subjects is not a serious issue, e.g., providing a social security number or other identifying information for
payment would not pose a serious risk to subjects.
 Choosing a Level 1 requires the researcher to maintain a record of the following: The payee's name, address, and social
security number and the amount paid.
 When Level 1 is selected, a formal notice is not issued by the IRB and the Travel Management Office assumes Level 1.
 Level 1 payment information will be retained in the extramural account folder at UWM/Research Services and attached to the
voucher in Accounts Payable. These are public documents, potentially open to public review.
[__] Level 2 indicates that confidentiality is an issue, but is not paramount to the study, e.g., the participant will be involved in a study researching
sensitive, yet not illegal issues.
 Choosing a Level 2 requires the researcher to maintain a record of the following: A list of names, social security numbers, home
addresses and amounts paid.
 When Level 2 is selected, a formal notice will be issued by the IRB.
 Level 2 payment information, including the names, are attached to the PIR and become part of the voucher in Accounts Payable.
The records retained by Accounts Payable are not considered public record.
[__] Level 3 indicates that confidentiality of the subjects must be guaranteed. In this category, identifying information such as a social security number
would put a subject at increased risk.
 Choosing a Level 3 requires the researcher to maintain a record of the following: research subject's name and corresponding
coded identification. This will be the only record of payee names, and it will stay in the control of the PI.
 Payments are made to the research subjects by either personal check or cash.
 Gift cards are considered cash.
 If a cash payment is made, the PI must obtain signed receipts.
SECTION I: Deception/ Incomplete Disclosure (INSERT “NA” IF NOT APPLICABLE)
Section Notes…
 If you cannot adequately state the true purpose of the study to the subject in the informed consent, deception/ incomplete disclosure is
involved.
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I1. Describe (a) what information will be withheld from the subject (b) why such deception/ incomplete disclosure is necessary, and (c) when
the subjects will be debriefed about the deception/ incomplete disclosure.
NA
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UNIVERSITY OF WISCONSIN – MILWAUKEE
CONSENT TO PARTICIPATE IN RESEARCH
Phase 1 Consent
This Consent Form has been approved by the IRB for a one year period

1. General Information
Study title:
Beneficial and Withdrawal Effects of Cranial Nerve Non-Invasive Neuromodulation on
Functional Mobility for Individuals with Traumatic Brain Injury with Multiyear Follow-up: Phase 1
Person in Charge of Study (Principal Investigator):
Study Advisor: Roger O. Smith, Ph.D., OT, FAOTA
Dr. Smith is the director of the Rehabilitation Research Design and Disability (R2D2) Center and
a professor in the Occupational Science and Technology Department at the University of
Wisconsin-Milwaukee.
Primary Researcher: Kati Liegl, B.S.
Ms. Liegl is a graduate assistant at the Rehabilitation Research Design and Disability (R2D2)
Center and completing her Master’s thesis in Occupational Therapy at the University of
Wisconsin-Milwaukee.

2. Study Description
You are being asked to participate in a research study. Your participation is completely
voluntary. You do not have to participate if you do not want to.
Study description:
This study is interested in studying the immediate and withdrawal effects of a very new
rehabilitation approach created at the University of Wisconsin – Madison. The approach uses
the same type of treatments to improve balance and walking that you participated in during
rehabilitation. However, you will have a small device in your mouth for 20 minutes at a time
while you are performing the rehabilitation activities. The device delivers mild electrical
stimulation to your tongue. Many people say the stimulation feels like drinking a carbonated
beverage. Four people who still have walking problems since their head injury will be in the
study.
We think the electrical stimulation helps prepare your brain to learn, especially areas that help
control your movements and areas that help your senses work together. We are interested in
what happens to your balance and walking. We are also interested in what happens when the
intervention stops and how long any changes last. This study hopes to provide another safe
option to help therapists treat people with walking or balance problems after they have a head
injury.
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This study will require a great deal of work and time. We think this study will last five weeks.
There is a small chance the researchers may ask you to continue the study for an extra week,
but this is not expected to happen unless you cannot come to the lab several days for any
reason. During the first, third, and fifth weeks, you will come to the lab every day, Monday
through Friday, for about 45 minutes each day. Every day you will be tested on your walking
and on Friday you will complete three surveys as well. During the second and fourth weeks, you
will come to the laboratory twice a day, once in the morning and once in the afternoon. Each of
these appointments will take about 90 minutes for a total of three hours in the laboratory every
day during both intervention weeks. During those weeks, you will also use the stimulation device
two times in the evening at home.
After the first five weeks, if you would like to continue to use the device, you will be able to
participate in a second part to the study. You can decide at the end of the first five weeks if you
would like to continue. If you decide not to continue, you will be asked to return the device. For
the second part, we will give you general guidelines on how to use the device but you will be
using it on your own at your home. We will be available for questions during this time. You will
be asked to track your usage of the intervention on a calendar we give to you and return to the
laboratory for 90 minute follow-up appointments every six months for the following three years.
Again, you can decide if you want to participate in that part of the study after completing the first
five weeks. Signing this form does NOT mean you will participate in the second part to the
study.

3. Study Procedures
What will I be asked to do if I participate in the study?
If you agree to participate, you will complete activities similar to the rehabilitation you completed
after your injury. The main difference is that this study will use a device that stimulates your
tongue with small, safe doses of electricity while you are doing the balance and walking
activities. In general, the study will last 5 weeks. During the first, third, and fifth weeks, you will
be tested every day on a walking test. These visits will be about 45 minutes. At the end of each
week you will take the three surveys. During the second and fourth weeks, you will do the same
testing, but you will also do training in the lab. The training will be twice per day (Monday
through Friday) for 90 minutes in the morning and 90 minutes in the afternoon. The training will
be similar to previous rehabilitation you have participated in. The last page of this document
shows what you will be doing each day for the study. During the study, we also would like to
videotape your walking test. If you decide you do not want to be videotaped, you can still
participate in the study. We will use the videotape to have another therapist score the walking
test you are completing to make sure the score is accurate.
You will provide your own transportation to the University of Wisconsin Milwaukee or
IndependenceFirst five times a week (Monday-Friday) for five weeks. Parking at UW-Milwaukee
will be paid by the researcher but you will not receive payment if you park at IndependenceFirst.
Basically, one week of daily testing only is followed by one week of daily training. This repeats
for 5 weeks. You will have one day of testing before starting the 5 weeks in a row. At the first
visit, you will be provided an Informed Consent. The Informed Consent will be explained to you
and you will get a copy to keep. After having time to read it, and after signing it, you will
complete three surveys on your own (the Community Integration Questionnaire, Participation
Objective Participation Subjective, and modified Gait Efficacy Scale). You will also be tested
using a walking test called the Community Balance & Mobility Scale. This test will be videotaped
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if you give us your permission During the first week, you will be tested every day with the
walking test. The second and fourth weeks will be training (intervention) weeks and the third and
fifth weeks will be withdrawal weeks where once again we test your walking every day and you
do not do training.
If you complete the study at IndependenceFirst, all the information will be kept as a paper copy
and on the disk for the videocamera. This information will be in the possession of the primary
researcher at all times. After the completion of each day’s training or testing, the primary
researcher will take the information directly back to a secured location at UW-Milwaukee.
During the second and fourth weeks, we will train you to know how to take care of and use the
device that delivers the mild electrical stimulation to your tongue. This device is called the
Portable Neurostimulator (PoNS™). The PoNS™device is an investigational device and has not
yet been approved by the FDA. The intervention we are studying combines the therapy activities
similar to those you have already completed in rehabilitation with stimulation of the tongue with
the PoNS™ device. Each intervention session during the second and fourth week will include 20
minutes of each training focused on balance, relaxation, and gait. You will use the PoNS™
device while you do the balance and gait activities. The balance activities include things like
standing on foam with your eyes closed, or standing on the floor with your feet close together
without shoes and with your eyes closed. Gait (walking) activities include things like walking on
a treadmill focused on fixing posture or the lengths of each step. Other gait activities might
include walking backwards or walking outside on uneven surfaces like the grass. Relaxation
training will help you focus on breathing and body awareness while you are sitting. You will
complete the trainings in the lab in the morning and in the afternoon. In the evening, you will use
the device two more times, each time for 20 minutes while doing activities you learned in the
lab. In addition to the training, you will be tested every day using the walking test. At the end of
the week, you will also fill out all 3 surveys that you did on the first day.
During the two withdrawal weeks, we do not want you to practice the trainings you learned or
use the PoNS™ device. You will be tested using the walking test every day.
During the whole study, we encourage you to write down any changes that you notice that you
think are related to the study. This information helps us plan research in the future, and
understand your progress.
After the five weeks to finish this study, you will be able to choose if you want to keep using the
device by completing the second part to this study. If you do not, you will be asked to return the
device. If you do continue with the study, you will return to the laboratory every six months to
complete the same test and surveys used on the first visit. Between follow-up visits, you would
record how often you use the device by marking a calendar we give you.
Any new findings that may impact your willingness to participate in this study will be reported to
you before your next visit to the laboratory and within two days.

4. Risks and Minimizing Risks
What risks will I face by participating in this study?
You will face minimal risks by participating in the study. There is a slight risk of the loss of
confidentiality. To reduce this risk, only the primary researcher and study advisor will have
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access to information that identifies you. If you complete the study at IndependenceFirst, the
information collected will be taken directly to UW-Milwaukee and secured at the end of the
testing or training each day. All information will be stored confidentially on a password protected
server that is only accessible to core administrators and the primary researcher. All your
information will also be encrypted when it is stored on the password protected server.
There is a slight risk of falling during the walking test and training activities. This risk is no
greater than the risk of falling during other standard rehabilitation interventions you may have
participated in. To reduce the risk of falling, a trained researcher with a therapy education and
background will be with you to make sure the activities are safe and help or steady you as
needed. You may be asked to wear a gait belt if necessary to further reduce the risk of falling
(the belt will help the researcher hold onto you and help steady you, if necessary).
In the unlikely event that you do fall during your time in the lab, the test or training will stop
immediately and the situation will be assessed. If you are injured while at the lab, emergency
care will be called. However, you will be responsible for the cost from the emergency care.
There is no commitment to provide compensation for research-related injury. You should
realize, however, that you have not released this institution from liability for negligence. Please
contact the Principal Investigator, Roger O. Smith at 414-229-5625 if you believe you are injured
or require further information.
In the research with the PoNS™ device and similar older versions, no one has described a
negative reaction to the device. You will always be in control of the device and the intensity of
the stimulation. If it is ever uncomfortable, you can turn down the intensity, turn off the device or
take it out of your mouth at any time. If you experience a negative or uncomfortable reaction,
you will stop using the device right away. Then you will meet with the study advisor, primary
researcher, and experts in the intervention from Madison to discuss the negative effect and the
options for continuing or discontinuing the study.
It is possible that your balance and walking abilities will not get better. This may result in
negative emotional reactions. This has not been recorded in previous research.
You may stop participating in this study at any time during the study for any reason. If you
choose to stop, you will be asked to return the PoNS™ device.

5. Benefits
Will I receive any benefit from my participation in this study?
Being in this study will add to the research on cranial nerve non-invasive neuromodulation (the
intervention created in Madison) used to improve walking ability. What we learn from this study
will help make rehabilitation better in the future for people who experience a traumatic brain
injury and have balance or walking problems because of the injury. It is important that we study
the effects and withdrawal effects of the intervention. Your participation in the study will help this
research.
It is possible that your walking will improve during the intervention weeks. You may notice an
improvement that lasts through the withdrawal weeks. Some of the people who used the device
in the past noticed other positive changes also. If you are interested, you can choose later to
participate in the second part to the study.
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6. Study Costs and Compensation
Will I be charged anything for participating in this study?
You will not be responsible for any of the costs from taking part in this research study. However,
you will be expected to provide your own transportation to and from the research lab without
compensation. Parking at UWM will be paid for you.
Are subjects paid or given anything for being in the study?
You will not be paid or given anything when you finish the study. When you finish the study, you
will be asked to return the PoNS™ device. If you decide to be in the second phase, you will keep
the device until you are finished with the second phase.

7. Confidentiality
What happens to the information collected?
All information collected about you during the study will be kept confidential to the extent
permitted by law. We may decide to present what we find to others, or publish our results in
scientific journals or at scientific conferences. Information that identifies you personally will not
be released without your written permission. All information will be kept on a password
protected computer on a secure University of Wisconsin-Milwaukee server. All files and back-up
files will be encrypted to further protect the information. Any paper forms will be stored in a
locked cabinet in a locked office in the R2D2 Center at UW-Milwaukee. If you complete the study
at IndependenceFirst, your information will be taken directly to this location after the training or
testing each day by the primary researcher. Information will be kept for five years after the study
for future use. Only the study principal investigator, Roger O. Smith, and primary researcher,
Kati Liegl will have access to identifying information. However, the Institutional Review Board at
UW-Milwaukee or appropriate federal agencies like the Office for Human Research Protections
and the U.S. Food and Drug Administration (FDA) may review this study’s records.

8. Alternatives
Are there alternatives to participating in the study?
There are no known direct alternatives available to you other than not taking part in this study. A
slightly different alternative may be to speak with your doctor to request more therapy services.
It is possible that insurance may pay for therapy services ordered by your doctor. It is also
possible that you may be responsible for paying for the extra therapy, depending whether you
qualify for additional therapy. Other alternatives not connected to this research study might
include Alternative and Complementary Medicine approaches, like yoga, acupuncture, or fitness
groups.

9. Voluntary Participation and Withdrawal
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What happens if I decide not to be in this study?
Your participation in this study is voluntary. You may choose not to take part in this study at any
time. If you decide to take part, you can change your mind at any time and withdraw from the
study. You are free to not answer any questions. If you withdraw from the study early, we will
ask you to return the PoNS™ device. Researchers may use the information collected to that
point. Your decision will not change any present or future relationships with the University of
Wisconsin Milwaukee and will not affect any insurance coverage.

10. Questions
Who do I contact for questions about this study?
For more information about the study or the study procedures or treatments, or to withdraw from
the study, contact:
Primary Researcher: Kati Liegl
University of Wisconsin-Milwaukee
Rehabilitation Research Design & Disability (R2D2) Center
P.O. Box 413
Milwaukee WI 53201
414-229-6803
Study Advisor: Dr. Roger O. Smith
University of Wisconsin-Milwaukee
Rehabilitation Research Design & Disability (R2D2) Center
P.O. Box 413
Milwaukee WI 53201
414-229-5625
Who do I contact for questions about my rights or complaints towards my treatment as a
research subject?
The Institutional Review Board may ask your name, but all complaints are kept in confidence.
Institutional Review Board
Human Research Protection Program
Department of University Safety and Assurances
University of Wisconsin – Milwaukee
P.O. Box 413
Milwaukee, WI 53201
(414) 229-3173

11. Signatures
Research Subject’s Consent to Participate in Research:
To voluntarily agree to take part in this study, you must sign on the line below. If you choose to
take part in this study, you may withdraw at any time. You are not giving up any of your legal
rights by signing this form. Your signature below indicates that you have read or had read to you
this entire consent form, including the risks and benefits, and have had all of your questions
answered, and that you are 18 years of age or older.
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___________________________________________
Printed Name of Subject
___________________________________________
Signature of Subject

____________________
Date

Research Subject’s Consent to Audio/Video/Photo Recording:
It is okay to videotape me while I am in this study and use my videotaped data in the research.
Choosing not to be videotaped will not affect my ability to be in the study.
Please initial: ____Yes

____No

Principal Investigator (or Designee)
I have given this research subject information on the study that is accurate and sufficient for the
subject to fully understand the nature, risks and benefits of the study.
___________________________________________
Printed Name of Person Obtaining Consent

____________________
Study Role

___________________________________________
Signature of Person Obtaining Consent

____________________
Date
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UNIVERSITY OF WISCONSIN – MILWAUKEE
CONSENT TO PARTICIPATE IN RESEARCH
Phase 2 Consent
This Consent Form has been approved by the IRB for a one year period

1. General Information
Study title:
Beneficial and Withdrawal Effects of Cranial Nerve Non-Invasive Neuromodulation on
Functional Mobility for Individuals with Traumatic Brain Injury with Multiyear Follow-up: Phase 2
Person in Charge of Study (Principal Investigator):
Study Advisor: Roger O. Smith, Ph.D., OT, FAOTA
Dr. Smith is the director of the Rehabilitation Research Design and Disability (R2D2) Center and
a professor in the Occupational Science and Technology Department at the University of
Wisconsin-Milwaukee.
Primary Researcher: Kati Liegl, B.S.
Ms. Liegl is a graduate assistant at the Rehabilitation Research Design and Disability (R2D2)
Center and completing her Master’s thesis in Occupational Therapy at the University of
Wisconsin-Milwaukee.

2. Study Description
You are being asked to participate in a research study. Your participation is completely
voluntary. You do not have to participate if you do not want to.
Study description:
Because you finished the first part of the study, you are being invited to participate in Phase II of
the study. We want to study any additional effects when you use this device over a longer
period of time. This is an investigational device and has not yet been approved by the FDA. This
part of the study uses the same small device you have been using to stimulate the tongue with
mild electrical current and the same training activities that were started in Madison. This study
will help us learn how you choose to use the device at home. You will come back to the lab two
times each year for three years to complete tests so we can track your progress. We expect that
four people who still have walking problems since their head injury will be in the study.
We think the electrical stimulation helps prepare your brain to learn, especially areas that help
control your movements and areas that help your senses work together. We are interested in
what happens to your balance and walking as well as any other changes you notice. We are
also interested in what happens when the intervention stops. Because this is a new intervention,
we want to study your walking and balance abilities for three more years. This study hopes to
provide another safe option to help therapists treat people with walking or balance problems
after they had a head injury.
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This study will require you to track how often you choose to use the device as you continue to
use it for three years. You can use the device as often as you would like (up to the amount you
used it in the first study) or as little as you want. We will give you guidelines on how to use it but
you will be using it on your own. We will be available for questions during this time. We will also
send you an email every month to remind you to keep writing down how often you use the
device. You will also come back to the lab every six months for three years to do the walking
test and the same three surveys you did in the first part of the study. Each visit will be to the
R2D2 Center Laboratory and will take about 90 minutes.

3. Study Procedures
What will I be asked to do if I participate in the study?
If you agree to participate, you will be asked to provide your own transportation to the University
of Wisconsin Milwaukee once every six months. Parking at UW-Milwaukee will be paid for you
at each of your visits. Each visit will take 90 minutes and you will complete three surveys on
your own (the Community Integration Questionnaire, Participation Objective Participation
Subjective, and modified Gait Efficacy Scale). You will also be tested by a researcher on a
walking test (the Community Balance & Mobility Scale). During the study, we also ask that we
can videotape your walking test. If you decide not to be videotaped, you can still participate in
the study. We will use the videotape to have another therapist score the walking test you are
completing to make sure the score is accurate.
You will also be asked to keep track of how many times per day you choose to use the device.
We will give you a calendar for each month, and you will be asked to put an ‘X’ on the day each
time you use the device. On the back of the calendar is a spot you can write down anything that
you think is important or notice changing. What you write will help us understand your
experience but you do not have to write anything. You will be asked to bring the calendars with
you when you come to the lab every six months.
We will send you an email once per month to remind you to use the calendar. We also welcome
any questions you have at any time. You do not have to reply to the emails, but you can contact
us if you have questions or would like to share your experiences between visits.
Any new findings that may impact your willingness to participate in this study will be reported to
you before your next visit to the laboratory and within two days.

4. Risks and Minimizing Risks
What risks will I face by participating in this study?
You will face minimal risks by participating in the study. There is a slight risk of the loss of
confidentiality. To reduce this risk, only the primary researcher and study advisor will have
access to information that identifies you. All information will be stored confidentially on a
password protected server that is only accessible to the primary researcher and study advisor.
All your information will also be encrypted when it is stored on the password protected server.
There is a slight risk of falling during the walking test. This risk is no greater than the risk of
falling during what you do every day or other standard rehabilitation interventions you may have
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participated in. To reduce the risk of falling, a trained researcher with a therapy education and
background will be with you. You will be asked to wear a gait belt to reduce the risk of falling, if
the researcher feels it is necessary. In the unlikely event that you do fall during your time in the
lab, the test or training will stop immediately and the situation will be assessed. If you are injured
while at the lab, emergency care will be called. However, you will be responsible for the cost
from the emergency care. There is no commitment to provide compensation for researchrelated injury. You should realize, however, that you have not released this institution from
liability for negligence. Please contact the Principal Investigator, Roger O. Smith at 414-2295625 if you believe you are injured or require further information.
In the research with the PoNS™ device and similar older versions, no one has described a
negative reaction to the device. If you experience a negative or uncomfortable reaction, you will
stop using the device immediately and meet with the study advisor, primary researcher, and
experts in the intervention from Madison to discuss the negative effect and the options for
continuing or discontinuing the study.
It is possible that your balance and walking abilities will not get better. This may result in
negative emotional reactions. This has not been recorded in previous research.
You may stop participating in this study at any time during the study for any reason. If you
choose to stop, you will be asked to return the PoNS™ device. At the end of the three years, you
will be asked to return the PoNS™ device.

5. Benefits
Will I receive any benefit from my participation in this study?
Being in this study will add to the research on cranial nerve non-invasive neuromodulation (the
intervention created in Madison) used to improve walking ability. What we learn from this study
will help make rehabilitation better in the future for people who experience a traumatic brain
injury and have balance or walking problems because of the injury. It is important that we study
any long-term effects of the intervention. Your participation in the study will help this research.
It is possible that your walking will improve over time if you continue to use the device.

6. Study Costs and Compensation
Will I be charged anything for participating in this study?
You will not be responsible for any of the costs from taking part in this research study. However,
you will be expected to provide your own transportation to and from the research lab without
compensation.
Are subjects paid or given anything for being in the study?
You will be allowed to keep the PoNS™ device during the three years of the study as long as
you are personally using it. If you decide to stop using the device, you will be asked to return it
to the primary researcher or study advisor. You will not be paid anything to be in the study, but if
you park on campus, your parking will be paid for you.
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7. Confidentiality
What happens to the information collected?
All information collected about you during the study will be kept confidential to the extent
permitted by law. We may decide to present what we find to others, or publish our results in
scientific journals or at scientific conferences. Information that identifies you personally will not
be released without your written permission. All information will be kept on a password
protected computer on a secure University of Wisconsin-Milwaukee server. All files and back-up
files will be encrypted to further protect the information. Any paper forms will be stored in a
locked cabinet in a locked office in the R2D2 Center at UW-Milwaukee. Information will be kept
for five years after the study for future use. Only the study principal investigator, Roger O.
Smith, and primary researcher, Kati Liegl will have access to identifying information. However,
the Institutional Review Board at UW-Milwaukee or appropriate federal agencies like the Office
for Human Research Protections and the U.S. Food and Drug Administration (FDA) may review
this study’s records.

8. Alternatives
Are there alternatives to participating in the study?
There are no known direct alternatives available to you other than not taking part in this study. A
slightly different alternative may be to speak with your doctor to request more therapy services.
It is possible that insurance may pay for therapy services ordered by your doctor. It is also
possible that you may be responsible for paying for the extra therapy, depending whether you
qualify for additional therapy. Other alternatives not connected to this research study might
include Alternative and Complementary Medicine approaches, like yoga, acupuncture, or fitness
groups.

9. Voluntary Participation and Withdrawal
What happens if I decide not to be in this study?
Your participation in this study is voluntary. You may choose not to take part in this study at any
time. If you decide to take part, you can change your mind at any time and withdraw from the
study. You are free to not answer any questions. If you withdraw from the study early, we will
ask you to return the PoNS™ device. Researchers may use the information collected to that
point. Your decision will not change any present or future relationships with the University of
Wisconsin Milwaukee and will not affect any insurance coverage.

10. Questions
Who do I contact for questions about this study?
For more information about the study or the study procedures or treatments, or to withdraw from
the study, contact:
Primary Researcher: Kati Liegl
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University of Wisconsin-Milwaukee
Rehabilitation Research Design & Disability (R2D2) Center
P.O. Box 413
Milwaukee WI 53201
414-229-6803
Study Advisor: Dr. Roger O. Smith
University of Wisconsin-Milwaukee
Rehabilitation Research Design & Disability (R2D2) Center
P.O. Box 413
Milwaukee WI 53201
414-229-5625
Who do I contact for questions about my rights or complaints towards my treatment as a
research subject?
The Institutional Review Board may ask your name, but all complaints are kept in confidence.
Institutional Review Board
Human Research Protection Program
Department of University Safety and Assurances
University of Wisconsin – Milwaukee
P.O. Box 413
Milwaukee, WI 53201
(414) 229-3173

11. Signatures
Research Subject’s Consent to Participate in Research:
To voluntarily agree to take part in this study, you must sign on the line below. If you choose to
take part in this study, you may withdraw at any time. You are not giving up any of your legal
rights by signing this form. Your signature below indicates that you have read or had read to you
this entire consent form, including the risks and benefits, and have had all of your questions
answered, and that you are 18 years of age or older.
___________________________________________
Printed Name of Subject
___________________________________________
Signature of Subject

____________________
Date

Research Subject’s Consent to Audio/Video/Photo Recording:
It is okay to videotape me while I am in this study and use my videotaped data in the research.
Choosing not to be videotaped will not affect my ability to be in the study.
Please initial: ____Yes

____No

Principal Investigator (or Designee)
I have given this research subject information on the study that is accurate and sufficient for the
subject to fully understand the nature, risks and benefits of the study.
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Printed Name of Person Obtaining Consent

____________________
Study Role

___________________________________________
Signature of Person Obtaining Consent

____________________
Date
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